

From: Snedden, Sheridan  
Sent: Tuesday, August 19, 2003 6:48 PM  
To: STIC-Biotech/ChemLib  
Subject: Seq Search 09820053

Sheridan SNEDDEN ID# 79298 Date: 8/19 /2003

AU 1653

308-4843

Serial # : 09820053

Room Location: 10A12

Mail Box: 9B01

Claims reads: Peptide 5 to 23 amino acids length, 70% identical to SEQ ID NO: 43, wherein 80% of the amino acids are Phe, Lys, Leu and Ala.

I am not sure how to request this search. Please advise.

Thanks,  
Examiner Snedden  
#79298  
A.U. 1653/ 9B01  
Office Location: 10A12  
Phone #: 305-4843


Searcher: D. S. L. 1000  
Phone: 305-4843  
Location: CM 1 6A03  
Date Picked Up: \_\_\_\_\_  
Date Completed: 8/22  
Searcher Prep/Review: 15  
Clerical: \_\_\_\_\_  
Online time: 6

## TYPE OF SEARCH:

NA Sequences: \_\_\_\_\_  
AA Sequences: 1  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

## VENDOR/COST (where applic.)

STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: Comp. Sys.  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_





# **STIC Search Report**

## **Biotech-Chem Library**

### **STIC Database Tracking**

**TO: Sheridan Snedden**  
**Location: CM1/10A12&9B01**  
**Art Unit: 1653**  
**Friday, August 22, 2003**

**Case Serial Number: 09/820053**

**From: David Schreiber**  
**Location: Biotech-Chem Library**  
**CM1-6A03**  
**Phone: 308-4292**

**david.schreiber@uspto.gov**

### **Search Notes**

Sheridan,

Since this specifically refers to seq 43 and that sequence has the preferred residues, it seemed the best way to run this was just by doing a standard search of seq 43 and saving 45 alignments so you can see what you got. Hope this helps. Call if you have any questions.

David Schreiber  
308-4292

5

20

59-50

60

OM protein protein search using sw model  
 Run on: August 21, 2003, 08:17:40 : Search time 28 seconds  
 (without alignments)  
 22.667 Million cell updates/sec  
 Title: US-09-820-053A-43  
 Perfect score: 66  
 Sequence: 1 FAKALEKALEKAI 15  
 Scoring table: RLSUM62  
 Gapop 10.0 , Gapext 0.5  
 Searched: 328717 seqs, 4240858 residues  
 Total number of hits satisfying chosen parameters: 168489

Minimum DB seq length: 0  
 Maximum DB seq length: 25  
 Post processing: Minimum Match 100%  
 Maximum Match 100%  
 Listing first 45 summaries

Database : Issued Patents, AA: \*  
 1: 2002-01-01 10:00:00 US-09-820-053A-43  
 2: 2002-01-01 10:00:00 US-09-820-053A-43  
 3: 2002-01-01 10:00:00 US-09-820-053A-43  
 4: 2002-01-01 10:00:00 US-09-820-053A-43  
 5: 2002-01-01 10:00:00 US-09-820-053A-43  
 6: 2002-01-01 10:00:00 US-09-820-053A-43

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Query			DB ID	Description
	Score	Match	Length		
1	51	77.3	21	1	US-07-908-455A-6
2	51	77.3	21	1	US-08-434-120-42
3	51	77.3	21	1	US-08-465-425-44
4	51	77.3	21	4	US-09-115-737-32
5	50	75.8	14	1	US-08-944-133-16
6	50	75.8	14	1	US-08-944-133-33
7	50	75.8	21	1	US-08-944-133-17
8	50	75.8	21	1	US-08-944-133-30
9	50	75.8	21	1	US-08-944-133-34
10	48	72.7	23	1	US-08-241-730A-39
11	48	72.7	23	1	US-08-427-001C-44
12	48	72.7	23	1	US-08-457-171-39
13	48	72.7	23	2	US-08-723-306-19
14	48	72.7	23	2	US-08-505-486-44
15	48	72.7	23	3	US-08-689-489C-39
16	48	72.7	23	3	US-08-801-028-44
17	48	72.7	23	3	US-09-340-154-44
18	48	72.7	23	4	US-09-242-902A-39
19	48	72.7	23	4	US-09-482-611B-44
20	48	72.7	23	4	US-09-019-922A-44
21	48	72.7	23	5	PCI-US94-12550-47
22	48	72.7	23	5	PCI-US95-04335-39
23	48	72.7	23	5	PCI-US95-04718-39
24	48	72.7	23	5	PCI-US95-09338-44
25	48	72.7	23	5	PCI-US95-09339-44
26	48	72.7	23	5	PCI-US96-10041-19
27	40	60.6	21	1	US-07-908-455A-6

# SUMMARIES

RESULT 1  
 US-07-908-455A-6  
 : Sequence 6, Application US/07908455A  
 : Patent No. 5459237  
 : GENERAL INFORMATION:  
 : APPLICANT: Beckwith, Barry A.  
 : APPLICANT: Kari, U. Prasad  
 : APPLICANT: Mallow, W. Lee  
 : TITLE OF INVENTION: Uses of...  
 : TITLE OF INVENTION: Uses of...  
 : NUMBER OF SPOTLIGHTS: 89  
 : CORRESPONDENCE ADDRESS:  
 : ADDRESS: Carella, Byrne, Harris, Williams  
 : ADDRESS: Carella & Stewart  
 : STREET: 6 Becker Farm Road  
 : CITY: Roseland  
 : STATE: New Jersey  
 : COUNTRY: USA  
 : ZIP: 07068  
 : COMPUTER READABLE FORM:  
 : MEDIUM TYPE: 3.5 inch diskette  
 : COMPUTER: IBM PS/2  
 : OPERATING SYSTEM: PC-DOS  
 : SOFTWARE: USA V2  
 : CURRENT APPLICATION DATA:  
 : APPLICATION NUMBER: US 07686115  
 : FILING DATE: 15-APR-1991  
 : APPLICATION NUMBER: US 07176629  
 : FILING DATE: 08-FEB-1990  
 : ATTORNEY/AGENT INFORMATION:  
 : NAME: Elliott, Elliot M.  
 : REGISTRATION NUMBER: 24,025  
 : REFERENCE/INFORMATION NUMBER: 421250-122  
 : TELEPHONE: 201-994-1700  
 : TELEFAX: 201-994-1744  
 : INFORMATION FOR SEQ ID NO: 6:  
 : SEQUENCE CHARACTERISTICS:  
 : LENGTH: 21 amino acids  
 : TYPE: AMINO ACID  
 : STRANDEDNESS:  
 : TOPOLOGY: Linear  
 : MOLECULE TYPE: Peptide  
 : FEATURE:  
 : OTHER INFORMATION: amide-terminated  
 US-07-908-455A-6

28 40 60.6 21 1 US-08-434-120-42  
 29 40 60.6 21 1 US-08-465-425-44  
 30 40 60.6 21 4 US-09-115-737-32  
 31 39 59.1 22 4 US-08-752-526-4  
 32 39 59.1 23 1 US-08-241-730A-39  
 33 39 59.1 23 2 US-08-505-486-44  
 34 39 59.1 23 3 US-08-689-489C-39  
 35 39 59.1 23 3 US-08-801-028-44  
 36 39 59.1 23 3 US-09-340-154-44  
 37 39 59.1 23 4 US-09-242-902A-39  
 38 39 59.1 23 4 US-09-482-611B-44  
 39 39 59.1 23 5 PCI-US94-12550-47  
 40 39 59.1 23 5 PCI-US95-04335-39  
 41 39 59.1 23 5 PCI-US95-04718-39  
 42 38 57.6 14 1 US-08-242-902A-39  
 43 38 57.6 14 1 US-08-443-133-39  
 44 38 57.6 21 1 US-07-908-455A-6  
 45 38 57.6 21 1 US-08-434-120-42

## ALIGNMENTS

```

Query Match: 77.8%; Score 51; DB 1; Length 21;
Best Local Similarity: 85.7%; Pref. Rs. 0.2;
Matches 12; Conservative 1; Mismatches 1; Gaps 0;

QY 2 AKAKALKALKAL 16
DB 4 SKAKALKALKAL 17

RESULT 2
US 08 444 120 42
Sequence 42, Application US/08444120
Patent No. 5665479
GENERAL INFORMATION:
APPLICANT: Baker, Margaret A.
APPLICANT: Jacob, Leonard S.
APPLICANT: Maloy, W. Lee
TITLE OF INVENTION: Treatment of Gynecological
TITLE OF INVENTION: Malignancies with
TITLE OF INVENTION: Biologically Active Peptides
NUMBER OF SEQUENCES: 117
CORRESPONDENCE ADDRESS:
ADDRESS: Carroll, Byron, Patel, Gillillan,
ADDRESS: Cecchi & Stewart
STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: USA
ZIP: 07068
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: DW4.V2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/297,950
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/297,950
FILING DATE:
APPLICATION NUMBER: US/08/226,108
FILING DATE:
APPLICATION NUMBER: US/07/947,462
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Gustin, Elliot M.
REGISTRATION NUMBER: 24,026
REFERENCE/DEPOSIT NUMBER: 13,000,004
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-954-1700
TELEFAX: 201-994-1744
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US 08 444 120 42

Query Match: 77.8%; Score 51; DB 1; Length 21;
Best Local Similarity: 85.7%; Pref. Rs. 0.2;
Matches 12; Conservative 1; Mismatches 1; Gaps 0;

QY 2 AKAKALKALKAL 16
DB 4 SKAKALKALKAL 17

RESULT 3
US-08-465-425 42

```

```

Sequence 42, Application US/08465425
Patent No. 5665563
GENERAL INFORMATION:
APPLICANT: MarinBio Pharmaceuticals Inc.
APPLICANT: Clio Campus Drive
APPLICANT: Plymouth Meeting, PA 19462
TITLE OF INVENTION: Biologically Active Peptides
TITLE OF INVENTION: Biologically Active Peptides
NUMBER OF SEQUENCES: 134
CORRESPONDENCE ADDRESS:
ADDRESS: Finnstrom, Henderson, Paradows, Karmaliy
ADDRESS: Finnstrom
STREET: 1400 1st Street, N.W. Suite 200
CITY: Washington
STATE: D.C.
ZIP: 20005 3415
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/465,425
FILING DATE: 05 JUN 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/184,414
FILING DATE: 18 JAN 94
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/994,201
FILING DATE: 01 JUN 92
ATTORNEY/AGENT INFORMATION:
NAME: Foidis, David W.
REGISTRATION NUMBER: 52,994
REFERENCE/DEPOSIT NUMBER: 05,000,000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 408-4000
TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US 08 465-425 42

Query Match: 77.8%; Score 51; DB 1; Length 21;
Best Local Similarity: 85.7%; Pref. Rs. 0.2;
Matches 12; Conservative 1; Mismatches 1; Gaps 0;

QY 2 AKAKALKALKAL 16
DB 4 SKAKALKALKAL 17

RESULT 4
US 09 115 747 42
Sequence 42, Application US/09115742
Patent No. 6,694,445
GENERAL INFORMATION:
APPLICANT: Dr. Prasad Kati
APPLICANT: Dr. J. Williams
APPLICANT: Michael Melano
TITLE OF INVENTION: Biologically Active Peptides
TITLE OF INVENTION: Biologically Active Peptides
NUMBER OF SEQUENCES: 136
CORRESPONDENCE ADDRESS:
ADDRESS: Finnstrom, Henderson, Paradows, Karmaliy
ADDRESS: Finnstrom
STREET: 1400 1st Street, N.W. Suite 200
CITY: Washington
STATE: D.C.

```

us-09-820-053a-43.ra1

Thu Aug 21 08:36:29 2003

```

1  COUNTRY: USA
2  ZIP: 20005-3415
3  COMPUTER READABLE FORM:
4  MEDIUM TYPE: Floppy disk
5  OPERATING SYSTEM: PC-DOS/MS-DOS
6  SOFTWARE: Patulin Release
7  CURRENT APPLICATION NUMBER: US/09/115,737
8  FILING DATE: 15-JUL-1998
9  CLASSIFICATION: <Unknown>
10 PRIOR APPLICATION DATA:
11 APPLICATION NUMBER: 03/465,330
12 FILING DATE: 05-JUN-1995
13 APPLICATION NUMBER: 08/184,462
14 FILING DATE: 18-JAN-94
15 APPLICATION NUMBER: 07/891,201
16 FILING DATE: 01-JUN-92
17 ATTORNEY/AGENT INFORMATION:
18 NAME: Fordis, Jean B
19 REGISTRATION NUMBER: 32,984
20 REFERENCE/SEQUENCE NUMBER: 05387 0021-06000
21 TELECOMMUNICATION INFORMATION:
22 TELEPHONE: (202) 408-4000
23 TELEFAX: (202) 408-4400
24 INFORMATION FOR SEQ ID NO: 32:
25 SEQUENCE CHARACTERISTICS:
26 LENGTH: 21 amino acids
27 TYPE: amino acid
28 TOPOLOGY: Linear
29 MOLECULE TYPE: peptide
30 SEQUENCE DESCRIPTION: SEQ ID NO: 32:
31
32 US-09-115-737-42
33
34 Query Match: 77.3%; Score 51; DB 4; Length 21;
35 Best Local Similarity: 85.7%; Pred. No. 0.2;
36 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
37
38 QY 2 AKALKALKALKAL 15
39 DB :||||| |||||
40 4 SKALKALKALKAL 17
41
42 RESULT 5
43 US-08-944-133-43
44 Sequence 16; Application US/08944133
45 Patent No. 5789542
46 GENERAL INFORMATION:
47 APPLICANT: McLaughlin, Mark L
48 APPLICANT: Becker, Calvin L
49 TITLE OF INVENTION: Amphipathic Peptides
50 NUMBER OF SEQUENCES: 54
51 CORRESPONDENCE ADDRESS:
52 ADDRESSEE: John H. Rannels
53 STREET: P. O. Box 2471
54 CITY: Baton Rouge
55 STATE: LA
56 COUNTRY: USA
57 ZIP: 70821-2471
58 COMPUTER READABLE FORM:
59 MEDIUM TYPE: Floppy disk
60 COMPUTER: IBM PC compatible
61 OPERATING SYSTEM: PC-DOS/MS-DOS
62 SOFTWARE: Patent Release #1.0, Version #1.15
63 CURRENT APPLICATION DATA:
64 APPLICATION NUMBER: US/08/944,133
65 FILING DATE: 06-OCT-1997
66 CLASSIFICATION: 5540
67 PRIOR APPLICATION DATA:
68 APPLICATION NUMBER: 08/789,077
69 FILING DATE: 03-FEB-1997
70 APPLICATION NUMBER: US/08/681,075
71 FILING DATE:
72 APPLICATION NUMBER: US/08/242,545
73 FILING DATE: 22-APR-1994
74 ATTORNEY/AGENT INFORMATION:
75 NAME: Rannels, John H
76 REGISTRATION NUMBER: 34451
77 REFERENCE/SEQUENCE NUMBER: ATTY File No. 5789542 0411
78 TELECOMMUNICATION INFORMATION:
79 TELEPHONE: 504 387-4221
80 TELEFAX: 504 346-8049
81 INFORMATION FOR SEQ ID NO: 34
82 SEQUENCE CHARACTERISTICS:
83 LENGTH: 14 amino acids
84 TYPE: amino acid
85 STRANDEDNESS: Single
86 TOPOLOGY: Linear
87 MOLECULE TYPE: peptide
88
89 US-08-944-133-16
90 Query Match: 75.8%; Score 50; DB 1; Length 14
91 Best Local Similarity: 92.8%; Pred. No. 0.19;
92 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
93
94 QY 3 KALKALKALKAL 15
95 DB :||||| |||||
96 1 KALKALKALKAL 14
97
98 RESULT 6
99 US-08-944-133-43
100 Sequence 33; Application US/08944133
101 Patent No. 5789542
102 GENERAL INFORMATION:
103 APPLICANT: McLaughlin, Mark L
104 APPLICANT: Becker, Calvin L
105 TITLE OF INVENTION: Amphipathic Peptides
106 NUMBER OF SEQUENCES: 54
107 CORRESPONDENCE ADDRESS:
108 ADDRESSEE: John H. Rannels
109 STREET: P. O. Box 2471
110 CITY: Baton Rouge
111 STATE: LA
112 COUNTRY: USA
113 ZIP: 70821-2471
114 COMPUTER READABLE FORM:
115 MEDIUM TYPE: Floppy disk
116 COMPUTER: IBM PC compatible
117 OPERATING SYSTEM: PC-DOS/MS-DOS
118 SOFTWARE: Patent Release #1.0, Version #1.15
119 CURRENT APPLICATION DATA:
120 APPLICATION NUMBER: US/08/944,133
121 FILING DATE: 06-OCT-1997
122 CLASSIFICATION: 5540
123 PRIOR APPLICATION DATA:
124 APPLICATION NUMBER: 08/789,077
125 FILING DATE: 03-FEB-1997
126 APPLICATION NUMBER: US/08/681,075
127 FILING DATE:
128 APPLICATION NUMBER: US/08/242,545
129 FILING DATE: 22-APR-1994
130 ATTORNEY/AGENT INFORMATION:
131 NAME: Rannels, John H
132 REGISTRATION NUMBER: 34451
133 REFERENCE/SEQUENCE NUMBER: ATTY File No. 5789542 0411
134 TELECOMMUNICATION INFORMATION:
135 TELEPHONE: 504 387-4221
136 TELEFAX: 504 346-8049
137 INFORMATION FOR SEQ ID NO: 34
138 SEQUENCE CHARACTERISTICS:
139 LENGTH: 14 amino acids
140 TYPE: amino acid
141 STRANDEDNESS: Single
142 TOPOLOGY: Linear
143 MOLECULE TYPE: peptide

```

US-08-944-133 43

Query Match 75.8%; Score 50; DB 1; Length 14;  
 Best Local Similarity 92.3%; Pref. No. 0.19;  
 Matches 12; Conservatv 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 KALKALKALKAL 15  
 11111 11111  
 DB 2 KALKALKALKAL 14

RESULT 7

US-08-944-133 17  
 Sequence 17; Application US/08944133  
 Patent No. 5789542

GENERAL INFORMATION:  
 APPLICANT: McLaughlin, Mark L.  
 APPLICANT: Becker, Calvin L.  
 TITLE OF INVENTION: Amphipathic Peptides  
 NUMBER OF SEQUENCES: 54

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: John H. Rummels

STREET: P. O. Box 2471

CITY: Baton Rouge

STATE: LA

COUNTRY: USA

ZIP: 70821 2471

COMPUTER PEAKABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compat file

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent In Release #1.0, Version #1.26

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/38/344,133

FILING DATE: 06 OCT 1997

CLASSIFICATION: 5540

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/789,077

FILING DATE: 03 FEB 1997

APPLICATION NUMBER: 02/38/9681,076

FILING DATE:

APPLICATION NUMBER: US/38/242,525

FILING DATE: 22 APR 1994

ATTORNEY/AGENT INFORMATION:

NAME: Rummels, John H

REGISTRATION NUMBER: 33451

REFERENCE/PACKET INFORMATION:

TELEPHONE: 504 387-3221

TELEFAX: 504 387-3221

INFORMATION FOR SEQ ID NO: 17:

SEQUENCE CHARACTERISTICS:

LENGTH: 21 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-944-133 17

RESULT 8

US-08-944-133 40  
 Sequence 30; Application US/08944133  
 Patent No. 5789542

GENERAL INFORMATION:

APPLICANT: McLaughlin, Mark L.

APPLICANT: Becker, Calvin L.

TITLE OF INVENTION: Amphipathic Peptides

NUMBER OF SEQUENCES: 54

CORRESPONDENCE ADDRESS:

ADDRESSEE: John H. Rummels

STREET: P. O. Box 2471

CITY: Baton Rouge

STATE: LA

COUNTRY: USA

ZIP: 70821 2471

COMPUTER PEAKABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compat file

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent In Release #1.0, Version #1.26

CURRENT APPLICATION DATA:

APPLICATION NUMBER: 08/789,077

FILING DATE: 03 FEB 1997

APPLICATION NUMBER: US/38/9681,076

FILING DATE:

APPLICATION NUMBER: 02/38/9681,076

FILING DATE: 22 APR 1994

ATTORNEY/AGENT INFORMATION:

NAME: Rummels, John H

REGISTRATION NUMBER: 33451

REFERENCE/PACKET INFORMATION:

TELEPHONE: 504 387-3221

TELEFAX: 504 387-3221

INFORMATION FOR SEQ ID NO: 40:

SEQUENCE CHARACTERISTICS:

LENGTH: 21 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-944-133 40

Query Match

Best Local Similarity

Matches 12; Conservatv 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 KALKALKALKAL 15

11111 11111

DB 5 KALKALKALKAL 17

RESULT 9

US-08-944-133 44  
 Sequence 44; Application US/08944133  
 Patent No. 5789542

GENERAL INFORMATION:

APPLICANT: McLaughlin, Mark L

APPLICANT: Becker, Calvin L

TITLE OF INVENTION: Amphipathic Peptides

NUMBER OF SEQUENCES: 54

CORRESPONDENCE ADDRESS:

ADDRESSEE: John H. Rummels

STREET: P. O. Box 2471

CITY: Baton Rouge

STATE: LA

COUNTRY: USA

ZIP: 70821 2471

COMPUTER PEAKABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compat file

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent In Release #1.0, Version #1.26



us-09-820-053a-43.ra1

Thu Aug 21 08:36:29 2003

```

1 CURRENT APPLICATION DATA:
2 APPLICATION NUMBER: 08/08/081,075
3 FILING DATE: 06-OCT-1997
4 CLASSIFICATION: 5530
5 PRIOR APPLICATION DATA:
6 APPLICATION NUMBER: 08/789,077
7 FILING DATE: 03-FEB-1997
8 APPLICATION NUMBER: US/08/081,075
9 FILING DATE:
10 APPLICATION NUMBER: US/08/212,525
11 FILING DATE: 22-APR-1994
12 ATTORNEY/AGENT INFORMATION:
13 NAME: Runnels, John B
14 REGISTRATION NUMBER: 33451
15 REFERENCE/SEQUENCE NUMBER: 5789542 9301
16 TELECOMMUNICATION INFORMATION:
17 TELEPHONE: 504 387 3221
18 TELEFAX: 504 346-8049
19 INFORMATION FOR SEQ ID NO: 44:
20 SEQUENCE CHARACTERISTICS:
21 LENGTH: 21 amino acids
22 TYPE: amino acid
23 STRANDEDNESS: single
24 TOPOLOGY: linear
25 MOLECULE TYPE: peptide
26 US 08-944-133-44

Query Match 75.8% Score 50: DB 1: Length 21:
Best Local Similarity 92.3% Pred. No. 0.28:
Matches 12: Conservative 0: Mismatches 1: Indels 0: Gaps 0:

QY 3 KALKALKALKAL 15
DB 2 KALKALKALKAL 14

RESULT 10
US-08-241-740A-49
1 Sequence 49: Application US/08241740A
2 Patent No. 5561107
3 GENERAL INFORMATION:
4 APPLICANT: JAYNES, JESSE M.
5 APPLICANT: JULIAN, GORDON R.
6 TITLE OF INVENTION: METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST AN
7 CORRESPONDENCE ADDRESS:
8 ADDRESS: STEVEN J. HULTQUIST
9 ADDRESS: INTELLECTUAL PROPERTY/TECHNOLOGY LAW
10 STREET: 200 PARK DRIVE, SUITE 210
11 STREET: P.O. BOX 14329
12 CITY: RESEARCH TRIANGLE PARK
13 STATE: NORTH CAROLINA
14 COUNTRY: USA
15 ZIP: 27709
16 COMPUTER READABLE FORM:
17 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
18 COMPUTER: APPLE MACINTOSH
19 OPERATING SYSTEM: MACINTOSH
20 SOFTWARE: M.S. WORD 5.0
21 CURRENT APPLICATION DATA:
22 APPLICATION NUMBER: US/08/251,740A
23 FILING DATE: 04-20-94
24 PRIOR APPLICATION DATA:
25 APPLICATION NUMBER: 08/225,476
26 FILING DATE: 04-08-94
27 APPLICATION NUMBER: 08/039,620
28 FILING DATE: 06-04-93
29 APPLICATION NUMBER: 08/148,491
30 FILING DATE: 11-08-93
31 APPLICATION NUMBER: 08/148,889
32 FILING DATE: 11-08-93
33 ATTORNEY/AGENT INFORMATION:
34 NAME: HULTQUIST, STEVEN J.

1 REGISTRATION NUMBER: 28021
2 REFERENCE/SEQUENCE NUMBER: 4313-106
3 TELECOMMUNICATION INFORMATION:
4 TELEPHONE: (919)990-9541
5 TELEFAX: (919)990-9542
6 INFORMATION FOR SEQ ID NO: 49:
7 SEQUENCE CHARACTERISTICS:
8 LENGTH: 23
9 TYPE: AMINO ACID
10 TOPOLOGY: LINEAR
11 MOLECULE TYPE: PEPTIDE
12 DESCRIPTION: NO
13 HYPOTHEICAL: NO
14 FRAGMENT TYPE: COMPLETE PEPTIDE
15 ORIGINAL SOURCE: SYNTHETIC
16 IMMEDIATE SOURCE: SYNTHETIC
17 PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
18 US-08-241-740A-49

Query Match 72.7% Score 48: DB 1: Length 23:
Best Local Similarity 80.0% Pred. No. 0.68:
Matches 12: Conservative 0: Mismatches 4: Indels 0: Gaps 0:

QY 1 FAKALKALKALKAL 15
DB 1 FALKALKALKALKAL 15

RESULT 11
US-08-427-001C-44
1 Sequence 44: Application US/38427001C
2 Patent No. 5717064
3 GENERAL INFORMATION:
4 APPLICANT: JULIAN, GORDON R.
5 TITLE OF INVENTION: METHYLATED LYSINE-RICH LYLLIN PEPTIDES.
6 TITLE OF INVENTION: AMB. RELE.
7 NUMBER OF SEQUENCES: 48
8 CORRESPONDENCE ADDRESS:
9 ADDRESSEE: ROTHWELL, FLOD, ERNST & KURZ
10 STREET: 565 THIRTEENTH STREET, N.W.
11 CITY: Washington
12 STATE: D.C.
13 COUNTRY: USA
14 ZIP: 20004
15 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
16 COMPUTER: IBM COMPATIBLE
17 OPERATING SYSTEM: DOS
18 SOFTWARE: WordPerfect
19 CURRENT APPLICATION DATA:
20 APPLICATION NUMBER: US/38/427,001C
21 FILING DATE: 24-APR-95
22 CLASSIFICATION: 530
23 PRIOR APPLICATION DATA:
24 APPLICATION NUMBER: U.S. 08/148,889
25 FILING DATE: 08-NOV-93
26 CLASSIFICATION: 530
27 ATTORNEY/AGENT INFORMATION:
28 NAME: WALKER, BARBARA W.
29 REGISTRATION NUMBER: 35,400
30 REFERENCE/SEQUENCE NUMBER: 2093 105A
31 TELECOMMUNICATION INFORMATION:
32 TELEPHONE: (202)783 6040
33 TELEFAX: (202)783-6041
34 INFORMATION FOR SEQ ID NO: 44:
35 SEQUENCE CHARACTERISTICS:
36 LENGTH: 23
37 TYPE: AMINO ACID
38 TOPOLOGY: LINEAR
39 MOLECULE TYPE: PEPTIDE
40 US-08-427-001C-44

Query Match 72.7% Score 48: DB 1: Length 23:

```



```

? COMPUTER: IBM COMPATIBLE
? OPERATING SYSTEM: DOS
? SOFTWARE: WORDPAC 5.1.1
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: 08/279,460
? FILING DATE: 21-JUL-1995
? CLASSIFICATION: 536
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/279,472
? FILING DATE: 22-JUL-1994
? CLASSIFICATION: 536
? ATTORNEY/AGENT INFORMATION:
? NAME: WALKER, BARBARA W.
? REGISTRATION NUMBER: 45,400
? REFERENCE/DOCKET NUMBER: 2093-117A
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (202)783-6040
? TELEFAX: (202)783-6031
? INFORMATION FOR SEQ ID NO: 44:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 23
? TYPE: AMINO ACID
? TOPOLOGY: LINEAR
? MOLECULE TYPE: PEPTIDE
? DESCRIPTION: PEPTIDE
? HYPOTHEICAL: NO
? FRAGMENT TYPE: COMPLETE PEPTIDE
? ORIGINAL SOURCE: SYNTHETIC
? IMMEDIATE SOURCE: SYNTHETIC
? PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US 08-505-486-44

```

```

Query Match 72.7% Score 48 DB 2 Length 23;
Best Local Similarity 80.0% Pred. No. 0.58;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 1 FAKALFAKAKAL 15
DB 1 FAKALFAKAKAL 15

```

```

RESULT 15
US-08-689-489C-49
? Sequence 49, Application US/08689489C
? Patent No. 6001805
? GENERAL INFORMATION:
? APPLICANT: JESSE M. JAYNES, Gordon R. Julian
? TITLE OF INVENTION: Method of Enhancing Wound Healing By
? TITLE OF INVENTION: Stimulating Fibroblast and Keratinocyte Growth in
? TITLE OF INVENTION: Vivo, Utilizing Amphipathic Peptides
? NUMBER OF SEQUENCES: 46
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: KOTHOWITZ, FIRM, Ernst & Kurz
? STREET: 555 14TH STREET
? CITY: Washington
? STATE: DC
? COUNTRY: USA
? ZIP: 20004
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC DOS/MS-DOS
? SOFTWARE: Patent in Release #1.0, Version #1.30
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/689,489C
? FILING DATE: August 12, 1996
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/231,730
? FILING DATE: April 20, 1994
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/235,476
? FILING DATE: April 8, 1994
? PRIOR APPLICATION DATA:

```

```

? APPLICATION NUMBER: US 08/049,620
? FILING DATE: June 4, 1994
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 08/148,889
? FILING DATE: No. 6001805, dated 8, 1994
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 08/148,491
? FILING DATE: No. 6001805, dated 8, 1994
? ATTORNEY/AGENT INFORMATION:
? NAME: MARK T. BOWDITCH
? REGISTRATION NUMBER: 40,415
? REFERENCE/DOCKET NUMBER: 2094-120
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: 202-784-6040
? TELEFAX: 202-783-6031
? INFORMATION FOR SEQ ID NO: 39:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 24 amino acids
? TYPE: amino acid
? STRANDEDNESS:
? TOPOLOGY: Linear
? MOLECULE TYPE: peptide
? HYPOTHEICAL: NO
? FRAGMENT TYPE: Linear
US-08-689-489C-39

```

```

Query Match 72.7% Score 48 DB 3 Length 24;
Best Local Similarity 80.0% Pred. No. 0.58;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 1 FAKALFAKAKAL 15
DB 1 FAKALFAKAKAL 15

```

```

RESULT 16
US-08-801-028-44
? Sequence 44, Application US/08801028
? Patent No. 6016102
? GENERAL INFORMATION:
? APPLICANT: JUAN GARRARINO
? APPLICANT: JESSE M. JAYNES
? TITLE OF INVENTION: URQUETIN LYTIC PEPTIDE FOR NON-GENE-EXPRESSION IN CELLS
? NUMBER OF SEQUENCES: 98
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: STEVEN J. BOLTQUEST
? ADDRESSEE: INTELLECTUAL PROPERTY/TECHNOLOGY LAW
? STREET: 200 PARK DRIVE, SUITE 210
? STREET: P.O. BOX 14329
? CITY: RESEARCH TRIANGLE PARK
? STATE: NORTH CAROLINA
? COUNTRY: USA
? ZIP: 27709
? COMPUTER READABLE FORM:
? MEDIUM TYPE: DISKETTE, 3.5 INCH 1.4 MB STORAGE
? COMPUTER: APPLE MACINTOSH
? OPERATING SYSTEM: MACINTOSH
? SOFTWARE: M.S. WORD 5.0
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: 08/238,301,028
? FILING DATE: 19-FEB-1997
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 08/279,472
? FILING DATE: JULY 22, 1994
? APPLICATION NUMBER: 08/235,476
? FILING DATE: 04-20-94
? APPLICATION NUMBER: 08/235,476
? FILING DATE: 04-08-94
? APPLICATION NUMBER: 08/039,620
? FILING DATE: 06-04-94
? APPLICATION NUMBER: 08/148,491
? FILING DATE: 11-08-94

```



```

? FRAGMENT TYPE: LINEAR
? SEQUENCE DESCRIPTION: SEQ ID NO: 39;
US-09-242-602A-39

Query Match
Best Local Similarity 80.0%; Score 48; DB 3; Length 23;
Matches 12; Conservatives 0; Mismatches 0; Gaps 0;

QY 1 FAKALKALKALKAL 15
DB 1 FALAKALKALKALKAL 15

RESULT 19
US-09-482-611R-44
? Sequence 44, Application US/09482611R
? Patent No. 644861
? GENERAL INFORMATION:
? APPLICANT: Belknap, Joan
? TITLE OF INVENTION: Ubiquitin-Lytic Peptide Fusion Gene Constructs, Protein Products
? FILE REFERENCE: 2093-149
? CURRENT FILING DATE: 2000-01-14
? PRIOR APPLICATION NUMBER: US 08/801,028
? PRIOR FILING DATE: 1997-02-19
? PRIOR APPLICATION NUMBER: 95-082076-473
? PRIOR FILING DATE: 1994-07-22
? NUMBER OF SEQ ID NOS: 102
? SOFTWARE: Patent in version 3.1
? SEQ ID NO: 44
? LENGTH: 23
? TYPE: PEPTIDE
? ORGANISM: Artificial Sequence
? OTHER INFORMATION: Lytic Peptide
US-09-482-611R-44

Query Match
Best Local Similarity 80.0%; Score 48; DB 4; Length 23;
Matches 12; Conservatives 0; Mismatches 0; Gaps 0;

QY 1 FAKALKALKALKAL 15
DB 1 FALAKALKALKALKAL 15

RESULT 20
US-09-019-922A-44
? Sequence 44, Application US/09019922A
? Patent No. 6559281
? GENERAL INFORMATION:
? APPLICANT: JAYNES, JESSE M.
? TITLE OF INVENTION: NON-NATURALLY OCCURRING SYNTHETIC LYTIC
? FILE REFERENCE: 45
? NUMBER OF SEQUENCES: 45
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: ROTHWELL, FIGG, ERNST & MANHECK
? STREET: 555 Thirteenth Street, N.W.
? CITY: Washington
? STATE: D.C.
? COUNTRY: USA
? ZIP: 20004
? COMPUTER READABLE FORM:
? MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
? COMPUTER: IBM COMPATIBLE
? OPERATING SYSTEM: DOS
? SOFTWARE: Wordpad
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US-09-019-922A
? FILING DATE: 06-FEB-98
? CLASSIFICATION:

```

```

? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: U.S.08/427,001
? FILING DATE: 24-APR-95
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: U.S.08/148,000
? FILING DATE: 08-NOV-94
? ATTORNEY/AGENT INFORMATION:
? NAME: BOWDITCH, MARK L.
? REGISTRATION NUMBER: 40,415
? REFERENCE/EXCERPT NUMBER: 2093-149A
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (202)783-6040
? TELEFAX: (202)783-6041
? INFORMATION FOR SEQ ID NO: 44:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 23
? TYPE: AMINO ACID
? TOPOLOGY: LINEAR
? MOLECULE TYPE: PEPTIDE
US-09-019-922A-44

Query Match
Best Local Similarity 80.0%; Score 48; DB 4; Length 23;
Matches 12; Conservatives 0; Mismatches 0; Gaps 0;

QY 1 FAKALKALKALKAL 15
DB 1 FALAKALKALKALKAL 15

RESULT 21
PCT US94-12550-47
? Sequence 47, Application PCT/US9412550
? GENERAL INFORMATION:
? APPLICANT: JULIAN, GORDON R.
? TITLE OF INVENTION: METHYLATED LYSINE RICH LYTIC
? FILE REFERENCE: PEPTIDES AND METHOD OF
? TITLE OF INVENTION: MAKING SAME BY REDUCTIVE
? NUMBER OF SEQUENCES: 47
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: STEVEN J. HOLLQUIST
? STREET: 200 PARK DRIVE, SUITE 210
? CITY: RESEARCH TRIANGLE PARK
? STATE: NORTH CAROLINA
? COUNTRY: USA
? ZIP: 27709
? COMPUTER READABLE FORM:
? MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
? COMPUTER: APPLE MACINTOSH
? OPERATING SYSTEM: MACINTOSH
? SOFTWARE: M.S. WORD 5.0
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: PCT/US94/12550
? FILING DATE: NOVEMBER 8, 1994
? PRIOR APPLICATION DATA: NONE
? ATTORNEY/AGENT INFORMATION:
? NAME: HOLLQUIST, STEVEN J.
? REGISTRATION NUMBER: 28021
? REFERENCE/EXCERPT NUMBER: 4013-101
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (919)990-9541
? TELEFAX: (919)990-9542
? INFORMATION FOR SEQ ID NO: 47:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 23
? TYPE: AMINO ACID
? TOPOLOGY: LINEAR
? MOLECULE TYPE: PEPTIDE
? DESCRIPTION: PEPTIDE
? HYPOTHETICAL: NO

```



```

1 PRIOR APPLICATION DATA: 08/279,472
2 APPLICATION NUMBER: 08/279,472
3 FILING DATE: 22-JUL-1994
4 INFORMATION FOR SEQ ID NO: 44:
5 SEQUENCE CHARACTERISTICS:
6 LENGTH: 23
7 TYPE: AMINO ACID
8 TOPOLOGY: LINEAR
9 MOLECULE TYPE: PEPTIDE
10 DESCRIPTION: NO
11 HYDROPHILIC: NO
12 FRAGMENT TYPE: COMPLETE PEPTIDE
13 ORIGINAL SOURCE: SYNTHETIC
14 IMMEDIATE SOURCE: SYNTHETIC
15 PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
16 PCT-US95-09439-44

```

```

Query Match 72.7% Score 48: DB 5: Length 23:
Best Local Similarity 80.0% Pred. No. 0.58:
Matches 12: Conservative 0: Mismatches 3: Indels 0: Gaps 0:

```

```

QY 1 FAKALKALKALKAL 15
11 11111111111
DB 1 FALAKALKALKALKL 15

```

```

1 RESULT 25
2 PCT-US95-09439-44
3 SEQUENCE 44: Application PCT/US95/09439
4 GENERAL INFORMATION:
5 APPLICANT:
6 TITLE OF INVENTION: UNQUILIN-LYLIC PEPTIDE FUSION GENE
7 TITLE OF INVENTION: CONSTRUCTS, PROTEIN PRODUCTS DERIVING THEREFROM, AND
8 TITLE OF INVENTION: METHODS OF MAKING AND USING THE SAME
9 NUMBER OF SEQUENCES: 98
10 COMPUTER READABLE FORM:
11 MEDIUM TYPE: FLOPPY disk
12 OPERATING SYSTEM: IBM PC compatible
13 SOFTWARE: WORDPERFECT 5.1
14 CURRENT APPLICATION DATA:
15 APPLICATION NUMBER: PCT/US95/09339
16 FILING DATE: 21-JUL-1994
17 PRIOR APPLICATION DATA:
18 APPLICATION NUMBER: 08/279,472
19 FILING DATE: 22-JUL-1994
20 INFORMATION FOR SEQ ID NO: 44:
21 SEQUENCE CHARACTERISTICS:
22 LENGTH: 23
23 TYPE: AMINO ACID
24 TOPOLOGY: LINEAR
25 MOLECULE TYPE: PEPTIDE
26 DESCRIPTION: NO
27 FRAGMENT TYPE: COMPLETE PEPTIDE
28 ORIGINAL SOURCE: SYNTHETIC
29 IMMEDIATE SOURCE: SYNTHETIC
30 PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
31 PCT-US95-09439-44

```

```

Query Match 72.7% Score 48: DB 5: Length 23:
Best Local Similarity 80.0% Pred. No. 0.58:
Matches 12: Conservative 0: Mismatches 3: Indels 0: Gaps 0:

```

```

QY 1 FAKALKALKALKAL 15
11 11111111111
DB 1 FALAKALKALKALKL 15

```

```

1 RESULT 26
2 PCT-US96-10041-19
3 SEQUENCE 19: Application PCT/US96/10041

```

```

1 GENERAL INFORMATION:
2 APPLICANT: WHITE PHD, Kenneth
3 APPLICANT: MORRY PHD, John
4 APPLICANT: ROAL, William
5 TITLE OF INVENTION: Casette for Expression of 1919
6 TITLE OF INVENTION: Peptides in Mammalian Transgenic Sequences
7 NUMBER OF SEQUENCES: 42
8 CORRESPONDENCE ADDRESS:
9 ADDRESSEE: Frank Reiff and Rossa
10 STREET: P.O. Box 2550
11 CITY: Salt Lake City
12 STATE: Utah
13 COUNTRY: USA
14 ZIP: 84110
15 COMPUTER READABLE FORM:
16 MEDIUM TYPE: Floppy disk
17 COMPUTER: IBM PC compatible
18 OPERATING SYSTEM: PC-DOS/MS-DOS
19 SOFTWARE: Patent in Release #1.0, Version #1.0
20 CURRENT APPLICATION DATA:
21 APPLICATION NUMBER: PCT/US96/10041
22 FILING DATE:
23 CLASSIFICATION:
24 ATTORNEY/AGENT INFORMATION:
25 NAME: Swigart PHD, Susan E
26 REGISTRATION NUMBER: 46,299
27 REFERENCE/DOCKET NUMBER: 2549
28 TELECOMMUNICATION INFORMATION:
29 TELEPHONE: 8015321922
30 TELEFAX: 8015349168
31 INFORMATION FOR SEQ ID NO: 19:
32 SEQUENCE CHARACTERISTICS:
33 LENGTH: 24 amino acids
34 TYPE: amino acid
35 STANDARDNESS: not relevant
36 TOPOLOGY: not relevant
37 MOLECULE TYPE: peptide
38 HYPOTHETICAL: YES
39 ANTI-SENSE: NO
40 PCT-US96-10041-19

```

```

Query Match 72.7% Score 48: DB 5: Length 23:
Best Local Similarity 80.0% Pred. No. 0.58:
Matches 12: Conservative 0: Mismatches 3: Indels 0: Gaps 0:

```

```

QY 1 FAKALKALKALKAL 15
11 11111111111
DB 1 FALAKALKALKALKL 15

```

```

1 RESULT 27
2 US-07-908-455A 8
3 SEQUENCE 8: Application US/07908455A
4 PATENT NO. 5459237
5 GENERAL INFORMATION:
6 APPLICANT: Bickwell, Barry A.
7 APPLICANT: Kari, D. Prasad
8 TITLE OF INVENTION: NO. 5459237a) Peptide Compositions and
9 TITLE OF INVENTION: Uses Thereof
10 NUMBER OF SEQUENCES: 69
11 CORRESPONDENCE ADDRESS:
12 ADDRESSEE: Catech, RYTHO, Bldg. 1111111111
13 STREET: Catech & Stewart
14 CITY: Roseland
15 STATE: New Jersey
16 COUNTRY: USA
17 ZIP: 07068
18 COMPUTER READABLE FORM:
19 MEDIUM TYPE: 3.5 inch diskette
20 COMPUTER: IBM PS/2
21 OPERATING SYSTEM: PC-DOS

```

```

3 SOFTWARE: DW4 V2
3 CURRENT APPLICATION DATA:
3 APPLICATION NUMBER: US/07/908,455A
3 FILING DATE: 19920702
3 CLASSIFICATION: 514
3 PRIOR APPLICATION DATA:
3 APPLICATION NUMBER: US 07686115
3 FILING DATE: 15 APR 1991
3 APPLICATION NUMBER: US 07476629
3 FILING DATE: 08 FEB 1990
3 ATTORNEY/AGENT INFORMATION:
3 NAME: Elstein, Elliot M.
3 REGISTRATION NUMBER: 24,025
3 REFERENCE/SEQUENCE NUMBER: 421,250-122
3 TELECOMMUNICATION INFORMATION:
3 TELEPHONE: 201-994-1700
3 TELEFAX: 201-994-1744
3 INFORMATION FOR SEQ ID NO: 8:
3 SEQUENCE CHARACTERISTICS:
3 LENGTH: 21 amino acids
3 TYPE: AMINO ACID
3 STRANDEDNESS:
3 TOPOLOGY: linear
3 MOLECULE TYPE: peptide
3 FEATURE:
3 OTHER INFORMATION: amide terminated
3
3 US 07-908 455A B
3
3 Query Match: 60.6%, Score 40, ID 1, Length 21:
3 Best Local Similarity: 61.5%, Prof. No. 7, 4:
3 Matches: 8; Conservative: 4; Mismatches: 1; Gaps: 0;
3
3 QY 3 KAIKAIKAIKAI 15
3 ID 5 KAIKAIKAIKAI 17
3
3 RESULT 28
3 US 08-444 120-44
3 Sequence 34, Application US/08/444,120
3 Patent No. 6666666
3 GENERAL INFORMATION:
3 APPLICANT: Baker, Margaret A.
3 APPLICANT: Jacob, Leonard S.
3 APPLICANT: Maloy, W. Lee
3 TITLE OF INVENTION: Treatment of Ophthalmological
3 TITLE OF INVENTION: Malignancies with
3 TITLE OF INVENTION: Biologically Active Peptides
3 NUMBER OF SEQUENCES: 117
3 CORRESPONDENCE ADDRESS:
3 ADDRESSEE: Carolina, Pyper, Bitt, Gilliland,
3 STREET: 6, Becker Farm Road
3 CITY: Roseland
3 STATE: New Jersey
3 COUNTRY: USA
3 ZIP: 07068
3 COMPUTER READABLE FORM:
3 MEDIUM TYPE: 3.5 inch diskette
3 OPERATING SYSTEM: PC-DOS
3 SOFTWARE: TW4 V2
3 CURRENT APPLICATION DATA:
3 APPLICATION NUMBER: US/08/444,120
3 FILING DATE:
3 CLASSIFICATION: 514
3 PRIOR APPLICATION DATA:
3 APPLICATION NUMBER: US/08/297,950
3 FILING DATE: US/08/297,950
3 FILING DATE: US/08/297,950
3 APPLICATION NUMBER: US/07/908,462
3 FILING DATE:

```

```

3 ATTORNEY/AGENT INFORMATION:
3 NAME: Elstein, Elliot M.
3 REGISTRATION NUMBER: 24,025
3 REFERENCE/SEQUENCE NUMBER: 421,250-122
3 TELECOMMUNICATION INFORMATION:
3 TELEPHONE: 201-994-1700
3 TELEFAX: 201-994-1744
3 INFORMATION FOR SEQ ID NO: 44:
3 SEQUENCE CHARACTERISTICS:
3 LENGTH: 21 amino acids
3 TYPE: amino acid
3 STRANDEDNESS:
3 TOPOLOGY: linear
3 MOLECULE TYPE: peptide
3
3 US 08-444 120-44
3
3 Query Match: 60.6%, Score 40, ID 1, Length 21:
3 Best Local Similarity: 61.5%, Prof. No. 7, 4:
3 Matches: 8; Conservative: 4; Mismatches: 1; Gaps: 0;
3
3 QY 3 KAIKAIKAIKAI 15
3 ID 5 KAIKAIKAIKAI 17
3
3 RESULT 29
3 US 08-465 425-44
3 Sequence 34, Application US/08/465,425
3 Patent No. 6666666
3 GENERAL INFORMATION:
3 APPLICANT: Maudlin Pharmaceuticals Inc.
3 APPLICANT: 5110 Campus Drive
3 APPLICANT: College Park, MD 20740
3 TITLE OF INVENTION: Biologically Active Peptides
3 TITLE OF INVENTION: Terminal Substitutions
3 NUMBER OF SEQUENCES: 154
3 CORRESPONDENCE ADDRESS:
3 ADDRESSEE: Maudlin Pharmaceuticals Inc.
3 STREET: 5110 Campus Drive
3 CITY: Washington
3 STATE: MD
3 COUNTRY: USA
3 ZIP: 20740
3 COMPUTER READABLE FORM:
3 MEDIUM TYPE: Floppy Disk
3 OPERATING SYSTEM: IBM PC compatible
3 SOFTWARE: Patent In Process #120, Volume 4, #1, 2
3 CURRENT APPLICATION DATA:
3 APPLICATION NUMBER: US/08/465,425
3 FILING DATE: 05 JUN 1999
3 CLASSIFICATION: 514
3 PRIOR APPLICATION DATA:
3 APPLICATION NUMBER: 09/184,407
3 FILING DATE: 18 JAN 94
3 PRIOR APPLICATION DATA:
3 APPLICATION NUMBER: 07/994,120
3 FILING DATE: 01 JUN 92
3 ATTORNEY/AGENT INFORMATION:
3 NAME: Fortis, John W.
3 REGISTRATION NUMBER: 51,064
3 REFERENCE/SEQUENCE NUMBER: 09/994,120
3 TELEPHONE: (202) 408-4400
3 TELEFAX: (202) 408-4400
3 INFORMATION FOR SEQ ID NO: 44:
3 SEQUENCE CHARACTERISTICS:
3 LENGTH: 21 amino acids
3 TYPE: amino acid
3 TOPOLOGY: linear
3 MOLECULE TYPE: peptide
3
3 US 08-465 425-44

```









QY 1 FAKALKALKALKAL 15  
 II III III  
 DB 1 FAIAKALKALKALKI 15

## RESULT 37

US 09 232 802A-42

Sequence 42, Application: US 09/00232802A  
 Patent No. 6191110  
 GENERAL INFORMATION:  
 APPLICANT: Jesse M. Jaynes, Gordon R. Julian  
 TITLE OF INVENTION: Method of Enhancing Wound Healing By  
 Stimulating Fibroblast and Keratinocyte Growth In  
 Vivo, Utilizing Amphipathic Peptides

NUMBER OF SEQUENCES: 46  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: RUTKOWSKI, FRANK & MARBECK  
 STREET: 555 14TH STREET  
 CITY: Washington  
 STATE: DC  
 COUNTRY: USA  
 ZIP: 20004

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC Compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: 09/00232802A

PRIOR APPLICATION DATA:  
 FILING DATE: 19-Jan-1999

APPLICATION NUMBER: 08/689,489

FILING DATE: August 12, 1996

APPLICATION NUMBER: 08/223,730

FILING DATE: April 20, 1994

APPLICATION NUMBER: 08/225,476

FILING DATE: April 8, 1994

APPLICATION NUMBER: 08/090,628

FILING DATE: June 4, 1994

APPLICATION NUMBER: 08/148,889

FILING DATE: Nov. 6, 1993

APPLICATION NUMBER: 08/148,491

FILING DATE: Nov. 6, 1993

ATTORNEY/AGENT INFORMATION:

NAME: Mark L. Bowditch

REGISTRATION NUMBER: 40,415

REFERENCE/WORK NUMBER: 2092 142

TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-783-6040

TELEFAX: 202-783-6041

INFORMATION FOR SEQ ID NO: 42:

SEQUENCE CHARACTERISTICS:

LENGTH: 23 amino acids

TYPE: amino acid

STRANDEDNESS: unknown

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: NO

FRAGMENT TYPE: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 42:

## Query Match

Best Local Similarity: 59.18; Score: 29; ID: 6; Length: 23;  
 Matches: 8; Conservative: 4; Mismatches: 4; Indels: 0; Gaps: 0;

QY 1 FAKALKALKALKAL 15

II III III

DB 1 FAIAKALKALKALKI 15

## RESULT 38

US 09 482-611B-47

Sequence 47, Application: US/09/0482611B

Patent No. 6448391

GENERAL INFORMATION:

APPLICANT: Garbath, William

TITLE OF INVENTION: Disruption of the

Titin of Invertebrate, The Titin, and Methods

File Reference: 2004 149

Current Application Number: US/09/0482611B

Current Filing Date: 2004 01 14

Prior Application Number: US 09/001,028

Prior Filing Date: 1997 02 19

Prior Application Number: US 09/001,028

Prior Filing Date: 1994 07 22

Number of Seq ID Nos: 102

Software: Patent version 4.3.1

Seq ID No: 47

Length: 23

Type: PPI

Organism: Artificial Sequence

Feature:

Other Information: Tytic Peptide

US 09 482-611B-47

## Query Match

Best Local Similarity: 59.18; Score: 29; ID: 4; Length: 23;  
 Matches: 8; Conservative: 4; Mismatches: 4; Indels: 0; Gaps: 0;

QY 1 FAKALKALKALKAL 15

II III III

DB 1 FAIAKALKALKALKI 15

## RESULT 39

US 09 0471B-42

Sequence 42, Application: US/09/0471B-42

Patent No. 6448391

GENERAL INFORMATION:

APPLICANT: JEMTER BUCHHEIM-OLGERS, LTD.

TITLE OF INVENTION: METHOD OF ENHANCING WOUND HEALING BY

NUMBER OF SEQUENCES: 46

CORRESPONDENCE ADDRESS:

ADDRESSEE: FRANK S. WASSERMAN

ADDRESS: 1000 LARK DRIVE, SUITE 210

STREET: P.O. BOX 14429

CITY: RESEARCH TRIANGLE PARK

STATE: NORTH CAROLINA

COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB

COMPILER: APPLE MACINTOSH

OPERATING SYSTEM: MACINTOSH

SOFTWARE: M.S. WORD 6.0

Current Application Data:

Application Number: US/09/0471B

Filing Date:

Prior Application Data:

Application Number: US/09/0471B

Filing Date: 20 04 94

Attorney/Agent Information:

Name: WASSERMAN, FRANK S.

Registration Number: 44274

Reference/Work Number: 404,107

Telecommunication Information:

Telephone: (919) 990-9541

Telefax: (919) 990-9542

Information for Seq ID No: 42:

Sequence Characteristics:

Length: 23

Type: AMINO-ACID

Topology: LINEAR

TELECOMMUNICATION INFORMATION  
TELEPHONE: (512) 418-3000  
TELEFAX: (512) 474-7577  
INFORMATION FOR SEQ ID NO: 41  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14 amino acids  
TYPE: amino acid

1 STRANDNESS: single  
2 topology: linear  
3 US 08 544 133-29

Query Match 57.6% Score 48 DB 1 Length 14  
Best local Similarity 90.0% Pred. No. 9.7  
Matches 0 Conservative 0 Mismatches 2 Indels 0 Gaps 0

01 4 KALKALKAL 12  
11111111  
02 4 KALKALKAL 13

RESULT 43

US 08 544 133-29  
Sequence 29 Application US/089542

1 GENERAL INFORMATION:  
2 APPLICANT: McLaughlin, Mark L  
3 APPLICANT: Becker, Calvin L  
4 TITLE OF INVENTION: Amphipathic Peptides  
5 NUMBER OF SEQUENCES: 54  
6 CORRESPONDENCE ADDRESS:  
7 ADDRESSEE: John H. Rannels  
8 STREET: P. O. Box 2471  
9 CITY: Baton Rouge  
10 STATE: LA  
11 COUNTRY: USA  
12 ZIP: 70821 2471

13 COMPUTER READABLE FORM:  
14 MEDIUM TYPE: floppy disk  
15 COMPUTER: IBM PC compatible  
16 OPERATING SYSTEM: PC DOS/MS DOS  
17 SOFTWARE: PATENT-RECORDS-1.1.0, Version #1.25

18 CURRENT APPLICATION DATA:  
19 APPLICATION NUMBER: US/95/044 133  
20 FILING DATE: 06-01-1997

21 PRIORITY INFORMATION: 5540  
22 CLASSIFICATION: 5540

23 PRIOR APPLICATION NUMBER: 08/789,077  
24 FILING DATE: 03 FEB 1997

25 APPLICATION NUMBER: 08/000,000  
26 FILING DATE: 02-09-97

27 APPLICATION NUMBER: 08/000,000  
28 FILING DATE: 02-09-97

29 APPLICATION NUMBER: 08/000,000  
30 FILING DATE: 02-09-97

31 APPLICATION NUMBER: 08/000,000  
32 FILING DATE: 02-09-97

33 APPLICATION NUMBER: 08/000,000  
34 FILING DATE: 02-09-97

35 APPLICATION NUMBER: 08/000,000  
36 FILING DATE: 02-09-97

37 APPLICATION NUMBER: 08/000,000  
38 FILING DATE: 02-09-97

39 APPLICATION NUMBER: 08/000,000  
40 FILING DATE: 02-09-97

41 APPLICATION NUMBER: 08/000,000  
42 FILING DATE: 02-09-97

43 APPLICATION NUMBER: 08/000,000  
44 FILING DATE: 02-09-97

45 APPLICATION NUMBER: 08/000,000  
46 FILING DATE: 02-09-97

47 APPLICATION NUMBER: 08/000,000  
48 FILING DATE: 02-09-97

49 APPLICATION NUMBER: 08/000,000  
50 FILING DATE: 02-09-97

51 APPLICATION NUMBER: 08/000,000  
52 FILING DATE: 02-09-97

53 APPLICATION NUMBER: 08/000,000  
54 FILING DATE: 02-09-97

55 APPLICATION NUMBER: 08/000,000  
56 FILING DATE: 02-09-97

57 APPLICATION NUMBER: 08/000,000  
58 FILING DATE: 02-09-97

59 APPLICATION NUMBER: 08/000,000  
60 FILING DATE: 02-09-97

61 APPLICATION NUMBER: 08/000,000  
62 FILING DATE: 02-09-97

63 APPLICATION NUMBER: 08/000,000  
64 FILING DATE: 02-09-97

65 APPLICATION NUMBER: 08/000,000  
66 FILING DATE: 02-09-97

67 APPLICATION NUMBER: 08/000,000  
68 FILING DATE: 02-09-97

69 APPLICATION NUMBER: 08/000,000  
70 FILING DATE: 02-09-97

71 APPLICATION NUMBER: 08/000,000  
72 FILING DATE: 02-09-97

1 Patent No. 5455247  
2 GENERAL INFORMATION:  
3 APPLICANT: Berkowitz, Barry A.  
4 APPLICANT: Kato, D. Prasad  
5 APPLICANT: Mahoy, W. Lee  
6 TITLE OF INVENTION: Novel 4-oxo-2-oxo-1-oxo-3-oxo-4-oxo-5-oxo-6-oxo-7-oxo-8-oxo-9-oxo-10-oxo-11-oxo-12-oxo-13-oxo-14-oxo-15-oxo-16-oxo-17-oxo-18-oxo-19-oxo-20-oxo-21-oxo-22-oxo-23-oxo-24-oxo-25-oxo-26-oxo-27-oxo-28-oxo-29-oxo-30-oxo-31-oxo-32-oxo-33-oxo-34-oxo-35-oxo-36-oxo-37-oxo-38-oxo-39-oxo-40-oxo-41-oxo-42-oxo-43-oxo-44-oxo-45-oxo-46-oxo-47-oxo-48-oxo-49-oxo-50-oxo-51-oxo-52-oxo-53-oxo-54-oxo-55-oxo-56-oxo-57-oxo-58-oxo-59-oxo-60-oxo-61-oxo-62-oxo-63-oxo-64-oxo-65-oxo-66-oxo-67-oxo-68-oxo-69-oxo-70-oxo-71-oxo-72-oxo-73-oxo-74-oxo-75-oxo-76-oxo-77-oxo-78-oxo-79-oxo-80-oxo-81-oxo-82-oxo-83-oxo-84-oxo-85-oxo-86-oxo-87-oxo-88-oxo-89-oxo-90-oxo-91-oxo-92-oxo-93-oxo-94-oxo-95-oxo-96-oxo-97-oxo-98-oxo-99-oxo-100-oxo-101-oxo-102-oxo-103-oxo-104-oxo-105-oxo-106-oxo-107-oxo-108-oxo-109-oxo-110-oxo-111-oxo-112-oxo-113-oxo-114-oxo-115-oxo-116-oxo-117-oxo-118-oxo-119-oxo-120-oxo-121-oxo-122-oxo-123-oxo-124-oxo-125-oxo-126-oxo-127-oxo-128-oxo-129-oxo-130-oxo-131-oxo-132-oxo-133-oxo-134-oxo-135-oxo-136-oxo-137-oxo-138-oxo-139-oxo-140-oxo-141-oxo-142-oxo-143-oxo-144-oxo-145-oxo-146-oxo-147-oxo-148-oxo-149-oxo-150-oxo-151-oxo-152-oxo-153-oxo-154-oxo-155-oxo-156-oxo-157-oxo-158-oxo-159-oxo-160-oxo-161-oxo-162-oxo-163-oxo-164-oxo-165-oxo-166-oxo-167-oxo-168-oxo-169-oxo-170-oxo-171-oxo-172-oxo-173-oxo-174-oxo-175-oxo-176-oxo-177-oxo-178-oxo-179-oxo-180-oxo-181-oxo-182-oxo-183-oxo-184-oxo-185-oxo-186-oxo-187-oxo-188-oxo-189-oxo-190-oxo-191-oxo-192-oxo-193-oxo-194-oxo-195-oxo-196-oxo-197-oxo-198-oxo-199-oxo-200-oxo-201-oxo-202-oxo-203-oxo-204-oxo-205-oxo-206-oxo-207-oxo-208-oxo-209-oxo-210-oxo-211-oxo-212-oxo-213-oxo-214-oxo-215-oxo-216-oxo-217-oxo-218-oxo-219-oxo-220-oxo-221-oxo-222-oxo-223-oxo-224-oxo-225-oxo-226-oxo-227-oxo-228-oxo-229-oxo-230-oxo-231-oxo-232-oxo-233-oxo-234-oxo-235-oxo-236-oxo-237-oxo-238-oxo-239-oxo-240-oxo-241-oxo-242-oxo-243-oxo-244-oxo-245-oxo-246-oxo-247-oxo-248-oxo-249-oxo-250-oxo-251-oxo-252-oxo-253-oxo-254-oxo-255-oxo-256-oxo-257-oxo-258-oxo-259-oxo-260-oxo-261-oxo-262-oxo-263-oxo-264-oxo-265-oxo-266-oxo-267-oxo-268-oxo-269-oxo-270-oxo-271-oxo-272-oxo-273-oxo-274-oxo-275-oxo-276-oxo-277-oxo-278-oxo-279-oxo-280-oxo-281-oxo-282-oxo-283-oxo-284-oxo-285-oxo-286-oxo-287-oxo-288-oxo-289-oxo-290-oxo-291-oxo-292-oxo-293-oxo-294-oxo-295-oxo-296-oxo-297-oxo-298-oxo-299-oxo-300-oxo-301-oxo-302-oxo-303-oxo-304-oxo-305-oxo-306-oxo-307-oxo-308-oxo-309-oxo-310-oxo-311-oxo-312-oxo-313-oxo-314-oxo-315-oxo-316-oxo-317-oxo-318-oxo-319-oxo-320-oxo-321-oxo-322-oxo-323-oxo-324-oxo-325-oxo-326-oxo-327-oxo-328-oxo-329-oxo-330-oxo-331-oxo-332-oxo-333-oxo-334-oxo-335-oxo-336-oxo-337-oxo-338-oxo-339-oxo-340-oxo-341-oxo-342-oxo-343-oxo-344-oxo-345-oxo-346-oxo-347-oxo-348-oxo-349-oxo-350-oxo-351-oxo-352-oxo-353-oxo-354-oxo-355-oxo-356-oxo-357-oxo-358-oxo-359-oxo-360-oxo-361-oxo-362-oxo-363-oxo-364-oxo-365-oxo-366-oxo-367-oxo-368-oxo-369-oxo-370-oxo-371-oxo-372-oxo-373-oxo-374-oxo-375-oxo-376-oxo-377-oxo-378-oxo-379-oxo-380-oxo-381-oxo-382-oxo-383-oxo-384-oxo-385-oxo-386-oxo-387-oxo-388-oxo-389-oxo-390-oxo-391-oxo-392-oxo-393-oxo-394-oxo-395-oxo-396-oxo-397-oxo-398-oxo-399-oxo-400-oxo-401-oxo-402-oxo-403-oxo-404-oxo-405-oxo-406-oxo-407-oxo-408-oxo-409-oxo-410-oxo-411-oxo-412-oxo-413-oxo-414-oxo-415-oxo-416-oxo-417-oxo-418-oxo-419-oxo-420-oxo-421-oxo-422-oxo-423-oxo-424-oxo-425-oxo-426-oxo-427-oxo-428-oxo-429-oxo-430-oxo-431-oxo-432-oxo-433-oxo-434-oxo-435-oxo-436-oxo-437-oxo-438-oxo-439-oxo-440-oxo-441-oxo-442-oxo-443-oxo-444-oxo-445-oxo-446-oxo-447-oxo-448-oxo-449-oxo-450-oxo-451-oxo-452-oxo-453-oxo-454-oxo-455-oxo-456-oxo-457-oxo-458-oxo-459-oxo-460-oxo-461-oxo-462-oxo-463-oxo-464-oxo-465-oxo-466-oxo-467-oxo-468-oxo-469-oxo-470-oxo-471-oxo-472-oxo-473-oxo-474-oxo-475-oxo-476-oxo-477-oxo-478-oxo-479-oxo-480-oxo-481-oxo-482-oxo-483-oxo-484-oxo-485-oxo-486-oxo-487-oxo-488-oxo-489-oxo-490-oxo-491-oxo-492-oxo-493-oxo-494-oxo-495-oxo-496-oxo-497-oxo-498-oxo-499-oxo-500-oxo-501-oxo-502-oxo-503-oxo-504-oxo-505-oxo-506-oxo-507-oxo-508-oxo-509-oxo-510-oxo-511-oxo-512-oxo-513-oxo-514-oxo-515-oxo-516-oxo-517-oxo-518-oxo-519-oxo-520-oxo-521-oxo-522-oxo-523-oxo-524-oxo-525-oxo-526-oxo-527-oxo-528-oxo-529-oxo-530-oxo-531-oxo-532-oxo-533-oxo-534-oxo-535-oxo-536-oxo-537-oxo-538-oxo-539-oxo-540-oxo-541-oxo-542-oxo-543-oxo-544-oxo-545-oxo-546-oxo-547-oxo-548-oxo-549-oxo-550-oxo-551-oxo-552-oxo-553-oxo-554-oxo-555-oxo-556-oxo-557-oxo-558-oxo-559-oxo-560-oxo-561-oxo-562-oxo-563-oxo-564-oxo-565-oxo-566-oxo-567-oxo-568-oxo-569-oxo-570-oxo-571-oxo-572-oxo-573-oxo-574-oxo-575-oxo-576-oxo-577-oxo-578-oxo-579-oxo-580-oxo-581-oxo-582-oxo-583-oxo-584-oxo-585-oxo-586-oxo-587-oxo-588-oxo-589-oxo-590-oxo-591-oxo-592-oxo-593-oxo-594-oxo-595-oxo-596-oxo-597-oxo-598-oxo-599-oxo-600-oxo-601-oxo-602-oxo-603-oxo-604-oxo-605-oxo-606-oxo-607-oxo-608-oxo-609-oxo-610-oxo-611-oxo-612-oxo-613-oxo-614-oxo-615-oxo-616-oxo-617-oxo-618-oxo-619-oxo-620-oxo-621-oxo-622-oxo-623-oxo-624-oxo-625-oxo-626-oxo-627-oxo-628-oxo-629-oxo-630-oxo-631-oxo-632-oxo-633-oxo-634-oxo-635-oxo-636-oxo-637-oxo-638-oxo-639-oxo-640-oxo-641-oxo-642-oxo-643-oxo-644-oxo-645-oxo-646-oxo-647-oxo-648-oxo-649-oxo-650-oxo-651-oxo-652-oxo-653-oxo-654-oxo-655-oxo-656-oxo-657-oxo-658-oxo-659-oxo-660-oxo-661-oxo-662-oxo-663-oxo-664-oxo-665-oxo-666-oxo-667-oxo-668-oxo-669-oxo-670-oxo-671-oxo-672-oxo-673-oxo-674-oxo-675-oxo-676-oxo-677-oxo-678-oxo-679-oxo-680-oxo-681-oxo-682-oxo-683-oxo-684-oxo-685-oxo-686-oxo-687-oxo-688-oxo-689-oxo-690-oxo-691-oxo-692-oxo-693-oxo-694-oxo-695-oxo-696-oxo-697-oxo-698-oxo-699-oxo-700-oxo-701-oxo-702-oxo-703-oxo-704-oxo-705-oxo-706-oxo-707-oxo-708-oxo-709-oxo-710-oxo-711-oxo-712-oxo-713-oxo-714-oxo-715-oxo-716-oxo-717-oxo-718-oxo-719-oxo-720-oxo-721-oxo-722-oxo-723-oxo-724-oxo-725-oxo-726-oxo-727-oxo-728-oxo-729-oxo-730-oxo-731-oxo-732-oxo-733-oxo-734-oxo-735-oxo-736-oxo-737-oxo-738-oxo-739-oxo-740-oxo-741-oxo-742-oxo-743-oxo-744-oxo-745-oxo-746-oxo-747-oxo-748-oxo-749-oxo-750-oxo-751-oxo-752-oxo-753-oxo-754-oxo-755-oxo-756-oxo-757-oxo-758-oxo-759-oxo-760-oxo-761-oxo-762-oxo-763-oxo-764-oxo-765-oxo-766-oxo-767-oxo-768-oxo-769-oxo-770-oxo-771-oxo-772-oxo-773-oxo-774-oxo-775-oxo-776-oxo-777-oxo-778-oxo-779-oxo-780-oxo-781-oxo-782-oxo-783-oxo-784-oxo-785-oxo-786-oxo-787-oxo-788-oxo-789-oxo-790-oxo-791-oxo-792-oxo-793-oxo-794-oxo-795-oxo-796-oxo-797-oxo-798-oxo-799-oxo-800-oxo-801-oxo-802-oxo-803-oxo-804-oxo-805-oxo-806-oxo-807-oxo-808-oxo-809-oxo-810-oxo-811-oxo-812-oxo-813-oxo-814-oxo-815-oxo-816-oxo-817-oxo-818-oxo-819-oxo-820-oxo-821-oxo-822-oxo-823-oxo-824-oxo-825-oxo-826-oxo-827-oxo-828-oxo-829-oxo-830-oxo-831-oxo-832-oxo-833-oxo-834-oxo-835-oxo-836-oxo-837-oxo-838-oxo-839-oxo-840-oxo-841-oxo-842-oxo-843-oxo-844-oxo-845-oxo-846-oxo-847-oxo-848-oxo-849-oxo-850-oxo-851-oxo-852-oxo-853-oxo-854-oxo-855-oxo-856-oxo-857-oxo-858-oxo-859-oxo-860-oxo-861-oxo-862-oxo-863-oxo-864-oxo-865-oxo-866-oxo-867-oxo-868-oxo-869-oxo-870-oxo-871-oxo-872-oxo-873-oxo-874-oxo-875-oxo-876-oxo-877-oxo-878-oxo-879-oxo-880-oxo-881-oxo-882-oxo-883-oxo-884-oxo-885-oxo-886-oxo-887-oxo-888-oxo-889-oxo-890-oxo-891-oxo-892-oxo-893-oxo-894-oxo-895-oxo-896-oxo-897-oxo-898-oxo-899-oxo-900-oxo-901-oxo-902-oxo-903-oxo-904-oxo-905-oxo-906-oxo-907-oxo-908-oxo-909-oxo-910-oxo-911-oxo-912-oxo-913-oxo-914-oxo-915-oxo-916-oxo-917-oxo-918-oxo-919-oxo-920-oxo-921-oxo-922-oxo-923-oxo-924-oxo-925-oxo-926-oxo-927-oxo-928-oxo-929-oxo-930-oxo-931-oxo-932-oxo-933-oxo-934-oxo-935-oxo-936-oxo-937-oxo-938-oxo-939-oxo-940-oxo-941-oxo-942-oxo-943-oxo-944-oxo-945-oxo-946-oxo-947-oxo-948-oxo-949-oxo-950-oxo-951-oxo-952-oxo-953-oxo-954-oxo-955-oxo-956-oxo-957-oxo-958-oxo-959-oxo-960-oxo-961-oxo-962-oxo-963-oxo-964-oxo-965-oxo-966-oxo-967-oxo-968-oxo-969-oxo-970-oxo-971-oxo-972-oxo-973-oxo-974-oxo-975-oxo-976-oxo-977-oxo-978-oxo-979-oxo-980-oxo-981-oxo-982-oxo-983-oxo-984-oxo-985-oxo-986-oxo-987-oxo-988-oxo-989-oxo-990-oxo-991-oxo-992-oxo-993-oxo-994-oxo-995-oxo-996-oxo-997-oxo-998-oxo-999-oxo-1000-oxo-1001-oxo-1002-oxo-1003-oxo-1004-oxo-1005-oxo-1006-oxo-1007-oxo-1008-oxo-1009-oxo-1010-oxo-1011-oxo-1012-oxo-1013-oxo-1014-oxo-1015-oxo-1016-oxo-1017-oxo-1018-oxo-1019-oxo-1020-oxo-1021-oxo-1022-oxo-1023-oxo-1024-oxo-1025-oxo-1026-oxo-1027-oxo-1028-oxo-1029-oxo-1030-oxo-1031-oxo-1032-oxo-1033-oxo-1034-oxo-1035-oxo-1036-oxo-1037-oxo-1038-oxo-1039-oxo-1040-oxo-1041-oxo-1042-oxo-1043-oxo-1044-oxo-1045-oxo-1046-oxo-1047-oxo-1048-oxo-1049-oxo-1050-oxo-1051-oxo-1052-oxo-1053-oxo-1054-oxo-1055-oxo-1056-oxo-1057-oxo-1058-oxo-1059-oxo-1060-oxo-1061-oxo-1062-oxo-1063-oxo-1064-oxo-1065-oxo-1066-oxo-1067-oxo-1068-oxo-1069-oxo-1070-oxo-1071-oxo-1072-oxo-1073-oxo-1074-oxo-1075-oxo-1076-oxo-1077-oxo-1078-oxo-1079-oxo-1080-oxo-1081-oxo-1082-oxo-1083-oxo-1084-oxo-1085-oxo-1086-oxo-1087-oxo-1088-oxo-1089-oxo-1090-oxo-1091-oxo-1092-oxo-1093-oxo-1094-oxo-1095-oxo-1096-oxo-1097-oxo-1098-oxo-1099-oxo-1100-oxo-1101-oxo-1102-oxo-1103-oxo-1104-oxo-1105-oxo-1106-oxo-1107-oxo-1108-oxo-1109-oxo-1110-oxo-1111-oxo-1112-oxo-1113-oxo-1114-oxo-1115-oxo-1116-oxo-1117-oxo-1118-oxo-1119-oxo-1120-oxo-1121-oxo-1122-oxo-1123-oxo-1124-oxo-1125-oxo-1126-oxo-1127-oxo-1128-oxo-1129-oxo-1130-oxo-1131-oxo-1132-oxo-1133-oxo-1134-oxo-1135-oxo-1136-oxo-1137-oxo-1138-oxo-1139-oxo-1140-oxo-1141-oxo-1142-oxo-1143-oxo-1144-oxo-1145-oxo-1146-oxo-1147-oxo-1148-oxo-1149-oxo-1150-oxo-1151-oxo-1152-oxo-1153-oxo-1154-oxo-1155-oxo-1156-oxo-1157-oxo-1158-oxo-1159-oxo-1160-oxo-1161-oxo-1162-oxo-1163-oxo-1164-oxo-1165-oxo-1166-oxo-1167-oxo-1168-oxo-1169-oxo-1170-oxo-1171-oxo-1172-oxo-1173-oxo-1174-oxo-1175-oxo-1176-oxo-1177-oxo-1178-oxo-1179-oxo-1180-oxo-1181-oxo-1182-oxo-1183-oxo-1184-oxo-1185-oxo-1186-oxo-1187-oxo-1188-oxo-1189-oxo-1190-oxo-1191-oxo-1192-oxo-1193-oxo-1194-oxo-1195-oxo-1196-oxo-1197-oxo-1198-oxo-1199-oxo-1200-oxo-1201-oxo-1202-oxo-1203-oxo-1204-oxo-1205-oxo-1206-oxo-1207-oxo-1208-oxo-1209-oxo-1210-oxo-1211-oxo-1212-oxo-1213-oxo-1214-oxo-1215-oxo-1216-oxo-1217-oxo-1218-oxo-1219-oxo-1220-oxo-1221-oxo-1222-oxo-1223-oxo-1224-oxo-1225-oxo-1226-oxo-1227-oxo-1228-oxo-1229-oxo-1230-oxo-1231-oxo-1232-oxo-1233-oxo-1234-oxo-1235-oxo-1236-oxo-1237-oxo-1238-oxo-1239-oxo-1240-oxo-1241-oxo-1242-oxo-1243-oxo-1244-oxo-1245-oxo-1246-oxo-1247-oxo-1248-oxo-1249-oxo-1250-oxo-1251-oxo-1252-oxo-1253-oxo-1254-oxo-1255-oxo-1256-oxo-1257-oxo-1258-oxo-1259-oxo-1260-oxo-1261-oxo-1262-oxo-1263-oxo-1264-oxo-1265-oxo-1266-oxo-1267-oxo-1268-oxo-1269-oxo-1270-oxo-1271-oxo-1272-oxo-1273-oxo-1274-oxo-1275-oxo-1276-oxo-1277-oxo-1278-oxo-1279-oxo-1280-oxo-1281-oxo-1282-oxo-1283-oxo-1284-oxo-1285-oxo-1286-oxo-1287-oxo-1288-oxo-1289-oxo-1290-oxo-1291-oxo-1292-oxo-1293-oxo-1294-oxo-1295-oxo-1296-oxo-1297-oxo-1298-oxo-1299-oxo-1300-oxo-1301-oxo-1302-oxo-1303-oxo-1304-oxo-1305-oxo-1306-oxo-1307-oxo-1308-oxo-1309-oxo-1310-oxo-1311-oxo-1312-oxo-1313-oxo-1314-oxo-1315-oxo-1316-oxo-1317-oxo-1318-oxo-1319-oxo-1320-oxo-1321-oxo-1322-oxo-1323-oxo-1324-oxo-1325-oxo-1326-oxo-1327-oxo-1328-oxo-1329-oxo-1330-oxo-1331-oxo-1332-oxo-1333-oxo-1334-oxo-1335-oxo-1336-oxo-1337-oxo-1338-oxo-1339-oxo-1340-oxo-1341-oxo-1342-oxo-1343-oxo-1344-oxo-13

```

1 CITY: Roseland
2 STATE: New Jersey
3 COUNTRY: USA
4 ZIP: 07068
5 COMPUTER REARABLE FORM:
6 MEDIUM TYPE: 3.5 inch diskette
7 COMPUTER: IBM PS/2
8 OPERATING SYSTEM: PC-DOS
9 SOFTWARE: DW4.V2
10 CURRENT APPLICATION DATA:
11 APPLICATION NUMBER: US/08/131,120
12 FILING DATE:
13 CLASSIFICATION: 514
14 PRIOR APPLICATION DATA:
15 APPLICATION NUMBER: US/08/297,950
16 FILING DATE:
17 APPLICATION NUMBER: US/08/226,108
18 FILING DATE:
19 APPLICATION NUMBER: US/07/937,462
20 FILING DATE:
21 ATTORNEY/AGENT INFORMATION:
22 NAME: Custodio, Elliot M.
23 REGISTRATION NUMBER: 24,025
24 REFERENCE/DOCKET NUMBER: 421250-194
25 TELECOMMUNICATION INFORMATION:
26 TELEPHONE: 201-994-1700
27 TELEFAX: 201-994-1744
28 INFORMATION FOR SEQ ID NO: 33:
29 SEQUENCE CHARACTERISTICS:
30 LENGTH: 21 amino acids
31 TYPE: amino acid
32 STRANDNESS:
33 TOPOLOGY: linear
34 MOLECULE TYPE: peptide
35 US-08-434-120-33

```

```

Query Match      57.6%  Score 38; DB 1; Length 21;
Best Local Similarity 76.9%  Pred. No. 14;
Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      4 KALKALKALKAL 15
        | | | | | | | |
Db      1 KIKKALKKLEKAL 13

```

```

Search completed: August 21, 2003, 09:22:34
Job time : 29 secs

```





Genware version 5.1.1.6  
Copyright (c) 1995-2003 Compugen Ltd

om protein protein search using sw model

Run on: August 21, 2003, 08:06:46 : Search time 8.2 seconds  
(without alignments)  
29.035 Million cell updates/sec

Title: US-09-820-053a-43  
Portect score: 60  
Sequence: 1 PARALELLELALALALALALAL

Scoring table: BLASTSUM62

Gap 10.0 : Gapext 0.5

Searched: 1107863 seqs, 158726572 residues

total number of hits satisfying chosen parameters: 414095

Minimum DB seq length: 0  
Maximum DB seq length: 25

Post processing: Minimum Match ok  
Maximum Match 100%  
Listed first 45 summaries

Database :	Accession	Protein	*
1	AA1989.001	Protein	AA1989.001
2	AA1989.002	Protein	AA1989.002
3	AA1989.003	Protein	AA1989.003
4	AA1989.004	Protein	AA1989.004
5	AA1989.005	Protein	AA1989.005
6	AA1989.006	Protein	AA1989.006
7	AA1989.007	Protein	AA1989.007
8	AA1989.008	Protein	AA1989.008
9	AA1989.009	Protein	AA1989.009
10	AA1989.010	Protein	AA1989.010
11	AA1989.011	Protein	AA1989.011
12	AA1989.012	Protein	AA1989.012
13	AA1989.013	Protein	AA1989.013
14	AA1989.014	Protein	AA1989.014
15	AA1989.015	Protein	AA1989.015
16	AA1989.016	Protein	AA1989.016
17	AA1989.017	Protein	AA1989.017
18	AA1989.018	Protein	AA1989.018
19	AA1989.019	Protein	AA1989.019
20	AA1989.020	Protein	AA1989.020
21	AA1989.021	Protein	AA1989.021
22	AA1989.022	Protein	AA1989.022
23	AA1989.023	Protein	AA1989.023
24	AA1989.024	Protein	AA1989.024

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	Pro	10	Description
1	60	100.0	15	24	AB000001	Reactive synthetic
2	60	99.9	15	24	AB000010	Reactive synthetic
3	61	77.3	21	15	AA050067	Cancer treatment, a
4	61	77.3	21	14	AA040053	Basic protein, a
5	61	77.3	21	14	AA040054	Basic protein, a
6	61	77.3	21	14	AA040055	Basic protein, a
7	61	77.3	21	14	AA040056	Basic protein, a
8	61	77.3	21	14	AA040057	Basic protein, a
9	61	77.3	21	14	AA040058	Basic protein, a

10	51	77.3	21	15	AA050068	
11	51	77.3	21	15	AA050069	
12	51	77.3	21	15	AA050070	
13	51	77.3	21	15	AA050071	
14	51	77.3	21	15	AA050072	
15	51	77.3	21	20	AA050073	
16	51	77.3	21	23	AA050074	
17	51	77.3	21	23	AA050075	
18	51	77.3	21	23	AA050076	
19	51	77.3	21	23	AA050077	
20	51	77.3	21	23	AA050078	
21	51	77.3	21	23	AA050079	
22	51	77.3	21	23	AA050080	
23	51	77.3	21	23	AA050081	
24	51	77.3	21	23	AA050082	
25	51	77.3	21	23	AA050083	
26	51	77.3	21	23	AA050084	
27	51	77.3	21	23	AA050085	
28	51	77.3	21	23	AA050086	
29	51	77.3	21	23	AA050087	
30	51	77.3	21	23	AA050088	
31	51	77.3	21	23	AA050089	
32	51	77.3	21	23	AA050090	
33	51	77.3	21	23	AA050091	
34	51	77.3	21	23	AA050092	
35	51	77.3	21	23	AA050093	
36	51	77.3	21	23	AA050094	
37	51	77.3	21	23	AA050095	
38	51	77.3	21	23	AA050096	
39	51	77.3	21	23	AA050097	
40	51	77.3	21	23	AA050098	
41	51	77.3	21	23	AA050099	
42	51	77.3	21	23	AA050100	
43	51	77.3	21	23	AA050101	
44	51	77.3	21	23	AA050102	
45	51	77.3	21	23	AA050103	
46	51	77.3	21	23	AA050104	
47	51	77.3	21	23	AA050105	
48	51	77.3	21	23	AA050106	
49	51	77.3	21	23	AA050107	
50	51	77.3	21	23	AA050108	
51	51	77.3	21	23	AA050109	
52	51	77.3	21	23	AA050110	
53	51	77.3	21	23	AA050111	
54	51	77.3	21	23	AA050112	
55	51	77.3	21	23	AA050113	
56	51	77.3	21	23	AA050114	
57	51	77.3	21	23	AA050115	
58	51	77.3	21	23	AA050116	
59	51	77.3	21	23	AA050117	
60	51	77.3	21	23	AA050118	
61	51	77.3	21	23	AA050119	
62	51	77.3	21	23	AA050120	
63	51	77.3	21	23	AA050121	
64	51	77.3	21	23	AA050122	
65	51	77.3	21	23	AA050123	
66	51	77.3	21	23	AA050124	
67	51	77.3	21	23	AA050125	
68	51	77.3	21	23	AA050126	
69	51	77.3	21	23	AA050127	
70	51	77.3	21	23	AA050128	
71	51	77.3	21	23	AA050129	
72	51	77.3	21	23	AA050130	
73	51	77.3	21	23	AA050131	
74	51	77.3	21	23	AA050132	
75	51	77.3	21	23	AA050133	
76	51	77.3	21	23	AA050134	
77	51	77.3	21	23	AA050135	
78	51	77.3	21	23	AA050136	
79	51	77.3	21	23	AA050137	
80	51	77.3	21	23	AA050138	
81	51	77.3	21	23	AA050139	
82	51	77.3	21	23	AA050140	
83	51	77.3	21	23	AA050141	
84	51	77.3	21	23	AA050142	
85	51	77.3	21	23	AA050143	
86	51	77.3	21	23	AA050144	
87	51	77.3	21	23	AA050145	
88	51	77.3	21	23	AA050146	
89	51	77.3	21	23	AA050147	
90	51	77.3	21	23	AA050148	
91	51	77.3	21	23	AA050149	
92	51	77.3	21	23	AA050150	
93	51	77.3	21	23	AA050151	
94	51	77.3	21	23	AA050152	
95	51	77.3	21	23	AA050153	
96	51	77.3	21	23	AA050154	
97	51	77.3	21	23	AA050155	
98	51	77.3	21	23	AA050156	
99	51	77.3	21	23	AA050157	
100	51	77.3	21	23	AA050158	

ALL RESULTS

AB000001  
Protein  
AA050067  
AA050068  
AA050069  
AA050070  
AA050071  
AA050072  
AA050073  
AA050074  
AA050075  
AA050076  
AA050077  
AA050078  
AA050079  
AA050080  
AA050081  
AA050082  
AA050083  
AA050084  
AA050085  
AA050086  
AA050087  
AA050088  
AA050089  
AA050090  
AA050091  
AA050092  
AA050093  
AA050094  
AA050095  
AA050096  
AA050097  
AA050098  
AA050099  
AA050100  
AA050101  
AA050102  
AA050103  
AA050104  
AA050105  
AA050106  
AA050107  
AA050108  
AA050109  
AA050110  
AA050111  
AA050112  
AA050113  
AA050114  
AA050115  
AA050116  
AA050117  
AA050118  
AA050119  
AA050120  
AA050121  
AA050122  
AA050123  
AA050124  
AA050125  
AA050126  
AA050127  
AA050128  
AA050129  
AA050130  
AA050131  
AA050132  
AA050133  
AA050134  
AA050135  
AA050136  
AA050137  
AA050138  
AA050139  
AA050140  
AA050141  
AA050142  
AA050143  
AA050144  
AA050145  
AA050146  
AA050147  
AA050148  
AA050149  
AA050150  
AA050151  
AA050152  
AA050153  
AA050154  
AA050155  
AA050156  
AA050157  
AA050158  
AA050159  
AA050160  
AA050161  
AA050162  
AA050163  
AA050164  
AA050165  
AA050166  
AA050167  
AA050168  
AA050169  
AA050170  
AA050171  
AA050172  
AA050173  
AA050174  
AA050175  
AA050176  
AA050177  
AA050178  
AA050179  
AA050180  
AA050181  
AA050182  
AA050183  
AA050184  
AA050185  
AA050186  
AA050187  
AA050188  
AA050189  
AA050190  
AA050191  
AA050192  
AA050193  
AA050194  
AA050195  
AA050196  
AA050197  
AA050198  
AA050199  
AA050200  
AA050201  
AA050202  
AA050203  
AA050204  
AA050205  
AA050206  
AA050207  
AA050208  
AA050209  
AA050210  
AA050211  
AA050212  
AA050213  
AA050214  
AA050215  
AA050216  
AA050217  
AA050218  
AA050219  
AA050220  
AA050221  
AA050222  
AA050223  
AA050224  
AA050225  
AA050226  
AA050227  
AA050228  
AA050229  
AA050230  
AA050231  
AA050232  
AA050233  
AA050234  
AA050235  
AA050236  
AA050237  
AA050238  
AA050239  
AA050240  
AA050241  
AA050242  
AA050243  
AA050244  
AA050245  
AA050246  
AA050247  
AA050248  
AA050249  
AA050250  
AA050251  
AA050252  
AA050253  
AA050254  
AA050255  
AA050256  
AA050257  
AA050258  
AA050259  
AA050260  
AA050261  
AA050262  
AA050263  
AA050264  
AA050265  
AA050266  
AA050267  
AA050268  
AA050269  
AA050270  
AA050271  
AA050272  
AA050273  
AA050274  
AA050275  
AA050276  
AA050277  
AA050278  
AA050279  
AA050280  
AA050281  
AA050282  
AA050283  
AA050284  
AA050285  
AA050286  
AA050287  
AA050288  
AA050289  
AA050290  
AA050291  
AA050292  
AA050293  
AA050294  
AA050295  
AA050296  
AA050297  
AA050298  
AA050299  
AA050300  
AA050301  
AA050302  
AA050303  
AA050304  
AA050305  
AA050306  
AA050307  
AA050308  
AA050309  
AA050310  
AA050311  
AA050312  
AA050313  
AA050314  
AA050315  
AA050316  
AA050317  
AA050318  
AA050319  
AA050320  
AA050321  
AA050322  
AA050323  
AA050324  
AA050325  
AA050326  
AA050327  
AA050328  
AA050329  
AA050330  
AA050331  
AA050332  
AA050333  
AA050334  
AA050335  
AA050336  
AA050337  
AA050338  
AA050339  
AA050340  
AA050341  
AA050342  
AA050343  
AA050344  
AA050345  
AA050346  
AA050347  
AA050348  
AA050349  
AA050350  
AA050351  
AA050352  
AA050353  
AA050354  
AA050355  
AA050356  
AA050357  
AA050358  
AA050359  
AA050360  
AA050361  
AA050362  
AA050363  
AA050364  
AA050365  
AA050366  
AA050367  
AA050368  
AA050369  
AA050370  
AA050371  
AA050372  
AA050373  
AA050374  
AA050375  
AA050376  
AA050377  
AA050378  
AA050379  
AA050380  
AA050381  
AA050382  
AA050383  
AA050384  
AA050385  
AA050386  
AA050387  
AA050388  
AA050389  
AA050390  
AA050391  
AA050392  
AA050393  
AA050394  
AA050395  
AA050396  
AA050397  
AA050398  
AA050399  
AA050400  
AA050401  
AA050402  
AA050403  
AA050404  
AA050405  
AA050406  
AA050407  
AA050408  
AA050409  
AA050410  
AA050411  
AA050412  
AA050413  
AA050414  
AA050415  
AA050416  
AA050417  
AA050418  
AA050419  
AA050420  
AA050421  
AA050422  
AA050423  
AA050424  
AA050425  
AA050426  
AA050427  
AA050428  
AA050429  
AA050430  
AA050431  
AA050432  
AA050433  
AA050434  
AA050435  
AA050436  
AA050437  
AA050438  
AA050439  
AA050440  
AA050441  
AA050442  
AA050443  
AA050444  
AA050445  
AA050446  
AA050447  
AA050448  
AA050449  
AA050450  
AA050451  
AA050452  
AA050453  
AA050454  
AA050455  
AA050456  
AA050457  
AA050458  
AA050459  
AA050460  
AA050461  
AA050462  
AA050463  
AA050464  
AA050465  
AA050466  
AA050467  
AA050468  
AA050469  
AA050470  
AA050471  
AA050472  
AA050473  
AA050474  
AA050475  
AA050476  
AA050477  
AA050478  
AA050479  
AA050480  
AA050481  
AA050482  
AA050483  
AA050484  
AA050485  
AA050486  
AA050487  
AA050488  
AA050489  
AA050490  
AA050491  
AA050492  
AA050493  
AA050494  
AA050495  
AA050496  
AA050497  
AA050498  
AA050499  
AA050500  
AA050501  
AA050502  
AA050503  
AA050504  
AA050505  
AA050506  
AA050507  
AA050508  
AA050509  
AA050510  
AA050511  
AA050512  
AA050513  
AA050514  
AA050515  
AA050516  
AA050517  
AA050518  
AA050519  
AA050520  
AA050521  
AA050522  
AA050523  
AA050524  
AA050525  
AA050526  
AA050527  
AA05

XX WP1: 2003 221247Z1.  
 XX  
 XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 PT ams, inhibiting growth of microbial cells, or promoting proliferation  
 PI of cells, comprises phenylalanine, leucine, alanine or lysine residues  
 PI  
 XX  
 XX Claim 7: Page 6: 13pp: English.  
 PS  
 XX the invention relates to a novel isolated peptide which is 5-23 amino  
 XX acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 XX residues, or contains at least 50 % of the residues, the peptides of the  
 XX invention have antibacterial, fungicidal, cytostatic, and cytotoxic  
 XX activity. The peptides are useful in treating cancer, cystic fibrosis or  
 XX ams, inhibiting the growth of microbial cells, promoting the  
 XX stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 XX promoting wound healing, and in enhancing the activity of a therapeutic  
 XX agent. The sequences shown in APP00759, APP00923 represent the bisecting  
 XX peptides of the invention.  
 XX  
 XX Sequence: 15 AA;  
 SQ

Query Match 100.0%: Score 66; DB 24; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 0.00094;  
 Matches 15; Conservation 0; Mismatches 0; Gaps 0;

QY 1 FAKALKALKALKAL 15  
 DB 1 FAKALKALKALKAL 15

RESULT 2  
 ABR00910  
 ID ABR00910 standard; peptide: 15 AA.

XX ABR00910;

XX 03 APR 2003 (first entry)  
 DE Bioactive synthetic peptide FIAK17CV.

XX Antibacterial; fungicide; cytostatic; cytotoxic; cancer, cystic fibrosis,  
 KW ams, antimicrobial; human fibroblast; human lymphocyte; wound healing;  
 KW bioactive.

XX Synthetic.

XX Key Location/Qualification  
 PI Modified-site 15 Note "c-terminal amide"

XX W22527-438 A2.

XX 10 OCT 2002.

XX 28 MAR 2002; 2002W-0509534.

XX 28 MAR 2001; 2001US-279505P.

XX 28 MAR 2001; 2001US-0820053.

XX (HELIX) HELIX BIOMEDIX INC.

XX OWN DB;

XX WP1: 2003 221247Z1.

XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 PT ams, inhibiting growth of microbial cells, or promoting proliferation  
 PI of cells, comprises phenylalanine, leucine, alanine or lysine residues  
 PI

XX Claim 7: Page 9: 13pp: English.

XX the invention relates to a novel isolated peptide which is 5-23 amino  
 XX acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 XX residues, or contains at least 50 % of the residues, the peptides of the  
 XX invention have antibacterial, fungicidal, cytostatic, and cytotoxic  
 XX activity. The peptides are useful in treating cancer, cystic fibrosis or  
 XX ams, inhibiting the growth of microbial cells, promoting the  
 XX stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 XX promoting wound healing, and in enhancing the activity of a therapeutic  
 XX agent. The sequences shown in APP00759, APP00923 represent the bisecting  
 XX peptides of the invention.  
 XX  
 XX Sequence: 15 AA;  
 SQ

Query Match 100.0%: Score 66; DB 24; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 0.00094;  
 Matches 15; Conservation 0; Mismatches 0; Gaps 0;

QY 2 AKALKALKALKAL 15  
 DB 2 AKALKALKALKAL 15

RESULT 3  
 AAR68967  
 ID AAR68967 standard; peptide: 20 AA.

XX AAR68967;

XX 25 MAR 2003 (updated)

XX 20 APR 1995 (first entry)

XX Cancer treatment, amphiphilic ion channel forming peptide; cancer treatment;

DE Amphiphilic ion channel forming peptide; cancer treatment;  
 KW protease inhibitors.

XX Synthetic.

XX W09419669-A1.

XX 01 SEP 1994.

XX 22 FEB 1994; 94WO 0362723.

XX 26 FEB 1993; 94US 0021602.

XX (MAGNA) MAGNAN PHARM INC.

XX Berlyn M, Jacob LS, Mulloy WL

XX WP1: 1994 274269/06.

XX Protein cancer inhibitors, 43; administered and treated with  
 PI peptide(s) and protease inhibitors.

XX Claim 2: Page 62: 124pp: English.

XX AAR68967 to AAR68967 and AAR68967 to AAR68967 are the first and only  
 XX ion channel forming peptides submitted to the same date  
 XX sequences, used in combination with one or more of the above

XX inhibitors and other amphiphilic ion channel forming peptides  
 XX or proteins; they are effective in the treatment of cancer,  
 XX ams, in particular during surgery and following therapy  
 XX they may be useful in inhibiting, promoting and/or killing cells  
 XX potential "toxic" mammalian cells capable of causing cancer

XX (Updated on 25 MAR 2004 to correct IN field).

XX Sequence: 20 AA;

Query Match 100.0%: Score 62; DB 24; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 0.034;

Matches 123 Conservation 11 Mismatches 11 Gaps 00

2 AKALAKALAKAL 15  
11111 11111  
4 SKALKAKAKAKAL 17

RESULT 4  
AAK45054  
AAK45054 standard: peptide: 21 AA.  
XX  
AC  
AAK45053;  
XX  
25-MAR-2003 (updated)  
DT 26 JUN 1994 (first entry)  
XX  
XX  
Basic (positively charged) polypeptide for N terminal  
lipophilic substitution.  
XX  
ion channel; madarin; RNA; XIP; cAMP; cAMP; sarcotoxin;  
KW amphiphilic; hydrophobic; hydrophilic; lipophilic; growth;  
KW inhibition; target cell; virus; virally-infected cell;  
KW anti-infectant; antiviral; antitumor; antiparasitic;  
KW spermicide; wound healing; burn; infection;  
XX  
XX  
OS Synthetic;  
XX  
W09424148-A1.  
XX  
XX  
09-DEC-1993;  
XX  
27 MAY 1993; 94W0 US05192;  
XX  
01 JUN 1993; 92US 0891201;  
XX  
XX  
DA (MAGA) MAGAININ PHARM INC.  
XX  
XX  
Karl D;  
XX  
WPI: 1993-405419/50;  
XX  
XX  
Peptide(s) or proteins with an N-terminal lipophilic substit. -  
PI used for inhibiting growth of target cell; virus or  
PI virally-infected cell  
XX  
PS Disclosure: Page 75-88; 113pp; English.  
XX  
A novel compsn. for inhibiting growth of a target cell; virus or  
CC virally-infected cell comprises a peptide of formula T-N(W)-X (1).  
CC X is a biologically active amphiphilic ion channel-forming peptide  
CC or protein; pref. a magainin peptide, a beta peptide, a XIP  
CC peptide, a cAMP peptide, a cAMP peptide, a sarcotoxin;  
CC N is the amino group of the N-terminal amino group.  
CC T is a lipophilic moiety; pref. R-30, where R is a 2-iso-  
CC hydrocarbon (alkyl or aralkyl or alkylaromatic).  
CC T is pref. an octanoyl group.  
CC W is I or hydrophen.  
CC the peptides given in AAK45054 8% are examples of X.  
CC the N terminal substit. peptides and proteins have increased  
CC biological activity as compared with unsubstit. peptides or proteins  
CC or peptides substit. at the N terminal with an acetyl gp.  
CC They can be used as antimicrobial agents; antiviral agents;  
CC antitumor agents; antiparasitic agents or spermicides and  
CC can also exhibit other biological activities. They can also be  
CC used in promoting or stimulating wound healing; for the treatment  
CC of external burn and infection and/or prevent skin and burn  
CC infections or eye infections.  
CC (Updated on 25 MAR 2003 to correct PN field.)  
XX  
XX  
Sequence 21 AA;

Quality Match 77.9%; Score 51; 10k 14; Length 21;  
Best Local Similarity 85.7%; Pref. No. 0.25;  
Matches 123 Conservation 11 Mismatches 11 Gaps 00

2 AKALAKALAKAL 15  
11111 11111  
4 SKALKAKAKAKAL 17

RESULT 5  
AAK45052  
AAK45052 standard: peptide: 21 AA.  
XX  
AC  
AAK45051;  
XX  
25-MAR-2003 (updated)  
DT 24 AUG 1994 (first entry)  
XX  
XX  
Amphiphilic ion channel forming peptide.  
XX  
Growth inhibitor; and lipid for lipid modification; XIP; 1744-9711;  
KW tetraacycline; pseudomonic acid; heparin;  
XX  
XX  
OS Synthetic;  
XX  
W09307892-A1.  
XX  
XX  
29-APR-1993;  
XX  
XX  
16-OCT-1992; 94W0 US08824;  
XX  
XX  
16-OCT-1991; 91US 0778771;  
XX  
XX  
DA (MILL) CHELLERENS HOSPITAL PHILADELPHIA;  
XX  
XX  
Berkowitz B; Eastaff M;  
XX  
XX  
WPI: 1993-162194/18;  
XX  
XX  
Inhibiting growth of bacteria. By co-administration of  
PI antibiotic and ion channel-forming peptide; e.g., magainin  
XX  
PS Disclosure: Page 26; 125pp; English.

Quality Match 77.9%; Score 51; 10k 14; Length 21;  
Best Local Similarity 85.7%; Pref. No. 0.25;  
Matches 123 Conservation 11 Mismatches 11 Gaps 00

2 AKALAKALAKAL 15  
11111 11111  
4 SKALKAKAKAKAL 17

RESULT 6  
AAK45083  
AAK45083 standard: peptide: 21 AA.  
XX  
AC  
AAK45082;  
XX  
25-MAR-2003 (updated)  
DT 24 AUG 1994 (first entry)  
XX  
XX  
Amphiphilic ion channel forming peptide.  
XX  
Growth inhibitor; and lipid for lipid modification; XIP; 1744-9711;  
KW tetraacycline; pseudomonic acid; heparin;  
XX  
XX  
OS Synthetic;  
XX  
W09307892-A1.  
XX  
XX  
29-APR-1993;  
XX  
XX  
16-OCT-1992; 94W0 US08824;  
XX  
XX  
16-OCT-1991; 91US 0778771;  
XX  
XX  
DA (MILL) CHELLERENS HOSPITAL PHILADELPHIA;  
XX  
XX  
Berkowitz B; Eastaff M;  
XX  
XX  
WPI: 1993-162194/18;  
XX  
XX  
Inhibiting growth of bacteria. By co-administration of  
PI antibiotic and ion channel-forming peptide; e.g., magainin  
XX  
PS Disclosure: Page 26; 125pp; English.

Quality Match 77.9%; Score 51; 10k 14; Length 21;  
Best Local Similarity 85.7%; Pref. No. 0.25;  
Matches 123 Conservation 11 Mismatches 11 Gaps 00

2 AKALAKALAKAL 15  
11111 11111  
4 SKALKAKAKAKAL 17

RESULT 6  
AAK45083  
AAK45083 standard: peptide: 21 AA.  
XX  
AC  
AAK45082;  
XX  
25-MAR-2003 (updated)  
DT 24 AUG 1994 (first entry)  
XX  
XX  
Amphiphilic ion channel forming peptide.  
XX  
Growth inhibitor; and lipid for lipid modification; XIP; 1744-9711;  
KW tetraacycline; pseudomonic acid; heparin;  
XX  
XX  
OS Synthetic;  
XX  
W09307892-A1.  
XX  
XX  
29-APR-1993;  
XX  
XX  
16-OCT-1992; 94W0 US08824;  
XX  
XX  
16-OCT-1991; 91US 0778771;  
XX  
XX  
DA (MILL) CHELLERENS HOSPITAL PHILADELPHIA;  
XX  
XX  
Berkowitz B; Eastaff M;  
XX  
XX  
WPI: 1993-162194/18;  
XX  
XX  
Inhibiting growth of bacteria. By co-administration of  
PI antibiotic and ion channel-forming peptide; e.g., magainin  
XX  
PS Disclosure: Page 26; 125pp; English.

Quality Match 77.9%; Score 51; 10k 14; Length 21;  
Best Local Similarity 85.7%; Pref. No. 0.25;  
Matches 123 Conservation 11 Mismatches 11 Gaps 00

2 AKALAKALAKAL 15  
11111 11111  
4 SKALKAKAKAKAL 17

RESULT 6  
AAK45083  
AAK45083 standard: peptide: 21 AA.  
XX  
AC  
AAK45082;  
XX  
25-MAR-2003 (updated)  
DT 24 AUG 1994 (first entry)  
XX  
XX  
Amphiphilic ion channel forming peptide.  
XX  
Growth inhibitor; and lipid for lipid modification; XIP; 1744-9711;  
KW tetraacycline; pseudomonic acid; heparin;  
XX  
XX  
OS Synthetic;  
XX  
W09307892-A1.  
XX  
XX  
29-APR-1993;  
XX  
XX  
16-OCT-1992; 94W0 US08824;  
XX  
XX  
16-OCT-1991; 91US 0778771;  
XX  
XX  
DA (MILL) CHELLERENS HOSPITAL PHILADELPHIA;  
XX  
XX  
Berkowitz B; Eastaff M;  
XX  
XX  
WPI: 1993-162194/18;  
XX  
XX  
Inhibiting growth of bacteria. By co-administration of  
PI antibiotic and ion channel-forming peptide; e.g., magainin  
XX  
PS Disclosure: Page 26; 125pp; English.

```

XX 25-MAR-2003 (updated)
DI 10 MAY-1993 (first entry)
XX C-terminal substd. amphiphilic peptide #12.
XX ion-channel forming; ionophore; antibiotic; anti-tumour; anti-virus;
KW wound healing.
XX Synthetic.
XX Key Location/Qualifiers
FT Region 1..7
FT Modified site 21
FT /label= repeat_unit
FT /note= "Leu-(C O) T,
FT T O R, Eit RH2, NH OH or SR'R",
FT R opt.substd. 1-10C aliphatic, aromatic or
FT alkyl ap.;
FT R', R" - R or from one of qps. i and ii;
FT qp.i 1-10C hydroxy-substd. aliphatic,
FT aromatic or alkyl ap.;
FT qp.ii amino-substd. aliphatic, aromatic,
FT alkyl or alkylaromatic qp. and
FT at least one of R' and R" qp.i or qp.ii"
XX W09222317-A1.
XX
XX 23-DEC-1992.
XX
XX 01-JUN-1992: 92W0-050463.
XX 12-JUN-1993: 91US-0713716.
XX (MAGA-) MAGAININ PHARM INC.
XX Kari UP, Maloy WL.
XX WPI: 1993-017904/02.
XX Now C-terminal-substd. amphiphilic peptide(s) - for treating
PT bacterial, viral or fungal infections and tumours, also useful as
PT spermicide
XX Claim 10: Page 76; 124pp; English.
XX This peptide is a preferred example of a highly generic amphiphilic
XX peptide with a C-terminal modification which increases the peptide's
XX biological activity i.e. the unmodified peptide. The preferred
XX C-terminal modification is -(60)-NHCH2CH2OH or -(20)-NHCH2CH2NH2.
XX Such substd. peptides may be used for inhibiting the growth of a
XX target cell, virus or virally infected cell in a host. The peptides
XX have a broad range of potent antibiotic activity, e.g. against gram-
XX negative and gram positive bacteria, fungi, protozoa and parasites.
XX The peptides can also be used to promote wound healing and treatment
XX of burns, other preferred amphiphilic peptides include madanins and
XX their analogues, BBA, XFF, etc. a coo-n-terminus and a sarcotoxin.
XX (Updated on 25-MAR-2003 to correct DN field.)
XX Sequence 21 AA:
XX
XX Query Match 77.8% Score 51 DB 14 Length 21.
XX Best Local Similarity 86.7% Pred. Res. 0.25%
XX Matches 12; Conservative 1; Mismatches 1; Gaps 0;
XX
XX 2 AKALKALKALKAL 15
XX
XX 4 SKALKALKALKAL 17
XX
XX RESULT 7
XX AAR45301
XX ID AAR45301 standard; peptide; 21 AA.

```

```

XX AAR45301;
XX
XX 25-MAR-2003 (updated)
DI 07-JUN-1993 (first entry)
XX Amphiphilic peptide #42 used to treat oral infections.
XX
XX Adverse oral conditions: amphoteric; anti-bacterial; anti-viral
XX anti-fungal; dental plaque; dental caries; periodontal disease;
XX gingivitis; ionophore; ion channel forming.
XX Synthetic.
XX Key Location/Qualifiers
FT Region 1..7
FT /note= "repeat unit"
XX W09401723-A1.
XX 04-FEB-1993.
XX
XX 09-JUL-1992: 92W0-050571.
XX 25-JUN-1993: 91US-0745070.
XX (MAGA-) MAGAININ PHARM INC.
XX Berkowitz B, Jacob LJ.
XX WPI: 1993-078434/07.
XX Peptide(s) for prophylaxis and treatment of oral diseases caused
XX for periodontal disease, plaque, dental caries, gingivitis etc.
XX Claim 2: Page 42; 144pp; English.
XX This is a specific example of a highly generic formula of a
XX preferred amphiphilic peptides for use in preventing or treating
XX adverse oral conditions, the peptides are tetrapeptides (1-4 amino acids)
XX channel forming peptide) which has anti-bacterial, anti-viral and
XX fungal activity etc, making it suitable for use as a C-terminal ap.
XX to treat or prevent periodontal disease, plaque, gingivitis etc.
XX halitosis and gingivitis. The anti-bacterial effect is well known to
XX useful against bacteria associated with dental caries and periodontal
XX the peptides can stimulate the healing of sores in the mouth etc.
XX (Updated on 25-MAR-2003 to correct DN field.)
XX Sequence 21 AA:
XX
XX Query Match 77.8% Score 51 DB 14 Length 21.
XX Best Local Similarity 86.7% Pred. Res. 0.25%
XX Matches 12; Conservative 1; Mismatches 1; Gaps 0;
XX
XX 2 AKALKALKALKAL 15
XX
XX 4 SKALKALKALKAL 17
XX
XX RESULT 8
XX AAR45015
XX ID AAR45015 standard; peptide; 21 AA.
XX
XX AAR45015;
XX
XX 25-MAR-2003 (updated)
DI 08-MAY-1993 (first entry)
XX Biologically active amphiphilic peptide.
XX Synthetic and imitatorial composition, comprising the C-terminal
XX combination, preservation, sterilization, formulation, etc.
XX control; treatment; prevention; external barrier, etc. etc.

```



PS Disclosure: Page 79; 140pp; English.

XX the sequences given in AAR50462-568 represent amphiphilic, ion forming  
XX peptides which may be used to treat dyneurological malquency.  
XX These peptides are based on maritain, pella, xpf or cpep, a cecropin, a  
XX sarcoxin, melittin, an apidocin, a defensin, major basic protein of  
XX eosinophils or a bacterial permeability increasing protein. These  
XX peptides are esp. used to treat ovarian, esp. stage IC, uterine or  
XX cervical cancers.  
XX (Updated on 25 MAR 2003 to correct PN field.)

XX Sequence: 21 AA;

Query Match 77.48; Score 51; DB 15; Length 21;  
Best Local Similarity 85.7%; Prod. No. 3.25.  
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 AKALKALKALKAL 15  
II 11111 11111  
DE 4 SKALKALKALKAL 17

RESULT 11

AAR50467 standard; peptide: 21 AA.

XX AAR50467;

XX 25 MAR 2004 (updated)  
XX 17 OCT 1994 (first entry)

XX Amphiphilic peptide # 42.

XX Amphiphilic peptide; aprotic organic solvent; alcohol; antitumor;  
XX actin; antimicrobial; antifungal; antiparasitic; anticancer;  
XX activity; human; animal; plant; ion-channel; forming peptide.

XX Synthesis:

XX W09406308 A1.

XX 17 MAR 1994.

XX 13 AUG 1994; 94WO-08076-4.

XX 28 AUG 1994; 92US-09365-04.

XX (MAGN) MAGNIN PHARM INC.

XX Williams JJ;

XX WPI: 1994 100846/12.

XX purifying amphiphilic protein or peptide by solvent, extn.,  
XX particle, for recombinant, ion-channel forming peptide(s) such as  
XX maritains, avoids use of chaotropic agents.

XX Disclosure: Page 84-85; 140pp; English.

XX the sequences given in AAR50466-451 are amphiphilic peptides which  
XX were isolated by the method of the invention. A material containing  
XX amphiphilic peptides such as these, was treated with a mixt. of  
XX aprotic organic solvent and alcohol to form a single miscible  
XX solution. This solution was then treated with a aqueous solution to  
XX form an aqueous phase solution containing the peptides and an  
XX organic solvent phase, and the peptides were isolated from the  
XX aqueous phase. The isolated peptides may be used as antibiotic,  
XX antimicrobial, antifungal, antiparasitic, antitumor, anticancer,  
XX and/or antiviral agents for treatment of humans, animals or plants.  
XX These peptides are esp. ion channel forming peptides which enable  
XX biologically active ions to enter cells.  
XX (Updated on 25 MAR 2003 to correct PN field.)

XX Sequence: 21 AA;

Query Match 77.48; Score 51; DB 15; Length 21;  
Best Local Similarity 85.7%; Prod. No. 3.25.  
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 AKALKALKALKAL 15  
II 11111 11111  
DE 4 SKALKALKALKAL 17

RESULT 12

AAR50462 standard; peptide: 21 AA.

XX AAR50462;

XX 25 MAR 2004 (updated)

XX 16 MAR 1995 (first entry)

XX Peptide which neutralises bacterial endotoxin.

XX septic shock; bacterial endotoxin; lipopolysaccharide; LPS  
XX gram negative bacteria; conjugated moiety; septic shock; septic shock  
XX ionising activity; polyvinylpyrrolidone; dextran; septic shock;  
XX polyvinyl alcohol; ion channel; forming; amphiphilic.

XX Synthesis:

XX W09410697 A1.

XX 23 JUN 1994.

XX 06 DEC 1994; 94WO-08194-1.

XX 07 DEC 1994; 92US-09344-3.

XX (MAGN) MAGNIN PHARM INC.

XX Ikeda M, Kato M, Williams JJ;

XX WPI: 1994 217604/26

XX New conjugates of biopolymer amphiphilic peptide and LPS, and  
XX moiety are useful for treatment of septic shock.

XX Disclosure: Page 76, 77; 140pp; English.

XX septic shock is often due to the body's reaction to LPS.  
XX lipopolysaccharide (LPS). The compounds of the invention are  
XX bacterial endotoxins without neutralising activity. They are  
XX plasma of patients, or heparins. They also have a high level of  
XX activity than unconjugated peptides. In contrast to other  
XX are ion channel forming peptides, the compounds of the invention  
XX peptides linked to a conjugate moiety, can enter cells. They  
XX polyvinylpyrrolidone, polyalkylene glycols and polyvinyl alcohol.  
XX the conjugate moiety may be linked at the C- or N-terminus.  
XX integrity of the peptide. AAR50462 and AAR50467 are  
XX of these peptide conjugate moiety compounds  
XX (Updated on 25 MAR 2003 to correct PN field.)

XX Sequence: 21 AA;

Query Match 77.48; Score 51; DB 15; Length 21;  
Best Local Similarity 85.7%; Prod. No. 3.25.  
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 AKALKALKALKAL 15  
II 11111 11111  
DE 4 SKALKALKALKAL 17

RESULT 13

AAR90075  
 ID AAR90075 standard; peptide; 21 AA.  
 XX  
 AC AAR90075;  
 XX  
 DT 03-JUL-1996 (first entry)  
 DT  
 XX (KALSKAL) 3 peptide modified by N-terminal lipophilic group.  
 DE  
 XX Ion channel forming peptide; lipophilic; N-terminal modification;  
 KW madamin; inhibition; cell growth; viral replication; ionophore;  
 KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;  
 KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.  
 XX  
 OS Synthetic.  
 XX  
 XX Key Location/Qualifiers  
 FH Modified-site 1  
 FT /note: "N-terminal amino group is mono- or  
 FT di-substd. by lipophilic moiety, esp.  
 FT octanoyl"  
 FT Peptide 1..7  
 FT /label repeat  
 FT /note: "first of 3 repeats of amphipathic  
 FT heptapeptide motif"  
 FT  
 FN W09519470-A1.  
 XX  
 XX 20-JUL-1995.  
 PD  
 XX 18-JAN-1995; 95W0-US00714.  
 XX  
 XX 18-JAN-1994; 94US-0184462.  
 XX  
 XX (MAGA-) MAGAININ PHARM INC.  
 PA  
 PI Kari UP, McLane M, Williams TJ;  
 XX  
 XX WPI: 1995-263826/34.  
 DR  
 XX Ion channel-forming amphiphilic peptide(s) with N-terminal  
 PT lipophilic ops. - useful e.g. as antiviral, antibacterial,  
 PT antiparasitic or antitumour agents  
 XX  
 XX Claim 21: Page 78: 139pp; English.  
 PS  
 CC The present peptide is a specific example corresp. to a highly  
 CC generic formula for ion channel forming peptides (ionophores)  
 CC consisting of 1-5 repeats of an amphipathic heptapeptide motif.  
 CC these ionophores are known to have a broad range of potent  
 CC antithiotic activity against microorganisms including gram-positive  
 CC and gram-negative bacteria, fungi, viruses, protozoa and parasites.  
 CC N-terminal modification (pref. mono-substd. by octanoyl) to produce  
 CC an ion channel forming peptide having a lipophilic N-terminus  
 CC increases the biological activity of the peptides against target cells,  
 CC viruses and virally-infected cells, compared to peptides substd. with  
 CC an acetyl group at the N-terminus. Compositions comprising the peptides  
 CC with lipophilic modifications are claimed for inhibiting growth of a  
 CC target cell, virus or virally-infected cell.  
 XX  
 SQ Sequence 21 AA;  
 Query Match 77.4%; Score 51; DB 16; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 0.25;  
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 AKALKALKALKAL 15  
 DB 4 SKALKALKALKAL 17  
 RESULT 14  
 AAR90075

ID  
 XX AAR84846 standard; peptide; 21 AA.  
 AC AAR84846;  
 XX  
 DT 25-MAR-2003 (updated)  
 DT 24-MAY-1996 (first entry)  
 XX  
 DE Ion channel forming amphiphilic peptide #6.  
 XX  
 KW Ion-channel; amphiphilic peptide; antimicrobial; antiviral; antitumour;  
 KW antitumour; antiparasitic; antifungal; spermicidal; cyst; spore; skin;  
 KW trophozoite; infection; wound healing; burn.  
 XX  
 OS Synthetic.  
 XX  
 XX Key Location/Qualifiers  
 FH Misc-difference 21  
 FT /note: "contains C-terminal amide at 20q"  
 FT  
 FN US5459237-A.  
 XX  
 XX 17 OCT-1995.  
 PD  
 XX 02-JUL-1992; 92US-0908455.  
 PF  
 XX 02-JUL-1992; 92US-0908455.  
 PR 08-FEB-1990; 90US-0476629.  
 PR 15-APR-1991; 91US-0686115.  
 XX  
 PA (MAGA-) MAGAININ PHARM INC.  
 PA  
 PI Berkowitz B, Kari UP, Maloy WL;  
 XX  
 XX WPI: 1995-365836/47.  
 DR  
 XX New ion channel-forming amphiphilic peptide(s) - useful as  
 PT antimicrobial, antiviral, antitumour, antiparasitic or antitumour  
 PT agents or for wound healing  
 XX  
 XX Disclosure: Column 5: 38pp; English.  
 PS  
 CC The peptides AAR84841-84848 are examples of novel ion-channel forming  
 CC amphiphilic peptides which can be used as antimicrobial, antiviral,  
 CC antibiotic, antitumour, antiparasitic, antitumour agents or as  
 CC spermicides. The peptides can be used as preservatives or sterilants  
 CC for materials susceptible to microbial or viral infections. The  
 CC peptides can also be used for killing cysts, spores or trophozoites of  
 CC infection-causing organisms. They can also be used to promote wound  
 CC healing or to treat or prevent skin and burn infections. The peptides  
 CC can be administered in combination with other infectious. The peptides  
 CC amphiphilic peptides such as AAR84841-48.  
 CC (Updated on 25-MAR-2003 to correct PF field.)  
 XX  
 SQ Sequence 21 AA;  
 Query Match 77.4%; Score 51; DB 16; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 0.25;  
 Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 2 AKALKALKALKAL 15  
 DB 4 SKALKALKALKAL 17  
 RESULT 15  
 AAY10671  
 ID AAY10671 standard; peptide; 21 AA.  
 XX  
 AC AAY10671;  
 XX  
 DT 11-MAY-1999 (first entry)  
 DT  
 XX Peptide used to make biologically active peptides.

```

XX KW Septic septic shock; bacteraemia; meningitis; cystic fibrosis;
XX KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
XX KW antiparasitic; spermicide; preservative; sterility; disinfectant;
XX KW wound healing; burn; skin infection; eye infection; solid tumour;
XX KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
XX KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.
XX OS Synthesis.
XX IN W090486 A2.
XX XX
XX PD 28-JAN-1999.
XX XX
XX DE 15-JUL-1998: 98WO-US14610.
XX XX
XX PR 15-JUL-1997: 97US-0893006.
XX XX
XX PA (MAGA-) MAGA/NIN PHARM INC.
XX XX
XX PI Karl DP, Williams TJ, Melane M.
XX XX
XX DP WPI: 1999-141869/11.
XX XX
XX PR Treating sepsis or septic shock with N-mediated ion-channel forming
XX KW peptide - or its methane sulphonate derivative of reduced toxicity.
XX KW also generally useful as antimicrobial and antitumour agents.
XX PS Disclosure: Page 154: 202pp; English.
XX XX
XX CV AAV1040 795 represent peptides used in the production of biologically
XX KW active peptide with reduced toxicity. The biologically active peptides
XX KW are used to treat sepsis or septic shock, and comprise the formula:
XX KW i (N-W) X, where X = biologically active, amphipathic, ion-channel
XX KW forming peptide or protein; i = lipophilic group; and W = hydrogen or T.
XX KW The peptides are particularly used to treat infections by pseudomonas
XX KW aeruginosa in patients with cystic fibrosis, but more generally as
XX KW antimicrobial, antiviral, antibacterial, antifungal, antitumour or
XX KW antiparasitic agents, and also as spermicides, e.g., as preservatives,
XX KW sterilants, and disinfectants in human and veterinary medicine. They
XX KW can be used to stimulate wound healing, treat burns and/or skin and
XX KW burn infections, eye infections, solid tumours or leukaemia
XX KW (particularly non-small cell lung cancer and adenocarcinoma, including
XX KW those resistant to other antitumour agents), and also for treatment of
XX KW infections in plants, and, when formulated in oral hyaline formulations,
XX KW for treating or preventing periodontal disease, plaque, gingivitis and/or
XX KW caries (specifically by action on Streptococcus mutans).
XX XX
XX SQ Sequence: 21 AA.
XX XX
XX Query Match 77.8% Score 51: DB 20: Length 21:
XX Best Local Similarity: 86.7% Prod. No. 0,257
XX Matches 12: Conserved 1: Mismatches 1: Indels 0: Gaps 9:
XX XX
XX CV 2 AKAKKALIKALIKAL 15
XX PD 111111111111
XX 4 SEAKKALIKALIKAL 19
XX XX
XX RESULT 16
XX AAE22464
XX ID AAE22464 standard: peptide: 21 AA.
XX AC AAE22464:
XX XX
XX DT 25-JUL-2002 (first entry)
XX DE Biologically active peptide #16.
XX KW Biologically active peptide, toxicity, antimicrobial; anti tumour;
XX KW methane sulphonate derivative; wound healing; burn; therapy; sepsis;
XX KW eye infection; cyst; sporotrichosis; tumour; lung infection;
XX KW cystic fibrosis; septic shock; bacterial endotoxin; bacteraemia.

```

```

XX KW and character: immunosuppression.
XX XX
XX OS Unidentified.
XX XX
XX PD 0804844 A1.
XX XX
XX PD 19-FEB-2002.
XX XX
XX PD 15-JUL-1998: 98US-0115747.
XX XX
XX PR 18-JAN-1994: 94US-0184402.
XX PR 03-JUN-1992: 92US-0801201.
XX PR 05-JUN-1995: 95US-0465340.
XX PR 15-JUL-1997: 97US-0893006.
XX XX
XX PA (MAGA-) MAGA/NIN PHARM INC.
XX XX
XX PI Karl DP, Williams TJ, Melane M.
XX XX
XX DP WPI: 2002-01197/08.
XX XX
XX PR Reducing toxicity of unsubstituted or N-terminal substituted peptide-
XX KW having antimicrobial and antitumour activity used in treatment of
XX KW infections and tumor, by forming methane sulphonate derivative of
XX KW peptide.
XX PS Disclosure: Column 17: 18pp; English.
XX XX
XX CV The invention relates to biologically active peptides which have
XX KW toxicity and methods of preparing them. The peptides are used to
XX KW treat infections and tumors, and also to stimulate wound healing.
XX KW While exhibiting reduced toxicity, the peptides are biologically
XX KW active. The method of related methane sulphonate derivative of
XX KW analogues. The method is useful for reduction of toxicity of
XX KW unsubstituted peptide or an N-terminal substituted peptide which has
XX KW utilised in promoting or stimulating healing of a wound that has
XX KW treatment of external tumor, prevention of cancer or cancer
XX KW caused by bacteria or fungi, in killing cysts, fungi, bacteria,
XX KW of infection causing organisms, and may also be employed in the
XX KW treatment of tumors, serious lung infections such as those caused by
XX KW in cystic fibrosis, for treating sepsis, septic shock and other
XX KW related ailments, and for treating bacterial infections. The
XX KW present sequence is a biologically active peptide which has a
XX XX
XX SQ Sequence: 21 AA.
XX XX
XX Query Match 77.8% Score 51: DB 20: Length 21:
XX Best Local Similarity: 86.7% Prod. No. 0,257
XX Matches 12: Conserved 1: Mismatches 1: Indels 0: Gaps 9:
XX XX
XX CV 2 AKAKKALIKALIKAL 15
XX PD 111111111111
XX 4 SEAKKALIKALIKAL 19
XX XX
XX RESULT 17
XX AAE22464
XX ID AAE22464 standard: peptide: 21 AA.
XX AC AAE22464:
XX XX
XX DT 02-JUL-1998 (first entry)
XX DE Minimalist lytic peptide.
XX KW Lytic peptide; channel forming peptide; anti-cancer; anti-cyst.
XX OS Synthesis.
XX XX
XX PR US5786542 A.
XX XX
XX PD 04-AUG-1998.
XX XX

```







XX PN W09012866 A1.  
 XX XX  
 XX ID 01 NOV 1990.  
 XX XX  
 XX PF 10 APR 1990; 90WS-US0445.  
 XX XX  
 XX PR 10 APR 1990; 89US-036181.  
 XX XX  
 XX PA (LOUISIANA) UNIV LOUISIANA STATE.  
 XX XX  
 XX PJ Jaynes JM;  
 XX XX  
 XX PR WPI: 1990 348469/46  
 XX XX  
 XX PT New lytic polypeptide(s) with proliferative activity - are  
 XX PT alpha helical peptide(s) having aligned amphipathic for treating  
 XX PT microbial infections and lysing cancer cells  
 XX XX  
 XX PS Claim 14; page 40; 57pp; English.  
 XX XX  
 XX CC This peptide is an analogue of a known lytic peptide. It comprises  
 XX CC an alpha helical conformation of amino acids. It is effective at  
 XX CC lysing e.g. gram-positive and -negative bacteria and mammalian neo-  
 XX CC plastic cells, cells infected with intracellular pathogenic micro-  
 XX CC organisms such as HIV. It stimulates the proliferation of fibro-  
 XX CC blasts and lymphocytes and can be used in wound healing.  
 XX CC See also AAR07744-37, AAR07739-41 and AAR07743-51.  
 XX CC (Updated on 25-MAR-2003 to correct PA field.)  
 XX XX  
 XX SQ Sequence 24 AA;  
 XX XX  
 XX QUOTY Match 72.78; Score 48; DB 11; Length 24;  
 XX XX Best Local Similarity 80.08; Pred. No. 0.8;  
 XX XX Matches 12; Conservation 0; Mismatches 3; Indels 0; Gaps 0;  
 XX XX  
 XX QY 1 FAKALKALKALKAL 15  
 XX XX 11 1111 1111 1  
 XX XX 1 FALAKALKALKALKAL 15  
 XX XX  
 XX ID AAR84166 standard; peptide: 24 AA.  
 XX AC AAR84166;  
 XX XX  
 XX DT 06-JUN-1996 (first entry)  
 XX XX  
 XX DE Peptide enhance of fibroblast and keratinocyte proliferation.  
 XX XX  
 XX KW amphipathic peptide; enhance; fibroblast; keratinocyte; proliferation;  
 XX KW wound healing; defensin; antimicrobial.  
 XX XX  
 XX CS Synthetic.  
 XX XX  
 XX PN W09528832 A1.  
 XX XX  
 XX XX 02-NOV 1995.  
 XX XX  
 XX PF 19 APR 1995; 95WS-US04718.  
 XX XX  
 XX PR 20-APR 1994; 94US-0241730.  
 XX XX  
 XX PA (DEME) DEMETER BIO-TECHNOLOGIES LTD.  
 XX XX  
 XX PJ Jaynes JM, Julian GR;  
 XX XX  
 XX PR WPI: 1995 482791/49.  
 XX XX  
 XX PT Use of amphipathic peptide(s) for enhancing fibroblast and  
 XX PT keratinocyte proliferation to promote wound healing in a mammal

PS Claim 7; Page 55; 64pp; English.  
 XX XX  
 XX CC AAR84128-73 are amphipathic peptides which are able to stimulate the  
 XX CC proliferative growth of fibroblasts and epithelial cells such as  
 XX CC keratinocytes, hence enhance wound healing in mammalian skin wounds.  
 XX CC The peptides concomitantly have an immunomodulatory effect on  
 XX CC microbial species including those which cause or enhance wound  
 XX CC sepsis and wound infection.  
 XX XX  
 XX SQ Sequence 24 AA;  
 XX XX  
 XX QUOTY Match 72.78; Score 48; DB 11; Length 24;  
 XX XX Best Local Similarity 80.08; Pred. No. 0.8;  
 XX XX Matches 12; Conservation 0; Mismatches 3; Indels 0; Gaps 0;  
 XX XX  
 XX QY 1 FAKALKALKALKAL 15  
 XX XX 11 1111 1111 1  
 XX XX 1 FALAKALKALKALKAL 15  
 XX XX  
 XX ID AAR77080 standard; peptide: 24 AA.  
 XX AC AAR77080;  
 XX XX  
 XX DT 20-MAY 1996 (first entry)  
 XX XX  
 XX DE Synthetic anti neoplastic lytic peptide.  
 XX XX  
 XX KW Anti cancer; lysis; amphipathic; neoplasia; cancer; cystic fibrosis;  
 XX KW bronchopneumonia; viral; virus; anti cancer; anti cancer; anti cancer;  
 XX KW melittin; defensin.  
 XX XX  
 XX CS Synthetic.  
 XX XX  
 XX PN W09527497 A1.  
 XX XX  
 XX ID 19-OCT 1995.  
 XX XX  
 XX PF 06-APR 1995; 95WS-US04435.  
 XX XX  
 XX PR 08-APR 1994; 94US-0225476.  
 XX XX  
 XX PA (DEME) DEMETER BIO-TECHNOLOGIES LTD.  
 XX XX  
 XX PJ Jaynes JM, Julian GR;  
 XX XX  
 XX PR WPI: 1995 366226/47.  
 XX XX  
 XX PT Method of combatting mammalian neoplasias and other diseases, such as  
 XX PT by delivering non-naturally occurring, non-immunogenic, lytic  
 XX PT proliferative lytic peptide.  
 XX XX  
 XX PS Claim 7; Page 53; 64pp; English.  
 XX XX  
 XX CC AAR77042-P77081 are synthetic, amphipathic, lytic peptides and analogues  
 XX CC melittin, cecropin, mannanin and defensin peptides. The peptides are  
 XX CC between 24 and 39 residues long, are amphipathic, carry an overall  
 XX CC positive charge and have anti neoplastic activity. The peptides are  
 XX CC specifically useful for the lysis of cancer cells. X-ray mammography  
 XX CC cells are resistant to lysis due to their highly organised  
 XX CC cytoskeleton, cancerous cells however, possess an altered and  
 XX CC structurally compromised cytoskeleton which when acted upon by lytic  
 XX CC peptides will cause cell lysis. This allows the lytic peptides to be  
 XX CC used for in vivo treatment of cancers. The peptides are also used as  
 XX CC for the treatment of female mammalian cancers of the breast, ovarian,  
 XX CC uterine and cervical cancers. The peptides can however be used to  
 XX CC treat most forms of cancer, cystic fibrosis, bronchopneumonia,  
 XX CC and bronchopulmonary viral and mycobacterial infection, etc.

	Query Match	72.7%	Score 48:	DB 16:	Length 23:
	Best Local Similarity	80.0%	Pred. No.	0.8:	
	Matches 12:	Conservative 9:	Mismatches 3:	Indels 0:	Gaps 0:
QY	1 FAKAIKALKAL 15				
DD	II IIIII IIII I 1 FAIAIKALKKKL 15				
RESULT 25					
ID	AAR#241% standard; peptide: 23 AA.				
AC	AAR#241%;				
XX	1' SPP-1996 (first entry)				
XX					
DE	Lytic peptide used in ubiquitin-lytic peptide fusion protein.				
KW	Ubiquitin: fusion protein; lysis; infection; neoplasia; wound healing; stability: reduced toxicity.				
OS	Synthetic.				
FN	W09603519 AL.				
PD	08-FEB-1996.				
XX	24 JUL 1995: 95W0-US09439.				
PF	22-JUL 1994: 94US-027472.				
PR	(DEMCO) DEMETER BIOTECHNOLOGIES LTD. (USA ) US SPEC OF AGRIC.				
PA	Belknap W., Garbarino J., Jaynes J.				
XX	WP1: 1996 117061/12.				
DR	New fusion protein of ubiquitin and a lytic peptide - for treating infections and neoplasia, healing wounds, etc. also related nucleic acid, vectors, and transformed cells				
FF	Claim 5; Page 23: 12pp; English.				
FPS	AAR#242 R92462 are lytic peptides used to create ubiquitin-lytic peptide fusion proteins in which the ubiquitin polypeptide is linked at its C' terminus to the lytic peptide. The lytic peptides are pre-selected from either the cerropins, detensins, sarcosins, melittin and mullerins. The fusion proteins (FPS) are useful for treating protozoal, bacterial, fungal and viral infections and neoplasia (in plants and animals) in the same way as the FP alone, they also promote wound healing. FPS produced in bacteria may be cleaved in vitro by ubiquitin hydrolases to recover the active lytic peptide. FPS produced in eukaryotic cells are cleaved by cytosolic enzymes to yield lytic peptide. Recombinant DNA encoding the FPS have greater stability in bacteria than DNA encoding the lytic peptide only.				
XX					
SSQ	Sequence     23 AA:				
Query Match	72.7%	Score 48:	DB 17:	Length 24:	
Best Local Similarity	80.0%	Pred. No.	0.8:		
Matches 12:	Conservative 9:	Mismatches 3:	Indels 0:	Gaps 0:	
QY	1 FAKAIKALKAL 15				
DD	II IIIII IIII I 1 FAIAIKALKKKL 15				
RESULT 26					
ID	AABR9972 standard; peptide: 23 AA.				
XX	AABR9972				

KW GnRH: lytic peptide; rat; gonadotrophin-releasing hormone; contraceptive;  
 KW sterility; uterine stimulating hormone; ad; LH-RH; LH; fertility; pituitary;  
 KW lampry; luteinising hormone-releasing hormone; gonadotropin; inhibitor;  
 KW tumor; ligan; fusion protein; reproductive capacity; insect; treatment;  
 KW growth rate; pest control; L-hecate; cancer; adenoma; lymphocyte;  
 KW autoimmune disease.  
 XX Rattus sp.  
 XX W09842465-A1.  
 XX 01-OCT-1998.  
 XX 27-MAR-1998; 98WO-US06114.  
 XX 04-SEP-1997; 97US-0057456.  
 XX 27-MAR-1997; 97US-0041009.  
 XX 04-JUN-1997; 97US-0869153.  
 XX (1000 ) UNIV LOUISIANA STATE & AGRIC & MECH COLL.  
 XX Elzer PL, Enright PM, Foil LD, Hansel W, Jaynes JM;  
 XX Koonce KL, McCann SM, Melrose PA, Yu WH;  
 XX WPI: 1998-531711/45.  
 XX New fusion of hormone and lytic peptide for selective cell killing .  
 XX particularly for controlling fertility in animals, insect pests,  
 XX fish etc., also for treatment of hormone-dependent cancer, viral  
 XX infections and auto-immune diseases  
 XX Example 1 6, Page 37: 59pp: English.  
 XX This sequence represents the rat hecate peptide which is used in a method  
 XX for producing long-term contraception or sterility by administering  
 XX gonadotrophin-releasing hormone (GnRH), beta luteinising hormone (LH) or  
 XX lampry; uterine stimulating hormone-releasing hormone (LHRH) or temporarily  
 XX restoring fertility in a mammal in which the pituitary gonadotropes have  
 XX been selectively destroyed by administration of GnRH or LHRH-III. This  
 XX sequence also has applications in methods for killing, or inhibiting  
 XX growth of hormone- or ligan-dependent tumours by administering the  
 XX relevant hormone- or ligan plus a lytic peptide, for killing a cell the  
 XX activity of which is dependent on binding of a cell-surface receptor to  
 XX a ligan by administering the ligan and lytic peptide, inhibiting  
 XX reproductive capacity of an insect by administration of a lytic peptide,  
 XX fusion proteins combining such proteins and lytic peptides can be fused  
 XX and may also include a carrier domain, specifically vitamin B12, that  
 XX facilitates intestinal uptake after oral administration. These methods  
 XX have applications for increasing the growth rate of mammals, for pest  
 XX control e.g. plants containing an exogenous gene encoding L-hecate. A  
 XX further application is in the treatment of ovarian, breast, prostate,  
 XX endometrial or testicular cancers, prolactinoma, growth hormone-  
 XX thyrotropin or gonadotropin-dependent adenomas, or any pituitary  
 XX adenoma. In addition the proteins can be used to kill lymphocytes  
 XX involved in a wide range of autoimmune diseases or to destroy  
 XX virus infected cells.  
 XX Sequence 23 AA:  
 XX Query Match 72.7%; Score 48; DB 19; Length 23;  
 XX Best Local Similarity 80.0%; Pred. No. 0.8;  
 XX Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 FAFALKALLKALKAL 15  
 Db 1 FAFALKALLKALKAL 15  
 RESULT 28  
 AAW49786  
 ID AAW49786 standard; peptide: 23 AA.  
 AC AAW49786;

XX 20 MAY-1998 (first entry)  
 XX Synthetic peptide DP-1.  
 XX lytic peptide; lysine-rich; proteolytic digestion; methylated; lysine-rich  
 KW protection; amphipathic alpha-helix; heteroprotein; sheet; treatment;  
 KW infection; viral; bacterial; yeast; fungal; proteolysis; cancer; cell;  
 XX Synthetic.  
 XX US5717064-A.  
 XX 10 FEB-1998.  
 XX 24-APR-1995; 95US-0427001.  
 XX 24-APR-1995; 95US-0427001.  
 XX 18-NOV-1993; 94US-0148889.  
 XX (DEME-) DEMETER BIOTECHNOLOGIES LTD.  
 XX Jaynes JM, Julian GR;  
 XX WPI: 1998-168370/14.  
 XX Cytolytic peptide analogues - with methylated lysine residues for  
 XX increase protease resistance  
 XX Example 2: column 9: 21pp: English.  
 XX Peptide AAW49796 (also known as DP-1) is used as a test substrate for a  
 XX reductive alkylation reaction used in the analysis of a family of  
 XX synthetic lytic peptides which are stabilised by having methylated  
 XX epsilon-amino groups at their lysine residues (see AAW49796, WPI 9505).  
 XX peptides AAW49750-W49771 and AAW49781-W49785 have amphipathic  
 XX alpha-helix conformation while peptides AAW49772-W49780 have a  
 XX beta-sheet conformation. These peptides have enhanced resistance  
 XX to proteolytic digestion by trypsin. Such peptides can be used to treat  
 XX infections by lysing bacterial, yeast, fungal and protozoan cells or to  
 XX treat cancers by lysing neoplastic or transformed cells. They can also be  
 XX used to treat viral infections by lysing enveloped viruses and  
 XX virus-infected cells.  
 XX Sequence 23 AA:  
 XX Query Match 72.7%; Score 48; DB 19; Length 23;  
 XX Best Local Similarity 80.0%; Pred. No. 0.8;  
 XX Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 FAFALKALLKALKAL 15  
 Db 1 FAFALKALLKALKAL 15  
 RESULT 29  
 AAW03857  
 ID AAW03857 standard; peptide: 23 AA.  
 AC AAW03857;  
 XX 16-JUN-1999 (first entry)  
 XX Amino acid sequence of a lytic peptide hecate.  
 XX Contraception; sterility; amphipathic; lytic peptide; hormone; gonadotrophin-releasing hormone; GnRH; anti-cancer; cell; cancer;  
 KW cow; bull; pig; horse; sheep.  
 XX Synthetic.  
 XX W09911282-A1.  
 XX



pt. acm., inhibiting growth of microbial cells, or promoting proliferation of cells, comprises phenylalanine, leucine, alanine or lysine residues

claim 7; page 5; 13pp; new list.

the invention relates to a novel isolated peptide which is 5-23 amino acids in length, and comprising phenylalanine, leucine, alanine or lysine residues, or contains at least 50 % of the residues, the peptides of the invention have antibacterial, fungicidal, cytostatic, and cytotoxic activity. The peptides are useful in treating cancer, cystic fibrosis or acne, inhibiting the growth of microbial cells, promoting the stimulation and/or proliferation of human fibroblasts and lymphocytes, promoting wound healing, and in enhancing the activity of a therapeutic agent. The sequences shown in AEP0759-AEP09923 represent the bioactive peptides of the invention.

23 AA:

Query Match	72.7%;	Score 48;	DB 24;	Length 23;
Best Local Similarity	80.0%;	Pred. No. 0.8;		

1 FAKALKALILKALKAL 15  
1 FALKALKALKALKAL 15

1 P A I A L K A I . K K A I . K K L 15

## RESUME

546(1)445

[11] ABR(0045) standard; peptide; 23 AA.

XX

Ac: 5, 6, 10, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 84

03-APR-2003 (first entry)

DE Bioactive synthetic peptide Hecate AC #1010.

XX Antibacterial; fungicide; cytostatic; vulvar; cancer; cystic fibrosis;  
XW acne; antimicrobial; human fibroblast; human lymphocyte; wound healing;  
XW bioactive.

Synthetic.

W0240279408-A2.

10-0887-2002.

28 - MAY - 2002: 2002WO-US09534

**X**

28-MAR-2001; 2001US-279505P.

28-MAR-2011: 2001US-0820053

XX

A (HELI-) HELIX BIOMED

new DR;  
WPI: 2003 221247/21.  
New isolated peptide for treating cancer, cystic fibrosis, wounds or acne, inhibiting growth of microbial cells, or promoting proliferation of cells, comprises phenylalanine-leucine-alanine or lysine residues.

St. Clair, 2000: 153

The invention relates to a novel isolated peptide which is 5-23 amino acids in length, and comprising phenylalanine, leucine, alanine or lysine residues, or contains at least 50 % of the residues. The peptides of the invention have antibacterial, tumoricide, cytostatic, and cytotoxic activity. The peptides are useful in treating cancer, cystic fibrosis or acne, inhibiting the growth of microbial cells, promoting the stimulation and/or proliferation of human fibroblasts and lymphocytes.







XX PF 26 MAR 2002: 2002W0-US09534.  
 XX  
 XX 26 MAR 2001: 2001US-279505P.  
 XX 26 MAR 2001: 2001US-0820053.  
 XX  
 XX (HBLI-) BELIX BIOMEDIX INC.  
 XX  
 XX Owen DR;  
 XX  
 XX WPI: 2003-221247/21.  
 XX  
 XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 XX acne, inhibiting growth of microbial cells, or promoting proliferation  
 XX of cells, comprises phenylalanine, leucine, alanine or lysine residues  
 XX  
 XX Claim 7: Page 5; 134pp; English.  
 XX  
 XX The invention relates to a novel isolated peptide which is 5-23 amino  
 XX acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 XX residues, or contains at least 50 % of the residues. The peptides of the  
 XX invention have antibacterial, tumoricide, cytostatic, and vulnerary  
 XX activity. The peptides are useful in treating cancer, cystic fibrosis or  
 XX acne, inhibiting the growth of microbial cells, promoting the  
 XX stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 XX promoting wound healing, and in enhancing the activity of a therapeutic  
 XX agent. The sequences shown in ABR00759-ABR00923 represent the bioactive  
 XX peptides of the invention.  
 XX  
 XX Sequence 19 AA;  
 XX  
 XX Query Match 64.6% Score 42; ID 24; Length 19;  
 XX Best Local Similarity 74.6%; Pred. No. 5.4;  
 XX Matches 11; Conservative 6; Mismatches 4; Indels 0; Gaps 0;  
 XX  
 XX QY 1 FAKAKALKALKALK 15  
 XX 11111111111  
 XX 1 FAKAKALKALKALK 15  
 XX  
 XX RESULT 40  
 XX ABR00826  
 XX ID ABR00826 standard; peptide: 20 AA  
 XX AC ABR00826;  
 XX  
 XX 03 APR 2003 (first entry)  
 XX  
 XX Bioactive synthetic peptide KA(1) allevate(11/23).  
 XX Act (bacterial, tumoricide, cytostatic, vulnerary, cancer, cystic fibrosis,  
 XX acne, antimicrobial); human fibroblast; human lymphocyte; wound healing;  
 XX bioactive.  
 XX  
 XX Synthesized.  
 XX  
 XX Key location/Qualifiers  
 XX FH  
 XX Modified site 20  
 XX /note "C-terminal amide"  
 XX  
 XX WZ00270408 AZ.  
 XX  
 XX 10 OCT 2002.  
 XX  
 XX 26 MAR 2002: 2002W0-US09534.  
 XX  
 XX 26 MAR 2001: 2001US-279505P.  
 XX 26 MAR 2001: 2001US-0820053.  
 XX  
 XX (HBLI-) BELIX BIOMEDIX INC.  
 XX  
 XX Owen DR;  
 XX

XX WPI: 2003-221247/21.  
 XX  
 XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 XX acne, inhibiting growth of microbial cells, or promoting proliferation  
 XX of cells, comprises phenylalanine, leucine, alanine or lysine residues  
 XX  
 XX Claim 7: Page 5; 134pp; English.  
 XX  
 XX The invention relates to a novel isolated peptide which is 5-23 amino  
 XX acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 XX residues, or contains at least 50 % of the residues. The peptides of the  
 XX invention have antibacterial, tumoricide, cytostatic, and vulnerary  
 XX activity. The peptides are useful in treating cancer, cystic fibrosis or  
 XX acne, inhibiting the growth of microbial cells, promoting the  
 XX stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 XX promoting wound healing, and in enhancing the activity of a therapeutic  
 XX agent. The sequences shown in ABR00759-ABR00923 represent the bioactive  
 XX peptides of the invention.  
 XX  
 XX Sequence 20 AA;  
 XX  
 XX Query Match 64.6% Score 42; ID 24; Length 20;  
 XX Best Local Similarity 76.6%; Pred. No. 5.4;  
 XX Matches 11; Conservative 6; Mismatches 4; Indels 0; Gaps 0;  
 XX  
 XX QY 1 FAKAKALKALKALK 15  
 XX 11111111111  
 XX 1 FAKAKALKALKALK 17  
 XX  
 XX RESULT 40  
 XX ABR00773  
 XX ID ABR00773 standard; peptide: 25 AA  
 XX AC ABR00773;  
 XX  
 XX 03 APR 2003 (first entry)  
 XX  
 XX Bioactive synthetic peptide KAL V.  
 XX Act (bacterial, tumoricide, cytostatic, vulnerary, cancer, cystic fibrosis,  
 XX acne, antimicrobial); human fibroblast; human lymphocyte; wound healing;  
 XX bioactive.  
 XX  
 XX Synthesized.  
 XX  
 XX Key location/Qualifiers  
 XX FH  
 XX Modified site 24  
 XX /note "C-terminal amide"  
 XX  
 XX WZ00270408 AZ.  
 XX  
 XX 10 OCT 2002.  
 XX  
 XX 26 MAR 2002: 2002W0-US09534.  
 XX  
 XX 26 MAR 2001: 2001US-279505P.  
 XX 26 MAR 2001: 2001US-0820053.  
 XX  
 XX (HBLI-) BELIX BIOMEDIX INC.  
 XX  
 XX Owen DR;  
 XX  
 XX WPI: 2003-221247/21.  
 XX  
 XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 XX acne, inhibiting growth of microbial cells, or promoting proliferation  
 XX of cells, comprises phenylalanine, leucine, alanine or lysine residues  
 XX  
 XX Claim 7: Page 5; 134pp; English.  
 XX

XX The invention relates to a novel isolated peptide which is 5-23 amino  
 CC acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 CC residues, or contains at least 50 % of the residues. The peptides of the  
 CC invention have antibacterial, fungicide, cytostatic, and vulnerary  
 CC activity. The peptides are useful in treating cancer, cystic fibrosis or  
 CC acne, inhibiting the growth of microbial cells, promoting the  
 CC stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 CC stimulating wound healing, and in enhancing the activity of a therapeutic  
 CC agent. The sequences shown in AB009759 AB009923 represent the bioactive  
 CC peptides of the invention.

XX Sequence 23 AA:

Query Match 63.6% Score 42; DB 24; Length 23;  
 Best Local Similarity 78.6% Pred. No. 6.5;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AAALFALEAKAL 15  
 DB 1 11111 11111  
 2 ALALEAKALEEL 15

# RESULT 41

AB009916  
 ID AB009916 standard; peptide; 23 AA.

AC AB009916;

XX 03-APR-2003 (first entry)

XX Bioactive synthetic peptide HECATE AMV.

XX Antibacterial; fungicide; cytostatic; vulnerary; cancer; cystic fibrosis;  
 KW acne; antimicrobial; human fibroblast; human lymphocyte; wound healing.

KW Bioactive.

OS Synthetic.

FB Key location/qualifiers

FT Modified-site 23 /note: "C-terminal amide"

XX W020279438 A2.

XX 10-OCT-2002.

XX 28-MAR-2002; 2002W0-US09534.

XX 28-MAR-2001; 2001US-274505P.

XX 28-MAR-2001; 2001US-0820053.

XX (HELI-) HELIX BIOMEDIX INC.

XX Owen DR;

XX WPI; 2003 221217/21.

XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 CC acne, inhibiting growth of microbial cells, or promoting proliferation  
 CC of cells, comprises phenylalanine, leucine, alanine or lysine residues

XX Example 2; Page 9; 13pp; English.

XX The invention relates to a novel isolated peptide which is 5-23 amino  
 CC acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 CC residues, or contains at least 50 % of the residues. The peptides of the  
 CC invention have antibacterial, fungicide, cytostatic, and vulnerary  
 CC activity. The peptides are useful in treating cancer, cystic fibrosis or  
 CC acne, inhibiting the growth of microbial cells, promoting the  
 CC stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 CC promoting wound healing, and in enhancing the activity of a therapeutic

CC agent. The sequences shown in AB009759 AB009923 represent the bioactive  
 CC peptides of the invention.

XX Sequence 23 AA:

Query Match 63.6% Score 42; DB 24; Length 23;  
 Best Local Similarity 78.6% Pred. No. 6.5;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AAALFALEAKAL 15  
 DB 1 11111 11111  
 2 ALALEAKALEEL 15

# RESULT 42

AB009917

ID AB009917 standard; peptide; 23 AA.

AC AB009917;

XX 03-APR-2003 (first entry)

XX Bioactive synthetic peptide HECATE AMV.

XX Antibacterial; fungicide; cytostatic; vulnerary; cancer; cystic fibrosis;  
 KW acne; antimicrobial; human fibroblast; human lymphocyte; wound healing.

OS Synthetic.

PN W0200279408 A2.

XX 10-OCT-2002.

XX 28-MAR-2002; 2002W0-US09534.

XX 28-MAR-2001; 2001US-274505P.

XX 28-MAR-2001; 2001US-0820053.

XX (HELI-) HELIX BIOMEDIX INC.

XX Owen DR;

XX WPI; 2003 221217/21.

XX New isolated peptide for treating cancer, cystic fibrosis, wounds or  
 CC acne, inhibiting growth of microbial cells, or promoting proliferation  
 CC of cells, comprises phenylalanine, leucine, alanine or lysine residues

XX Claim 7; Page 9; 13pp; English.

XX The invention relates to a novel isolated peptide which is 5-23 amino  
 CC acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 CC residues, or contains at least 50 % of the residues. The peptides of the  
 CC invention have antibacterial, fungicide, cytostatic, and vulnerary  
 CC activity. The peptides are useful in treating cancer, cystic fibrosis or  
 CC acne, inhibiting the growth of microbial cells, promoting the  
 CC stimulation and/or proliferation of human fibroblasts and lymphocytes,  
 CC promoting wound healing, and in enhancing the activity of a therapeutic  
 CC agent. The sequences shown in AB009759 AB009923 represent the bioactive  
 CC peptides of the invention.

XX Sequence 23 AA:

Query Match 63.6% Score 42; DB 24; Length 23;  
 Best Local Similarity 78.6% Pred. No. 6.5;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AAALFALEAKAL 15  
 DB 1 11111 11111  
 2 ALALEAKALEEL 15



FT Modified-site 24 /note- "C-terminal amide"

XX W0200279408-A2.

XX 10-OCT-2002.

XX 28-MAR-2002; 2002W0-050534.

XX 28-MAR-2001; 200105-279505P.

XX 28-MAR-2001; 200105-082053.

XX (HELIX) HELIX BIOMEDIX INC.

XX OPEN DR.

XX WP: 2002 22124721.

PT Now isolated peptide for treating cancer, cystic fibrosis, wounds or  
 PT acne, inhibiting growth of microbial cells, or promoting proliferation  
 PT of cells, comprises phenylalanine, leucine, alanine or lysine residues  
 PT

XX Example 2: Page 9; 13pp; English.

XX The invention relates to a novel isolated peptide which is 5-23 amino  
 CC acids in length, and comprising phenylalanine, leucine, alanine or lysine  
 CC residues, or contains at least 50 % of the residues. The peptides of the  
 CC invention have antibacterial, fungicide, cytostatic, and vulcerary  
 CC activity. The peptides are useful in treating cancer, cystic fibrosis or  
 CC acne, inhibiting the growth of microbial cells, promoting the  
 CC stimulation and/or proliferation of microbial cells, promoting the  
 CC promoting wound healing, and in enhancing the activity of a therapeutic  
 CC agent. The sequences shown in AB00759-AB00923 represent the bioactive  
 CC peptides of the invention.

XX Sequence 24 AA:

Query Match 62.1% Score 41; DB 24; Length 23;  
 Best Local Similarity 76.9%; Pred. NO. 9.3;  
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4 KALKALKALKAL 15

DB 6 KALKALKALKAL 18

|||||

Search completed: August 21, 2003, 08:19:04

Job Time : 84 secs



GenCore version 5.1.6  
Copyright (c) 1993-2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 21, 2003, 08:08:00 ; Search time 94 Seconds  
(without alignments)

41.179 Million cell updates/sec

Title: US-09-820-053A-43

Perfect score: 66

Sequence: 1 FAKALKALKALEAL 15

Scoring table: BLOSUM62

Gapop 10.0 ; Gapov 0.5

Searched: 840525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 10083

Minimum DB seq length: 0

Maximum DB seq length: 25

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPREMMI\_23:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_nhr:\*  
8: sp\_orqanelle:\*  
9: sp\_phage:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp\_vertebrate:\*  
14: sp\_unclassified:\*  
15: sp\_rvirus:\*  
16: sp\_bacteriaph:\*  
17: sp\_archaea:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	29	43.9	20	2 Q56130	Q56130 salmonella
2	26	39.4	21	2 Q46010	Q46010 clostridium
3	26	39.4	21	2 Q46011	Q46011 clostridium
4	26	39.4	25	15 Q98828	Q98828 human lamina
5	26	39.4	25	15 Q98826	Q98826 human lamina
6	26	39.4	25	15 Q98817	Q98817 human lamina
7	25	37.9	18	1 Q90827	Q90827 methanococcus
8	24	36.4	11	2 P77404	P77404 escherichia
9	24	36.4	11	2 P95518	P95518 pasteurella
10	24	36.4	19	2 Q98510	Q98510 arthrobacter
11	24	36.4	20	3 P82876	P82876 rana clamit
12	24	36.4	24	5 Q96885	Q96885 strongyloides
13	23	34.8	15	13 P83333	P83333 oncorhynchus
14	23	34.8	17	8 Q93468	Q93468 brassica ju
15	23	34.8	19	4 Q97111	Q97111 homo sapien
16	23	34.8	23	12 Q97799	Q97799 pseudotuberc

#### ALIGNMENTS

##### RESULT 1

Q56130 ID Q56130 PRELIMINARY: PRI: 20 AA.  
AC Q56130:  
DI 01-NOV-1996 (JEMBLREL\_01, Created)  
DI 01-NOV-1996 (JEMBLREL\_01, Last sequence update)  
DI 01-DEC-2001 (JEMBLREL\_19, Last annotation update)  
DE typhimurium ipos RNA polymerase beta subunit (Flamm et al.)  
OS Salmonella typhimurium.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
OC Enterobacteriaceae; Salmonella.  
OX NCBI\_TaxID:602;  
RN [1]  
RP SEQUENCE FROM N.A.  
EA Svetlich E.P., Lisitsyn N.A., Gurev S.A., Muznytykaya G.S.:  
RT "Nucleotide sequence of the ipos gene of Salmonella typhimurium  
ET Coding for the beta subunit of RNA polymerase."  
RL Dck1, Biochem, 287:232-246(1986).  
RN [2]  
RP SEQUENCE FROM N.A.  
KA Svetlich E.P., Lisitsyn N.A., Gurev S.A., Muznytykaya G.S.:  
RT "Nucleotide sequence of the ipos gene of Salmonella typhimurium  
ET for the beta subunit of RNA polymerase."  
RL Dck1, Biochem, 287:62-65(1986).  
RN [3]  
RP SEQUENCE FROM N.A.  
KA Svetlich E.P., Lisitsyn N.A., Muznytykaya G.S.:  
RT "Sequences coding for RNA polymerase beta subunit in bacteria."  
RL Eur J Biochem, 177:363-369(1988).  
OK EMBL, X54542, 20-20  
ET NCBI  
SQ SEQUENCE: 23 AA, 2376 MW, 6246.64209 kDa (P77404)

Query Match 43.9% Score 29.00  
Best local similarity 70.0% Pred. No. 6, seq. 23  
Matches 7, Conservative 1, Mismatches 23 Indels 0 Gaps 0

5 FAKALKALKALEAL 14







[illegible]





Matches 6: Conservative 0: Mismatches 3: Indels 0: Gaps 0:

QY 2 AKALKALK 16  
11111111

DB 4 AKALKALK 12

#### RESULT 23

Q14001

ID Q14001 PRELIMINARY: PRI: 17 AA.

AC Q14001

DT 01 NOV 1996 (FEBRELL, 01, Created)

DT 01 NOV 1996 (FEBRELL, 01, Last sequence update)

DT 01 DEC 2001 (FEBRELL, 19, Last annotation update)

DE Cyclic nucleotide phosphodiesterase (Fragment).

OS HUMAN

OC Homo sapiens (Human)

OC Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi:

OC Mammalia: Eutheria: Primates: Catarrhini: Hominoidea: Homo.

OX NCBI TaxID 9606

RN 111

RP SEQUENCE FROM N.A.

RX MEDLINE 97074687; PubMed 89214987

RA Leichter R.W., Winterpacht A., Seipel R., Zabel R.D.:

RF "Molecular cloning and chromosomal assignment of the human homologue

RI of the rat cAMP-inhibited phosphodiesterase 1 (PDE1A) A gene involved

RI in fat metabolism located at 11p15.1."

RL Genomics 87:211-218(1997).

DR EMBL: X95822; CAA64776.1 (1)

FT NON\_TER 17

SQ SEQUENCE 17 AA; 2057 MW; 69311734FAE11543 CRC64.

#### Query Match

Best Local Similarity 33.48; Score 22; DB 4; Length 17;

Matches 4: Conservative 3: Mismatches 0: Indels 0: Gaps 0:

QY 2 AKALKALK 9  
11111111

DB 8 AKALKALK 14

#### RESULT 24

Q26342

ID Q26342 PRELIMINARY: PRI: 18 AA.

AC Q26342

DT 01 MAY 1999 (FEBRELL, 16, Created)

DT 01 MAY 1999 (FEBRELL, 16, Last sequence update)

DT 01 MAY 1999 (FEBRELL, 16, Last annotation update)

DE Proline transport protein (Fragment).

OS Chlamydia trachomatis.

OC Bacteria: Chlamydia: Chlamydiales: Chlamydiaceae: Chlamydia.

OX NCBI TaxID 617

RN 111

RP SEQUENCE FROM N.A.

RX STRAIN L2 4349

RA Wang L., Steenborg S.D., Zheng Y., Larson S.H.:

RF "Gene identification of Chlamydia trachomatis by random DNA

RI sequencing."

RL Submitted (603-1998) to the EMBL/Genbank/DBJ databases.

DR EMBL: AF067425; AA064100.1 (1)

FT NON\_TER 18

SQ SEQUENCE 18 AA; 2236 MW; 550A82FD42C0261 CRC64;

#### Query Match

Best Local Similarity 33.48; Score 22; DB 4; Length 18;

Matches 5: Conservative 0: Mismatches 1: Indels 0: Gaps 0:

QY 1 FAKALK 6  
11111111

DB 10 FFAKALK 15

#### RESULT 25

Q964P1

ID Q964P1

AC Q964P1 PRELIMINARY: PRI: 19 AA.

DT 01 MAY 2000 (FEBRELL, 13, Created)

DT 01 MAY 2000 (FEBRELL, 13, Last sequence update)

DT 01 JUN 2000 (FEBRELL, 14, Last annotation update)

DE Ribosomal protein S21 (Fragment).

OS Brugia malayi (Nematoda: Secernentea: Secernentea).

OC Bacteria: Proteobacteria: Alphaproteobacteria: Rickettsiales: Rickettsiaceae: Brugia malayi.

OX NCBI TaxID 41276

RN 111

RP SEQUENCE

RX MEDLINE 95244409; PubMed 7727274

RA Gell R.:

RF "Comparative ribosomal protein sequence analysis for 13S ribosomal

RI protein S21, Brugia malayi, and B. malayi (1995)."

RL Int. J. Syst. Bacteriol. 45:268-273(1995).

SQ SEQUENCE 19 AA; 2071 MW; 233A59141F11111111 CRC64;

#### Query Match

Best Local Similarity 43.48; Score 22; DB 2; Length 19;

Matches 5: Conservative 1: Mismatches 0: Indels 0: Gaps 0:

QY 2 FAKALK 8  
11111111

DB 12 FAKALK 17

#### RESULT 26

Q95B18

ID Q95B18

AC Q95B18 PRELIMINARY: PRI: 19 AA.

DT 01 MAY 2000 (FEBRELL, 13, Created)

DT 01 MAY 2000 (FEBRELL, 13, Last sequence update)

DT 01 DEC 2001 (FEBRELL, 19, Last annotation update)

DE Potato patatin (Fragment).

OS Solanum tuberosum (Potato).

OC Eukaryota: Viridiplantae: Streptophyta: Embryophyta: Eudicotyledones: Magnoliopsida: Solanales: Solanaceae: Solanum.

OC Spermatophyta: Magnoliophyta: Euphorbiales: Euphorbiaceae: Euphorbia.

OX NCBI TaxID 4118

RN 111

RP SEQUENCE FROM N.A.

RX Well D., Gans G.:

RF "The 5' flanking DNA of a patatin gene directs tuber-specific

RI expression of a chimeric gene in potato."

RL Plant Mol. Biol. 9:445-475(1992).

DR EMBL: M17640; AAA34818.1 (1)

FT NON\_TER 1

SQ SEQUENCE 19 AA; 2109 MW; 120F5A660710620 CRC64;

#### Query Match

Best Local Similarity 43.48; Score 22; DB 10; Length 19;

Matches 8: Conservative 2: Mismatches 4: Indels 0: Gaps 0:

QY 1 FAKALK 14  
11111111111111

DB 1 FAKALK 14

#### RESULT 27

Q90K05

ID Q90K05

AC Q90K05 PRELIMINARY: PRI: 19 AA.

DT 01 MAY 2000 (FEBRELL, 13, Created)

DT 01 MAY 2000 (FEBRELL, 13, Last sequence update)

DT 01 MAY 2000 (FEBRELL, 13, Last annotation update)

DE Verticillium dactylarum (Fungi: Ascomycota: Ascomycota).

OS Verticillium

OC Eukaryota: Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi:



RP	SEQUENCE FROM N.A.
RQ	STRAIN Becker;
KX	MEDLINE 96070924; PubMed 7499261;
KA	Kyan P., Edwards C.G.;
KI	"Systematic introduction of proline in a eukaryotic signal sequence
KJ	and its effect on the hydrophobic core.";
KL	J. Biol. Chem. 270:27876-27879(1995).
DR	EMBL: U29125; AAC54545.1; .
KW	SIGNAL.
FT	SIGNAL.
FI	NON_TER
SQ	SEQUENCE 23 AA; 2271 MW; B711E0B81406F3F CRC64; 1 22 23 25 POTENTIAL.
QY	Query Match: Best Local Similarity 33.3%; Score 22; DB 12; Length 23; Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
DG	2 AKALKALL 9 1 1 1 1 1 5 ARAMALL 12
RESULT 42	
Q69491	PRELIMINARY; PRT; 23 AA. AC Q69491 DT 01-NOV-1996 (TrEMBLrel. 01, Created) DI 01-NOV-1996 (TrEMBLrel. 01, Last sequence update) DE Glycoprotein C precursor (fragment). GN GC. OS Psudovirales virus. OC Viruses; dsDNA viruses, no RNA stage; herpesviridae; CC Alphaherpesvirinae; Varicellovirus. OX NCBI_TaxID:10345; [1] RP SEQUENCE FROM N.A. RQ STRAIN-Recker; KX MEDLINE=95081163; PubMed=7993378; KA Tomita M., Wilkinson F.S., Kyte J.; KI "Can a signal sequence become too hydrophobic?"; KL J. Biol. Chem. 269:32016-32021(1994). DR EMBL: L30969; AAA79966.1; . KW Signal. FT SIGNAL. FI NON_TER SQ SEQUENCE 23 AA; 2293 MW; B711261E9746D96F CRC64; 1 22 23 25 POTENTIAL.
QY	Query Match: Best Local Similarity 33.3%; Score 22; DB 12; Length 23; Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
DG	2 AKALKALL 9 1 1 1 1 1 5 ARAMALL 12
RESULT 43	
Q87084	PRELIMINARY; PRT; 23 AA. ID Q87084 AC Q87084 DI 01-NOV-1996 (TrEMBLrel. 01, Created) DI 01-NOV-1996 (TrEMBLrel. 01, Last sequence update) DE Glycoprotein C precursor (fragment). GN GC. OS Psudovirales virus. OC Viruses; dsDNA viruses, no RNA stage; herpesviridae; CC Alphaherpesvirinae; Varicellovirus. OX NCBI_TaxID:10345; [1] RP SEQUENCE FROM N.A. RQ STRAIN Becker;

[illegible]



us-09-820-053a-43.rspt

Thu Aug 21 08:36:30 2003

OC Viruses; Retroviral viruses; Retroviridae; Lentiviruses.

OX NCBI\_TaxID:11676;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN:TV001-25;  
 RX MEDLINE:21422026; PubMed:11429118;  
 RA Scriba T.J., Tournicht F.K., Zeller M., Engelbrecht S.,  
 RA van Kousburg E.J.;  
 RI "Characterization and phylogenetic analysis of South African HIV-1  
 RT subtype C accessory genes."  
 RL AIDS Res. Hum. Retroviruses 17:775-781(2001).  
 DR EMBL: AF425742; AAK09100.1;  
 DR InterPro: IPR000625; REV\_protein.  
 DR Pfam: PF00424; REV: 1;  
 FT NON\_TER 25  
 SQ SEQUENCE 25 AA; 2735 MW; 4E934F445E4F224B CRG64

Query Match 34.4% Score 22; DB 15; Length 25;  
 Best Local Similarity 40.0% Prod. No. 9.2e+03;  
 Matches 4; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 6 KALLKALKAL 15 0; Gaps 0;  
 DB 10 EALLQAVRII 19

RESULT 42

Q99BQ0 PRELIMINARY; PRI: 25 AA.  
 AC Q99BQ0;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-oct-2002 (TrEMBLrel. 22, Last annotation update)  
 DE Rev protein (Fragment).  
 GN REV.  
 OS human immunodeficiency virus 1.  
 OC Viruses; Retroviral viruses; Retroviridae; Lentiviruses.

OX NCBI\_TaxID:11676;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN:TV001-25;  
 RX MEDLINE:21422026; PubMed:11429118;  
 RA Scriba T.J., Tournicht F.K., Zeller M., Engelbrecht S.,  
 RA van Kousburg E.J.;  
 RI "Characterization and phylogenetic analysis of South African HIV-1  
 RT subtype C accessory genes."  
 RL AIDS Res. Hum. Retroviruses 17:775-781(2001).  
 DR EMBL: AF425742; AAK09100.1;  
 DR InterPro: IPR000625; REV\_protein.  
 DR Pfam: PF00424; REV: 1;  
 FT NON\_TER 25  
 SQ SEQUENCE 25 AA; 2735 MW; 4E934F445E4F224B CRG64

Query Match 34.4% Score 22; DB 15; Length 25;  
 Best Local Similarity 40.0% Prod. No. 9.2e+03;  
 Matches 4; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 6 KALLKALKAL 15 0; Gaps 0;  
 DB 10 EALLQAVRII 19

RESULT 43

Q99BQ0 PRELIMINARY; PRI: 25 AA.  
 AC Q99BQ0;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-oct-2002 (TrEMBLrel. 22, Last annotation update)  
 DE Rev protein (Fragment).  
 GN REV.  
 OS human immunodeficiency virus 1.  
 OC Viruses; Retroviral viruses; Retroviridae; Lentiviruses.

OX NCBI\_TaxID:11676;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN:TV001-25;  
 RX MEDLINE:21422026; PubMed:11429118;  
 RA Scriba T.J., Tournicht F.K., Zeller M., Engelbrecht S.,  
 RA van Kousburg E.J.;  
 RI "Characterization and phylogenetic analysis of South African HIV-1  
 RT subtype C accessory genes."  
 RL AIDS Res. Hum. Retroviruses 17:775-781(2001).  
 DR EMBL: AF425742; AAK09100.1;  
 DR InterPro: IPR000625; REV\_protein.  
 DR Pfam: PF00424; REV: 1;  
 FT NON\_TER 25  
 SQ SEQUENCE 25 AA; 2735 MW; 4E934F445E4F224B CRG64

Query Match 34.4% Score 22; DB 15; Length 25;  
 Best Local Similarity 40.0% Prod. No. 9.2e+03;  
 Matches 4; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 6 KALLKALKAL 15 0; Gaps 0;  
 DB 10 EALLQAVRII 19

RESULT 44

Q99BQ0 PRELIMINARY; PRI: 25 AA.  
 AC Q99BQ0;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-oct-2002 (TrEMBLrel. 22, Last annotation update)  
 DE Rev protein (Fragment).  
 GN REV.  
 OS human immunodeficiency virus 1.  
 OC Viruses; Retroviral viruses; Retroviridae; Lentiviruses.

OX NCBI\_TaxID:11676;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN:TV001-25;  
 RX MEDLINE:21422026; PubMed:11429118;  
 RA Scriba T.J., Tournicht F.K., Zeller M., Engelbrecht S.,  
 RA van Kousburg E.J.;  
 RI "Characterization and phylogenetic analysis of South African HIV-1  
 RT subtype C accessory genes."  
 RL AIDS Res. Hum. Retroviruses 17:775-781(2001).  
 DR EMBL: AF425742; AAK09100.1;  
 DR InterPro: IPR000625; REV\_protein.  
 DR Pfam: PF00424; REV: 1;  
 FT NON\_TER 25  
 SQ SEQUENCE 25 AA; 2735 MW; 4E934F445E4F224B CRG64

Query Match 34.4% Score 22; DB 15; Length 25;  
 Best Local Similarity 40.0% Prod. No. 9.2e+03;  
 Matches 4; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 6 KALLKALKAL 15 0; Gaps 0;  
 DB 10 EALLQAVRII 19

RESULT 45

Q99BQ0 PRELIMINARY; PRI: 25 AA.  
 AC Q99BQ0;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-oct-2002 (TrEMBLrel. 22, Last annotation update)  
 DE Rev protein (Fragment).  
 GN REV.  
 OS human immunodeficiency virus 1.  
 OC Viruses; Retroviral viruses; Retroviridae; Lentiviruses.

OX NCBI\_TaxID:11676;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN:TV001-25;  
 RX MEDLINE:21422026; PubMed:11429118;  
 RA Scriba T.J., Tournicht F.K., Zeller M., Engelbrecht S.,  
 RA van Kousburg E.J.;  
 RI "Characterization and phylogenetic analysis of South African HIV-1  
 RT subtype C accessory genes."  
 RL AIDS Res. Hum. Retroviruses 17:775-781(2001).  
 DR EMBL: AF425742; AAK09100.1;  
 DR InterPro: IPR000625; REV\_protein.  
 DR Pfam: PF00424; REV: 1;  
 FT NON\_TER 25  
 SQ SEQUENCE 25 AA; 2735 MW; 4E934F445E4F224B CRG64

Query Match 34.4% Score 22; DB 15; Length 25;  
 Best Local Similarity 40.0% Prod. No. 9.2e+03;  
 Matches 4; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 6 KALLKALKAL 15 0; Gaps 0;  
 DB 10 EALLQAVRII 19

```

OX  NBL TaxID 11676;
RN  111
RP  SEQUENCE FROM N.A.
RC  STRAIN 1V002-84; PubMed 11429118;
RX  MEDLINE 21422026; PubMed 11429118;
RA  Takahashi T, Zokora T, 140 F., Yamaguchi-Kabata Y., Mitsujioka T.,
KA  Harada Y., Miura T., Katoe I., Hayami M.;
PC  "Human immunodeficiency virus type 1 infection (HIV) recombination in
RT  Cameroon";
RL  J. Virol. 73:6810-6820(1999);
LR  EMBL: AF556732; AAD44399.1;
DR  EMBL: AF055741; AAD44392.1;
LR  InterPro: IPR000625; REV_Protein.
DR  PIR: P00424; REV: 1;
FI  NON TER 25
SQ  SEQUENCE 25 AA: 2514 MW: 409965818745610 CRC64;

Query Match
Best Local Similarity 43.48; Score 22; DB 15; Length 25;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

CY  6 KALKAL 16
ID  111111
ID  10 KALKAL 16

RESULT 44
QUERY:
ID  Q09081 PRELIMINARY; PRI: 25 AA.
DI  01 JUN 2001 (Fremont, 17, Created)
DI  01 JUN 2001 (Fremont, 17, Last sequence update)
DI  01 OCT 2002 (Fremont, 22, Last annotation update)
DE  Rev protein (Fragment).
CN  REV.
OS  Human immunodeficiency virus 1.
OC  Viruses; Retroviruses; Retroviridae; Lentivirus.
OX  NBL TaxID 11676;
RN  111
RP  SEQUENCE FROM N.A.
RC  STRAIN 1V002-84;
RX  MEDLINE 21422026; PubMed 11429118;
RA  Setbon L.J., Tremblat F.R., Zetor M., Ennelbrecht S.,
RI  "Characterization and phylogenetic analysis of South African HIV 1
RL  subtype 'c' accessory genes.";
RL  AIDS Res. Hum. Retroviruses 17:775-781(2001).
DR  EMBL: AF527343; AAK0105.1;
DR  InterPro: IPR000625; REV_Protein.
DR  PIR: P00424; REV: 1;
FI  NON TER 25
SQ  SEQUENCE 25 AA: 2762 MW: 48865735642248 CRC64;

Query Match
Best Local Similarity 43.48; Score 22; DB 15; Length 25;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

CY  6 KALKAL 16
ID  111111
ID  10 KALKAL 16

RESULT 45
QUERY:
ID  Q09088 PRELIMINARY; PRI: 25 AA.
DI  01 JUN 2001 (Fremont, 17, Created)
DI  01 JUN 2001 (Fremont, 17, Last sequence update)
DI  01 OCT 2002 (Fremont, 22, Last annotation update)
DE  Rev protein (Fragment).
CN  REV.
OS  Human immunodeficiency virus 1.
OC  Viruses; Retroviruses; Retroviridae; Lentivirus.

```

```

OX  NBL TaxID 11676;
RN  111
RP  SEQUENCE FROM N.A.
RC  STRAIN 1V002-84;
RX  MEDLINE 21422026; PubMed 11429118;
RA  Setbon L.J., Tremblat F.R., Zetor M., Ennelbrecht S.,
KA  van Rensburg E.J.;
PC  "Characterization and phylogenetic analysis of South African HIV 1
RL  subtype 'c' accessory genes.";
RL  AIDS Res. Hum. Retroviruses 17:775-781(2001).
DR  EMBL: AF527343; AAK0105.1;
DR  InterPro: IPR000625; REV_Protein.
DR  PIR: P00424; REV: 1;
FI  NON TER 25
SQ  SEQUENCE 25 AA: 2762 MW: 48865735642248 CRC64;

Query Match
Best Local Similarity 43.48; Score 22; DB 15; Length 25;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

CY  6 KALKAL 16
ID  111111
ID  10 KALKAL 16

```

Search completed: August 21, 2003, 08:36:30  
 Build time: 1:49:50





```

DI 15 SEP-2003 (Rel. 42, Last annotation update)
DE Bombinin.
OS Bombina variegata (Yellow-bellied toad).
OC Fukuyofa; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID-8448;
RN 111
RP SEQUENCE.
RC TISSUE: Skin secretion;
RA "Isolation and structural resolution of a haemolytically active
RI polypeptide from the immune secretion of a European toad.";
RL Monatsheft Chem. 101:182-189(1970);
CC -1- FUNCTION: Has antimicrobial and hemolytic activities.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Skin.
CC -1- SIMILARITY: BELONGS TO THE BOMBININ FAMILY.
DE PIR: A01766; HMTD.
FW Amphibian defense peptide. Antibiolic; Hemolysis; Amidation.
FT MOD_RES 24 24 AMIDATION.
SQ SEQUENCE 24 AA: 2294 MW: A009CEB37402E95 CRC64;

Query Match 37.9%; Score 25; DB 1; Length 24;
Best Local Similarity 62.7%; Pred. No. 5.5e+02;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4 ALKALKAL 12
DB 10 ALKGLAKL 18

RESULT 7
MAST_VESOR STANDARD; PRT: 14 AA.
AC P17238;
DI 01-AUG-1990 (Rel. 15, Last sequence update)
DI 28-FEB-2003 (Rel. 41, Last annotation update)
DE Mustoparan (Histamine releasing peptide 1) (HR-1).
OS Vespa orientalis (Oriental hornet).
OC Eukaryota; Metazoa; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Hymenoptera; Apoecrita; Aculeata; Vespoidea;
OC Vespidae; Vespinae; Vespa.
OX NCBI_TaxID-7447;
RN 111
RP SEQUENCE.
RC TISSUE: Venom;
RA Mitushige A. I., Suda H. and Ito S., Ratime I.V., Keshetova O.I.,
RA Romyay B.V., Gushchin I.S.;
RI "Structure and properties of histamine releasing peptides from the
RI venom of Vespa orientalis hornet.";
RL Bioorg. Khim. 7:1467-1477(1981).
CC -1- FUNCTION: Mast cell degranulating peptide. Activates G proteins
CC that couple to phospholipase C.
DE PIR: JN0489; JN0489;
KW Mast cell degranulation; Amidation.
FT MOD_RES 14 14 AMIDATION.
SQ SEQUENCE 14 AA: 1494 MW: C84F9ECA026R00DD CRC64;

Query Match 36.4%; Score 24; DB 1; Length 14;
Best Local Similarity 62.5%; Pred. No. 4.8e+02;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 4 KALKALK 10
DB 4 KATAALK 11

RESULT 8
CHEP_PAKID STANDARD; PRT: 13 AA.
DI 01-NOV-1995 (Rel. 32, Created)

```

```

DI 01-NOV-1995 (Rel. 32, Last sequence update)
DI 01-NOV-1995 (Rel. 32, Last annotation update)
DE Chemotactic peptide.
OS Parapolybia indica.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Hymenoptera; Apoecrita; Aculeata; Vespoidea;
OC Vespidae; Polistinae; Parapolybia.
OX NCBI_TaxID-31921;
RN 111
RP SEQUENCE.
RC TISSUE: Venom;
RA Toki T., Yasuhara T., Nakajima T.;
RI "Isolation and sequential analysis of peptides on the venom sac of
RI Parapolybia indica.";
RL Eisai Dobutsu 39:105-111(1988).
KW Chemotaxis; Amidation.
FT MOD_RES 13 13 AMIDATION.
SQ SEQUENCE 13 AA: 1298 MW: 529530 EEF92P873CR94;

Query Match 44.8%; Score 23; DB 1; Length 13;
Best Local Similarity 62.5%; Pred. No. 5.5e+02;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 8 LKALKAL 15
DB 4 LKGLSAL 11

RESULT 9
VIOL_VACV STANDARD; PRT: 20 AA.
AC P16714;
DI 01-AUG-1990 (Rel. 15, Created)
DI 16-OCT-2001 (Rel. 40, Last annotation update)
DE protein 11 (fragment).
GN 11.
OS Vaccinia virus (strain WR).
OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC Orthopoxvirus.
CC NCI_TaxID-10254;
RN 111
RP SEQUENCE: VR-8 N.A.
RX MEDLINE 88215015; PubMed-2835195;
RA Schmitt J.F.C., Stuenkel B.G.;
RI "Sequence and transcriptional analysis of the vaccinia virus B10111
RI 1 fragment.";
RL J. Virol. 62:1889-1897(1988).
CC -1- SIMILARITY: BELONGS TO THE POXVIRUSES 1 FAMILY.
CC THIS SWISS PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on the
CC use by non-profit institutions as long as its copyright is acknowledged
CC modified and this statement is not removed using any software
CC entities requires a license agreement (See http://www.isdb.scripps.edu/
CC or send an email to license@isdb.scripps.edu).

EMBL: J04399; AAR59803.1;
DE InterPro: IPR004965; Fox_11.
DE Pfam: PF04289; Fox_11; 1.
KW Late protein.
FT NON_TER 20 20
SQ SEQUENCE 20 AA: 2241 MW: C97A786664B1CR94;

Query Match 44.8%; Score 23; DB 1; Length 20;
Best Local Similarity 83.4%; Pred. No. 4.6e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 AVALKA 7
DB 15 AVALKA 20

```



RT "Peptides, new antibacterial and insecticidal peptides from the  
 RL venom of the ant *Pachycondyla goeldii*.";  
 CC J. Biol. Chem. 276:17827-17829(2001).  
 CC -!- FUNCTION: BROAD SPECTRUM OF ACTIVITY AGAINST BOTH GRAM-POSITIVE  
 CC AND GRAM-NEGATIVE BACTERIA. HAS NON-HEMOLYTIC ACTIVITY.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- MASS SPECTROMETRY: MW:2576.67; METHOD=MALDI.  
 KW Antituberc; Insect immunity; Amidation.  
 FT MOD\_RES 24 24  
 SQ SEQUENCE 24 AA: 2578 MW: 37830D5761515E8F CRC64;

Query Match 34.3%; Score 22; DB 1; Length 24;  
 Best Local Similarity 50.0%; Pred. No. 1.6e+03;  
 Matches 5; Conservatv 2; Mismatches 3; Indels 0; Gaps 0;

QY 6 KALKALKAL 15  
 DB 14 KAVLCCKKGL 23

RESULT 14  
 PQX\_XENIA  
 ID PQX\_XENIA STANDARD; PRT: 24 AA.  
 AC P34080;  
 DT 01-FEB-1995 (Rel. 31, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 15-SEP-2003 (Rel. 42, Last annotation update)  
 DE Antimicrobial peptide PQX.  
 OS *Xenopus laevis* (African clawed frog).  
 CC Enkaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 CC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoia; Pipidae;  
 CC Xenopodinae; Xenopus.  
 CC NCBI\_TaxID=8455;  
 RN [1]  
 RP SEQUENCE.

TISSUE: Stomach;  
 CC MEDLINE=92011794; PubMed=1717472;  
 RA Moore K.S., Bevins C.L., Brasseur M.M., Tomassini N., Turner K.,  
 RA Eck H., Zasloff M.;  
 RT "Antimicrobial peptides in the stomach of *Xenopus laevis*.";  
 RL J. Biol. Chem. 266:19851-19857(1991).  
 CC -!- FUNCTION: ANTIMICROBIAL PEPTIDE.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: IS SYNTHESIZED IN THE STOMACH AND STORED  
 CC IN A NOVEL GRANULAR MULTINUCLEATED CELL IN THE GASTRIC MUCOSA.  
 CC IT IS STORED AS ACTIVE, PROCESSED PEPTIDES IN LARGE GRANULES.  
 CC WITHIN THE GRANULAR GLAND SECRETIONS OF THE SKIN.  
 CC -!- SIMILARITY: BELONGS TO THE MAGA1IN FAMILY OF ANTIMICROBIAL  
 CC PEPTIDES.  
 DR PIR: A41037; A41037.  
 KW Amphibian defense peptide; Antibiotic.  
 SQ SEQUENCE 24 AA: 2457 MW: 7E6A875B7CF2269C CRC64;

Query Match 33.4%; Score 22; DB 1; Length 24;  
 Best Local Similarity 71.4%; Pred. No. 1.6e+03;  
 Matches 5; Conservatv 1; Mismatches 1; Indels 0; Gaps 0;

QY 4 ALKALK 10  
 DB 17 ALNVLK 24

RESULT 15  
 ALRX\_PSEPU  
 ID ALRX\_PSEPU STANDARD; PRT: 16 AA.  
 AC P17916;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Broad specificity amino acid racemase (EC 5.1.1.-) (Fragment).  
 OS *Pseudomonas putida*.  
 CC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;  
 CC Pseudomonadaceae; Pseudomonas.

OX NCBI\_TaxID=303;  
 RN [1]  
 RP SEQUENCE.  
 RA STRAIN AKU 0813;  
 RX MEDLINE 85072810; PubMed=6419247;  
 RA Koise D., Soda K., Yagi T., Walsh C.L.;  
 RT "Inactivation of the *Pseudomonas striata* broad specificity amines and  
 RT racemase by D and L isomers of beta substituted amines: Kinetics,  
 RT stoichiometry, active site peptide, and mechanistic studies.";  
 RL Biochemistry 23:5195-5201(1984).  
 CC -!- COFACTOR: Pyridoxal phosphate.  
 CC -!- SIMILARITY: Belongs to the amino racemase family.  
 DR HAMAP: MF01201; atypical; 1.  
 DR InterPro: IPR000821; Ala\_racemase.  
 DR PROSITE: PS00395; ALANINE\_4C/EMAS1; 1.  
 KW Isomerase; Pyridoxal phosphate.  
 FT NON\_TER 1 1  
 FT ACT\_SITE 6 6  
 PT CATALYTIC BASE SITE: 1-6; ALANINE 1-6  
 PT BINDING 6 6  
 FT NON\_TER 16 16  
 SQ SEQUENCE 16 AA: 1572 MW: 966226A134 seqlen=1572

Query Match 31.8%; Score 21; DB 1; Length 16;  
 Best Local Similarity 71.4%; Pred. No. 1.6e+03;  
 Matches 5; Conservatv 1; Mismatches 1; Indels 0; Gaps 0;

QY 5 LKALLKA 11  
 DB 1 LIAVLKA 7

RESULT 16  
 Y194\_ARCF9  
 ID Y194\_ARCF9 STANDARD; PRT: 25 AA.  
 AC Q40045;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Hypothetical protein AF0194.  
 GN AF0194.  
 OS *Archaeoglobus fulgidus*.  
 CC Archaea; Euryarchaeota; Archaeobacteria; Archaeobacteria;  
 CC Archaeobacteriia; Archaeobacteria;  
 CC NCBI\_TaxID=2234;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN V.13 / DSM 4504 / ATCC 49558;  
 RX MEDLINE 92011794; PubMed=1717472;  
 RA Fleck H., Clayton R.A., Tomb J.F., White O., Nelson K.L.,  
 RA Richardson K.A., Dodson R., Paulsen O., Karp P., Karp P.,  
 RA Richardson K.A., Dodson R., Paulsen O., Karp P., Karp P.,  
 RA Fleischmann R.D., Quackenbush J., Lee N.A., Sutton G., Smith T.,  
 RA Kirkness E.F., Boudger P.A., McQuay K., Adams M.L., Loftus B.,  
 RA Peterson S., Reich C.L., McNeil L.K., Barker J., White O., Nelson K.L.,  
 RA Overbeek R., Gocayne J.D., Weidman J.F., McQuay K., Adams M.L.,  
 RA Cotton M.D., Spillars T., Artach P., Karp P., Karp P., Karp P.,  
 RA Sadow P.W., Anderson K.P., Beaman C., Bult C., Gabor S.A.,  
 RA Mason T.M., Olsen G.J., Fraser J.M., Smith H., Weiss R.,  
 RA Venter J.C.;  
 RT "The complete genome sequence of the hyperthermophilic archaeon  
 RT reducing archaeon *Archaeoglobus fulgidus*.";  
 RL Nature 400:464-470(1997).

CC This SWISS-Prot entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL European  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non profit institutions as long as it is stated in the  
 CC modified and this statement is not removed, usage by and for commercial  
 CC entities requires a license agreement (See <http://www.ebi.ac.uk/submit/>)  
 CC or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk).

```

DB EMBL: AF010943; AAB91054.1;
DB PIR: B69274; B69274.
DB TrEMBL: AF010943.
KW Hydrophobic protein; Complete proteome.
SQ SEQUENCE 25 AA: 2828 MW: 54380.60 647419F CRG64;

Query Match 31.8% Score 21; DB 1; Length 25;
Best Local Similarity 57.1% Prod. No. 2,460,043;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 6 KALKAL 12
   1 1 1 1 1
DB 4 KAVIKGM 10

RESULT 17
DB UP36_UPEMJ STANDARD; PRI: 17 AA.
A* P82043;
DT 30-MAY-2000 (Rel. 39, created)
DT 30-MAY-2000 (Rel. 49, last sequence update)
DT 15-SEP-2003 (Rel. 42, last annotation update)
DE Uperin 3.6.
OS Uperoleia mjobergii (Australian toadlet).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Bufonidae; Myobatrachidae;
OC Myobatrachinae; Uperoleia.
CX NCBI TaxID 104964;
KW [1]
KW SEQUENCE, AND MASS SPECTROMETRY.
KW TISSUE SKIN SECRETION.
RA Bradford A.M., Bowie J.H., Taylor M.D., Wallace J.C.;
RT "New antitoxic opiorin peptides from the dorsal glands of the
RL Aust. J. Chem. 49:1325-1331(1996).
CV 1 FUNCTION: SHOWS ANTIBACTERIAL ACTIVITY AGAINST B.CEREUS, L.LACTIS,
CV 1 LISTERIA, M.DUTTER, S.AGRIUS, S.EPIDERMIS AND STREPT.
CV 1 SUBCELLULAR LOCATION: Secreted.
CV 1 TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
CV 1 MASS SPECTROMETRY: MW 1826; METHOD0 FAB.
KW Amphibian defense peptide; Antibiotic; Amidation.
PI M02RES 17
SQ SEQUENCE 17 AA: 1778 MW: 7840884626 6A3D CRG64;

Query Match 40.4% Score 20; DB 1; Length 17;
Best Local Similarity 41.7% Prod. No. 2,560,043;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 4 ALKALKAL 15
   1 1 1 1 1
DB 5 AAKVVNVVUKNL 16

RESULT 18
DB ORP_LYMOJ STANDARD; PRI: 18 AA.
A* P43174;
DT 01 FEB 1994 (Rel. 28, created)
DT 01 FEB 1994 (Rel. 28, last sequence update)
DT 01 NOV 1997 (Rel. 35, last annotation update)
DE General odorant-binding protein (G99) (Fragment).
OS Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Noctuidae;
OC Lymantriidae; Lymantria.
CX NCBI TaxID 14124;
KW [1]
KW SEQUENCE.
FX MEDLINE 91186129; PubMed 2010751;
RA Vaut R.G., Prestwich G.D., Berner M.R.;
RT "Odorant-binding protein subfamilies associate with distinct classes
KL of olfactory receptor neurons in insects."
RL J. Neurobiol. 22:74-84(1991).

```

```

CV 1 FUNCTION: PRESENT IN THE ALD AND FOLD, OTHER IN THE
CV SENSORY PERIPHERIES AND APART FROM THE ALD AND FOLD, IN THE
CV TRANSFER OF HYDROPHOBIC SUBSTANCES INTO AND OUT OF THE
CV 1 SUBUNIT: Homodimer (Predicted)
CV 1 TISSUE SPECIFICITY: ANTENNA.
CV 1 SIMILARITY: HOMOLOGS TO THE PRO/2000 FAMILY.
KW Collection: Transport.
PI NON_TER 18
SQ SEQUENCE 18 AA: 1904 MW: 8684408100 1A 9E 94

Query Match 40.0% Score 20; DB 1; Length 18;
Best Local Similarity 40.7% Prod. No. 2,000,000;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 FAKALK 6
   1 1 1 1
DB 12 EKALE 17

RESULT 19
DB JHHP_BOMMO STANDARD; PRI: 20 AA.
A* P81627;
DT 15-JUL-1999 (Rel. 40, created)
DT 15-JUL-1999 (Rel. 49, last sequence update)
DT 15-SEP-2003 (Rel. 42, last annotation update)
DE Juvenile hormone binding protein (Fragment).
OS JHHP.
OS Bombyx mori (Silk moth).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Bombyx.
CX NCBI TaxID 7094;
KW [1]
KW SEQUENCE.
KW STRAIN BacKokJung TISSUE Bombyx;
KW Calk C. H. Kim H.R.;
RT "Characterization of high affinity juvenile hormone binding
RL the Bombyx mori Bombyx mori."
RL Insect Mol. Biol. 3:49-55(1994).
KW [2]
KW IDENTIFICATION OF CYS 9.
KW Park C. H.;
RL Submitted (JUL 1998) To The Swiss Prot Data Bank
CV 1 SUBUNIT: PRESENT IN THE JHHP BOMMO FROM THE BOMBYX MORI.
CV 1 GENERAL ESTIMATION BY "MANNING" WITH 1.31% GAPS.
CV 1 SUBCELLULAR LOCATION: Secreted.
PI NON_TER 20
SQ SEQUENCE 20 AA: 2090 MW: 8669240400 9E 94;

Query Match 40.0% Score 20; DB 1; Length 20;
Best Local Similarity 41.4% Prod. No. 2,000,000;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 7 ALKALK 14
   1 1 1 1
DB 4 ALKALK 16

RESULT 20
DB SVR_RAI STANDARD; PRI: 21 AA.
A* P40479;
DT 01 FEB 1998 (Rel. 41, created)
DT 01 FEB 1998 (Rel. 41, last sequence update)
DT 01 NOV 1997 (Rel. 35, last annotation update)
DE Arthropod RNA synthesis (Protein 1.10) (Fragment).
OS SVR.
KW RAI.
OS RAIUS for proteins (RAI).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Batrachia; Rodentia; Sciurotrachia; Muridae; Murinae;
CX NCBI TaxID 10114;

```





















GenCov version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 21, 2003, 08:14:35 : Search time 39 seconds  
(without alignments)  
36,988 Million cell updates/sec

File: us-09-820-053a-43  
Portion score: 66  
Sequence: 1 FAKKALKALKAL 15

Search table: 80 SIM62  
GapPen 10.0 : GapExt 0.5

Score used: 28200 Score: 9614832 residues

Total number of hits satisfying chosen parameters: 4986

Minimum DB seq length: 25  
Maximum DB seq length: 25

Post processing: Minimum Match 0%

Listing first 45 summaries

Database:  
1: p1r\_76: \*  
2: p1r1: \*  
3: p1r2: \*  
4: p1r3: \*  
5: p1r4: \*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	26	49.4	14	2	methyloccoenzyme M
2	26	49.4	21	2	hypothetical prote
3	26	49.4	21	2	hypothetical prote
4	25	47.9	14	1	mastoparan - yello
5	25	47.9	14	1	mastoparan M - hor
6	25	47.9	14	1	mastoparan G - for
7	25	47.9	21	2	glutamate-aminola
8	24	46.4	24	1	bombin - Bombina
9	24	46.4	14	2	histamine-releasin
10	24	46.4	19	2	L-2,4-diaminobuty
11	24	46.4	22	2	unidentifed low M
12	23	44.8	15	2	hemoglobin alpha c
13	23	44.8	25	2	of 13 3' of mada -
14	22	43.4	17	2	phenylalanine-tRNA
15	22	43.4	20	2	tyrosine 57-me
16	22	43.4	20	2	ribosomal protein
17	22	43.4	21	2	hypothetical prote
18	22	43.4	22	2	t-complex polypept
19	22	43.4	24	2	threonine ammonia-
20	22	43.4	24	2	antimicrobial pept
21	22	43.4	25	2	photosystem I 16.1
22	21	41.8	16	2	amino-acid racemas
23	21	41.8	19	2	3H 4-oxovaline
24	21	41.8	18	2	translation elonga
25	21	41.8	20	2	H-transporing tw
26	21	41.8	20	2	histone H2B - huma
27	21	41.8	20	2	urinary tract ston
28	21	41.8	22	2	plantaricin A - la
29	21	41.8	24	2	H-transporing tw

30	21	31.8	24	2	H20554
31	21	31.8	25	2	FN0642
32	21	31.8	25	2	869274
33	20	30.3	14	2	S29789
34	20	30.3	15	2	PT0095
35	20	30.3	18	2	S78767
36	20	30.3	20	2	B44581
37	20	30.3	20	2	A15867
38	20	30.3	22	2	A17345
39	20	30.3	22	2	S17769
40	20	30.3	23	2	A11944
41	20	30.3	23	2	S34739
42	20	30.3	24	2	G20554
43	20	30.3	25	2	H64710
44	19.5	29.5	15	2	FN0118
45	19	28.8	11	2	A38841

#### ALIGNMENTS

##### RESULT 1

methyloccoenzyme M reductase (75.1% identity) in alpha chain Methanobacterium thermophilum  
C:Species: Methanobacterium thermophilum  
A:Variety: strain Marburg  
C:Date: 19-Mar-1997 #sequence\_revision 13 Sep 1998 #text\_update 30 oct 1998  
C:Accession: S13864  
R:Rospor, S.; Linder, D.; Ellermann, J.; Haury, R.K.  
Eur. J. Biochem. 194, 871-877, 1990  
A:Title: Two genetically distinct methyloccoenzyme M reductases in Methanobacterium th  
A:Reference number: S13864; M01D:1094370; M01D:2269306  
A:Accession: S13864  
A:Molecule type: protein  
A:Residues: 1-14 <ROS>  
A:Experimental source: strain Marburg  
C:Keywords: methanogenesis; oxidoreductase

Query Match 49.4% Score 26 DB 2 Length 14  
Best local similarity 75.0% Prod. No. 3,660-02  
Matches 6 Conservative 0 Mismatches 2 Gaps 0

QY 5 KALKALK 13  
P 1 ELFLALK 12

##### RESULT 2

140659  
Hypothetical protein (Clostridium cothlicarum (strain))  
C:Species: Clostridium cothlicarum  
C:Date: 12-Aug-1996 #sequence\_revision 18 oct 1996 #text\_update 15 oct 1999  
C:Accession: 140659; S47461  
R:Reicher, O.; Beatrix, B.; Leinbacher, U.; Bokel, W.  
Eur. J. Biochem. 225, 577-585, 1994  
A:Title: Characterization of the coenzyme-B12-dependent glutamate mutase from Clostrid  
A:Reference number: 140659; M01D:95094816; M01D:788025  
A:Accession: 140659  
A:Title: Hypothetical protein (Clostridium cothlicarum (strain))  
A:Molecule type: DNA  
A:Residues: 1-21 <KLS>  
A:Cross-references: EMBL:XR0997; NID:9530005; PIR:AA56920.1; P1D:9530006

Query Match 49.4% Score 26 DB 2 Length 21  
Best local similarity 53.8% Prod. No. 5,160-02  
Matches 7 Conservative 2 Mismatches 4 Gaps 0

QY 4 KALKALKALKAL 15  
P 1 1 1 1 1  
DB 8 KALKALKALKALKAL 20

##### RESULT 4









## RESULT 27

Accession

Human liver mitochondrial gamma chain - rat (fragment)  
 (Accession: A45914) (Accession: A45914) (Accession: A45914)

Submitted to the Protein Sequence Database, February 1991

Accession number: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Query Match: 41.8% Score 21: 108 22: Length 207  
 Host Local Similarity: 62.5% Prod. No. 4500043  
 Matches: 57 Conservative: 47 Mismatches: 10 Indels: 02 Gaps: 02

1 EKALAKAL 15

1 EKALAKAL 15

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

## RESULT 28

Accession

Plantaricin A - lactobacillus plantarum  
 (Accession: A45914) (Accession: A45914) (Accession: A45914)

Submitted to the Protein Sequence Database, April 1991

Accession number: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

## RESULT 29

Accession

Plantaricin A - lactobacillus plantarum  
 (Accession: A45914) (Accession: A45914) (Accession: A45914)

Submitted to the Protein Sequence Database, April 1991

Accession number: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

## RESULT 30

Accession

Plantaricin A - lactobacillus plantarum  
 (Accession: A45914) (Accession: A45914) (Accession: A45914)

Submitted to the Protein Sequence Database, April 1991

Accession number: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

Accession: A45914

14 2 LKALIKAL 12

RESULT 43

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

Protein: Pseudomonas sp.

Clade: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 12-Apr-1995

Accession: F00632

A: Molecule type: DNA  
A: Residues: 1-14 (KRL)  
A: Cross-reference: EMBL:X59788

Query Match

Best Local Similarity 40.3% Score 20: DB 2: Length 14:

Post Local Similarity 45.5% Pred. No. 4: 100.0%

Matches 5: Conservative 2: Mismatches 4: Indels 0: Gaps 0:

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

A: Molecule type: DNA  
A: Residues: 1-14 (KRL)  
A: Cross-reference: EMBL:X59788

Query Match

Best Local Similarity 40.3% Score 20: DB 2: Length 14:

Post Local Similarity 45.5% Pred. No. 4: 100.0%

Matches 5: Conservative 2: Mismatches 4: Indels 0: Gaps 0:

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

A: Molecule type: DNA  
A: Residues: 1-14 (KRL)  
A: Cross-reference: EMBL:X59788

Query Match

Best Local Similarity 40.3% Score 20: DB 2: Length 14:

Post Local Similarity 45.5% Pred. No. 4: 100.0%

Matches 5: Conservative 2: Mismatches 4: Indels 0: Gaps 0:

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB

5 LKALIKAL 15

1 MKDLKRLD 11

DB









Genetic version 5.1.6  
 Ferris (c) 1994 - 2004 Compugen Ltd.

CM FastCell Protein search, using SW model

Run date: August 21, 2003, 08:19:10 : Search time 55 Seconds  
 (without alignments)

Run size: 45,990 Million cell updates/sec

Filter: US-09-820-053A-43

Sequences: 1 PARAFAC/ALFALFA: 15

Sequences: 436, 13.0, Gapcut 0.5

Sequences: 436, 13.0, Gapcut 0.5

Low number of hits satisfaction chosen parameters: 111949

Minimum hit seq length: 0

Maximum hit seq length: 25

Post-proposition: Minimum Match 0%

Listing first 45 summaries

Database: Published\_Applications-AA\*

1. US-09-820-053A-43, US07\_Protein\_Pep\*  
 2. US-09-820-053A-43, US07\_Protein\_Pep\*  
 3. US-09-820-053A-43, US07\_Protein\_Pep\*  
 4. US-09-820-053A-43, US07\_Protein\_Pep\*  
 5. US-09-820-053A-43, US07\_Protein\_Pep\*  
 6. US-09-820-053A-43, US07\_Protein\_Pep\*  
 7. US-09-820-053A-43, US07\_Protein\_Pep\*  
 8. US-09-820-053A-43, US07\_Protein\_Pep\*  
 9. US-09-820-053A-43, US07\_Protein\_Pep\*  
 10. US-09-820-053A-43, US07\_Protein\_Pep\*  
 11. US-09-820-053A-43, US07\_Protein\_Pep\*  
 12. US-09-820-053A-43, US07\_Protein\_Pep\*  
 13. US-09-820-053A-43, US07\_Protein\_Pep\*  
 14. US-09-820-053A-43, US07\_Protein\_Pep\*  
 15. US-09-820-053A-43, US07\_Protein\_Pep\*  
 16. US-09-820-053A-43, US07\_Protein\_Pep\*  
 17. US-09-820-053A-43, US07\_Protein\_Pep\*  
 18. US-09-820-053A-43, US07\_Protein\_Pep\*  
 19. US-09-820-053A-43, US07\_Protein\_Pep\*  
 20. US-09-820-053A-43, US07\_Protein\_Pep\*  
 21. US-09-820-053A-43, US07\_Protein\_Pep\*  
 22. US-09-820-053A-43, US07\_Protein\_Pep\*  
 23. US-09-820-053A-43, US07\_Protein\_Pep\*  
 24. US-09-820-053A-43, US07\_Protein\_Pep\*  
 25. US-09-820-053A-43, US07\_Protein\_Pep\*  
 26. US-09-820-053A-43, US07\_Protein\_Pep\*  
 27. US-09-820-053A-43, US07\_Protein\_Pep\*  
 28. US-09-820-053A-43, US07\_Protein\_Pep\*  
 29. US-09-820-053A-43, US07\_Protein\_Pep\*  
 30. US-09-820-053A-43, US07\_Protein\_Pep\*  
 31. US-09-820-053A-43, US07\_Protein\_Pep\*  
 32. US-09-820-053A-43, US07\_Protein\_Pep\*  
 33. US-09-820-053A-43, US07\_Protein\_Pep\*  
 34. US-09-820-053A-43, US07\_Protein\_Pep\*  
 35. US-09-820-053A-43, US07\_Protein\_Pep\*  
 36. US-09-820-053A-43, US07\_Protein\_Pep\*  
 37. US-09-820-053A-43, US07\_Protein\_Pep\*  
 38. US-09-820-053A-43, US07\_Protein\_Pep\*  
 39. US-09-820-053A-43, US07\_Protein\_Pep\*  
 40. US-09-820-053A-43, US07\_Protein\_Pep\*  
 41. US-09-820-053A-43, US07\_Protein\_Pep\*  
 42. US-09-820-053A-43, US07\_Protein\_Pep\*  
 43. US-09-820-053A-43, US07\_Protein\_Pep\*  
 44. US-09-820-053A-43, US07\_Protein\_Pep\*  
 45. US-09-820-053A-43, US07\_Protein\_Pep\*

Prod. No. 18: The number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

STPAPPV05

Seq. No.	Seq. ID	Match Length	Prod. No.	Description
1	US-09-820-053A-43	15	11	Sequence 43, Appl
2	US-09-820-053A-43	15	12	Sequence 44, Appl
3	US-09-820-053A-43	15	13	Sequence 45, Appl
4	US-09-820-053A-43	15	14	Sequence 46, Appl
5	US-09-820-053A-43	15	15	Sequence 47, Appl
6	US-09-820-053A-43	15	16	Sequence 48, Appl
7	US-09-820-053A-43	15	17	Sequence 49, Appl
8	US-09-820-053A-43	15	18	Sequence 50, Appl
9	US-09-820-053A-43	15	19	Sequence 51, Appl
10	US-09-820-053A-43	15	20	Sequence 52, Appl
11	US-09-820-053A-43	15	21	Sequence 53, Appl
12	US-09-820-053A-43	15	22	Sequence 54, Appl
13	US-09-820-053A-43	15	23	Sequence 55, Appl
14	US-09-820-053A-43	15	24	Sequence 56, Appl
15	US-09-820-053A-43	15	25	Sequence 57, Appl
16	US-09-820-053A-43	15	26	Sequence 58, Appl
17	US-09-820-053A-43	15	27	Sequence 59, Appl
18	US-09-820-053A-43	15	28	Sequence 60, Appl
19	US-09-820-053A-43	15	29	Sequence 61, Appl
20	US-09-820-053A-43	15	30	Sequence 62, Appl
21	US-09-820-053A-43	15	31	Sequence 63, Appl
22	US-09-820-053A-43	15	32	Sequence 64, Appl
23	US-09-820-053A-43	15	33	Sequence 65, Appl
24	US-09-820-053A-43	15	34	Sequence 66, Appl
25	US-09-820-053A-43	15	35	Sequence 67, Appl
26	US-09-820-053A-43	15	36	Sequence 68, Appl
27	US-09-820-053A-43	15	37	Sequence 69, Appl
28	US-09-820-053A-43	15	38	Sequence 70, Appl
29	US-09-820-053A-43	15	39	Sequence 71, Appl
30	US-09-820-053A-43	15	40	Sequence 72, Appl
31	US-09-820-053A-43	15	41	Sequence 73, Appl
32	US-09-820-053A-43	15	42	Sequence 74, Appl
33	US-09-820-053A-43	15	43	Sequence 75, Appl
34	US-09-820-053A-43	15	44	Sequence 76, Appl
35	US-09-820-053A-43	15	45	Sequence 77, Appl

15	42	64.6	19	15	US-10-109-171-15	Sequence 13, Appl
17	42	64.6	20	11	US-09-820-053A-43	Sequence 69, Appl
18	42	64.6	20	15	US-10-109-171-15	Sequence 60, Appl
19	42	64.6	24	11	US-09-820-053A-43	Sequence 15, Appl
20	42	64.6	24	11	US-09-820-053A-43	Sequence 108, Appl
21	42	64.6	24	11	US-09-820-053A-43	Sequence 109, Appl
22	42	64.6	24	11	US-10-109-171-15	Sequence 107, Appl
23	42	64.6	24	11	US-10-109-171-15	Sequence 106, Appl
24	42	64.6	24	15	US-10-109-171-15	Sequence 105, Appl
25	42	64.6	15	11	US-09-820-053A-43	Sequence 22, Appl
26	41	62.1	15	15	US-10-109-171-15	Sequence 104, Appl
27	41	62.1	16	11	US-09-820-053A-43	Sequence 103, Appl
28	41	62.1	16	15	US-10-109-171-15	Sequence 102, Appl
29	41	62.1	23	11	US-09-820-053A-43	Sequence 101, Appl
30	41	62.1	23	15	US-10-109-171-15	Sequence 100, Appl
31	41	62.1	12	11	US-09-820-053A-43	Sequence 99, Appl
32	40	60.6	12	15	US-10-109-171-15	Sequence 98, Appl
33	40	60.6	24	11	US-09-820-053A-43	Sequence 97, Appl
34	40	60.6	23	15	US-10-109-171-15	Sequence 96, Appl
35	40	60.6	25	9	US-09-820-053A-43	Sequence 95, Appl
36	40	60.6	21	12	US-09-798-0248-17	Sequence 94, Appl
37	40	60.6	21	11	US-09-820-053A-43	Sequence 93, Appl
38	40	60.6	23	11	US-09-820-053A-43	Sequence 92, Appl
39	40	60.6	23	15	US-10-109-171-15	Sequence 91, Appl
40	40	60.6	17	11	US-09-820-053A-43	Sequence 90, Appl
41	40	60.6	17	11	US-09-820-053A-43	Sequence 89, Appl
42	40	60.6	17	15	US-10-109-171-15	Sequence 88, Appl
43	40	60.6	17	15	US-10-109-171-15	Sequence 87, Appl
44	40	60.6	18	10	US-09-765-6148-12	Sequence 86, Appl
45	40	60.6	18	10	US-09-925-715-12	Sequence 85, Appl

# RESULTS

RESULT 1  
 US-09-820-053A-43  
 Published Application No. US07\_Protein\_Pep\*  
 Title: 1 INVENTION: A NOVEL PEPTIDE  
 Filed: 10/10/97  
 Inventor: 1 INVENTOR: DONALD R.  
 Attorney: 1 ATTORNEY: DONALD R.  
 Length: 15  
 Type: PRT  
 Organism: ARTIFICIAL SEQUENCE  
 Feature: OTHER INFORMATION: SYNTHETIC SEQUENCE  
 Name: 1 NAME: 15  
 Location: 1 (15)  
 Other Information: AMINATION  
 US-09-820-053A-43

Query Match	Similarity	Prod. No.	Length
15	100.0%	US-09-820-053A-43	15
16	100.0%	US-09-820-053A-43	15
17	100.0%	US-09-820-053A-43	15
18	100.0%	US-09-820-053A-43	15
19	100.0%	US-09-820-053A-43	15
20	100.0%	US-09-820-053A-43	15
21	100.0%	US-09-820-053A-43	15
22	100.0%	US-09-820-053A-43	15
23	100.0%	US-09-820-053A-43	15
24	100.0%	US-09-820-053A-43	15
25	100.0%	US-09-820-053A-43	15
26	100.0%	US-09-820-053A-43	15
27	100.0%	US-09-820-053A-43	15
28	100.0%	US-09-820-053A-43	15
29	100.0%	US-09-820-053A-43	15
30	100.0%	US-09-820-053A-43	15
31	100.0%	US-09-820-053A-43	15
32	100.0%	US-09-820-053A-43	15
33	100.0%	US-09-820-053A-43	15
34	100.0%	US-09-820-053A-43	15
35	100.0%	US-09-820-053A-43	15
36	100.0%	US-09-820-053A-43	15
37	100.0%	US-09-820-053A-43	15
38	100.0%	US-09-820-053A-43	15
39	100.0%	US-09-820-053A-43	15
40	100.0%	US-09-820-053A-43	15
41	100.0%	US-09-820-053A-43	15
42	100.0%	US-09-820-053A-43	15
43	100.0%	US-09-820-053A-43	15
44	100.0%	US-09-820-053A-43	15
45	100.0%	US-09-820-053A-43	15



Q7 1 FALAKALAKAL 15  
 1111111111  
 DE 1 FALAKALAKAL 15

## RESULT 7

US-10-109-171-1  
 1 Sequence 1: Application US/10109171  
 1 Publication No. US20060109452A1  
 1 GENERAL INFORMATION:  
 1 APPLICANT: Ogoni, Donald R.  
 1 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
 1 FILE REFERENCE: HELIX028  
 1 CURRENT ATTENTIVE NUMBER: 02/02/109,171  
 1 CURRENT FILING DATE: 2002-03-28  
 1 NUMBER OF SEQ ID NOS: 165  
 1 SOFTWARE: Patent In Vol. 2.1  
 1 SEQ ID NO 1  
 1 LENGTH: 23  
 1 TYPE: PRI  
 1 ORGANISM: ARTIFICIAL SEQUENCE  
 1 FEATURE:  
 1 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 US-10-109-171-1

Query Match 72.78% Score 48; DR 15; Length 23;  
 Best Local Similarity 80.08; Prod. No. 0.35;  
 Matches 12; Conserved 10; Mismatches 3; Indels 0; Gaps 0;

Q7 1 FALAKALAKAL 15  
 1111111111  
 DE 1 FALAKALAKAL 15

## RESULT 8

US-1-109-171-2  
 1 Sequence 2: Application US/10109171  
 1 Publication No. US20060109452A1  
 1 GENERAL INFORMATION:  
 1 APPLICANT: Ogoni, Donald R.  
 1 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
 1 FILE REFERENCE: HELIX028  
 1 CURRENT ATTENTIVE NUMBER: 02/02/109,171  
 1 CURRENT FILING DATE: 2002-03-28  
 1 NUMBER OF SEQ ID NOS: 165  
 1 SOFTWARE: Patent In Vol. 2.1  
 1 SEQ ID NO 2  
 1 LENGTH: 23  
 1 TYPE: PRI  
 1 ORGANISM: ARTIFICIAL SEQUENCE  
 1 FEATURE:  
 1 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 1 NAME/KEY: MOD.RES  
 1 LOCATION: (23)-(14)  
 1 OTHER INFORMATION: MOD. RES  
 US-1-109-171-2

Query Match 72.78% Score 48; DR 15; Length 23;  
 Best Local Similarity 80.08; Prod. No. 0.35;  
 Matches 12; Conserved 10; Mismatches 3; Indels 0; Gaps 0;

Q7 1 FALAKALAKAL 15  
 1111111111  
 DE 1 FALAKALAKAL 15

## RESULT 9

US-09-820-053A-9  
 1 Sequence 9: Application US/09820053A  
 1 Publication No. US20060080249A1  
 1 GENERAL INFORMATION:  
 1 APPLICANT: Ogoni, Donald R.  
 1 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES

1 FILE REFERENCE: HELIX027  
 1 CURRENT ATTENTIVE NUMBER: 02/02/920,053A  
 1 CURRENT FILING DATE: 2001-03-28  
 1 NUMBER OF SEQ ID NOS: 165  
 1 SOFTWARE: Patent In Vol. 2.1  
 1 SEQ ID NO 9  
 1 LENGTH: 23  
 1 TYPE: PRI  
 1 ORGANISM: ARTIFICIAL SEQUENCE  
 1 FEATURE:  
 1 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 1 NAME/KEY: MOD.RES  
 1 LOCATION: (23)  
 1 OTHER INFORMATION: MOD. RES  
 US-09-820-053A-9

Query Match 65.28% Score 43; DR 11; Length 23;  
 Best Local Similarity 73.38; Prod. No. 2;  
 Matches 11; Conserved 9; Mismatches 4; Indels 0; Gaps 0;

Q7 1 FALAKALAKAL 15  
 1111111111  
 DE 1 FALAKALAKAL 15

## RESULT 10

US-09-820-053A-19  
 1 Sequence 19: Application US/09820053A  
 1 Publication No. US20060080249A1  
 1 GENERAL INFORMATION:  
 1 APPLICANT: Ogoni, Donald R.  
 1 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES  
 1 FILE REFERENCE: HELIX027  
 1 CURRENT ATTENTIVE NUMBER: 02/02/920,053A  
 1 CURRENT FILING DATE: 2001-03-28  
 1 NUMBER OF SEQ ID NOS: 165  
 1 SOFTWARE: Patent In Vol. 2.1  
 1 SEQ ID NO 19  
 1 LENGTH: 23  
 1 TYPE: PRI  
 1 ORGANISM: ARTIFICIAL SEQUENCE  
 1 FEATURE:  
 1 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 1 NAME/KEY: MOD.RES  
 1 LOCATION: (13)-(14)  
 1 OTHER INFORMATION: MOD. RES  
 US-09-820-053A-19

Query Match 65.28% Score 43; DR 11; Length 23;  
 Best Local Similarity 73.38; Prod. No. 2;  
 Matches 11; Conserved 9; Mismatches 4; Indels 0; Gaps 0;

Q7 1 FALAKALAKAL 15  
 1111111111  
 DE 1 FALAKALAKAL 15

## RESULT 11

US-10-109-171-9  
 1 Sequence 9: Application US/10109171  
 1 Publication No. US20060109452A1  
 1 GENERAL INFORMATION:  
 1 APPLICANT: Ogoni, Donald R.  
 1 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
 1 FILE REFERENCE: HELIX028  
 1 CURRENT ATTENTIVE NUMBER: 02/02/109,171  
 1 CURRENT FILING DATE: 2002-03-28  
 1 NUMBER OF SEQ ID NOS: 165  
 1 SOFTWARE: Patent In Vol. 2.1  
 1 SEQ ID NO 9  
 1 LENGTH: 23  
 1 TYPE: PRI  
 1 ORGANISM: ARTIFICIAL SEQUENCE

# RESULT 14

US-09-820-053A-14  
 Application No. US/09820053A  
 Publication No. US2004008324A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

Query Match: 65.68% Score: 423 DB: 15 Length: 243  
 Best Local Similarity: 75.38% Prod. No. 243  
 Matches: 11 Conservative 0 Mismatches 4 Indels 0 Gaps 0

1 FALAKKALAKKAL 15  
 1 FALAKKALAKKAL 15

US-10-109-171-14

US-10-109-171-14  
 Application No. US/10109171  
 Publication No. US200400452A1

```

1  APPLICANT: OWEN, DONALD R.
2  TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
3  FILE REFERENCE: HELIX028
4  CURRENT FILING DATE: 2002-04-28
5  NUMBER OF SEQ ID NOS: 165
6  SOFTWARE: PATENTIN VET. 2.1
7  SEQ ID NO: 14
8  LENGTH: 19
9  TYPE: PRT
10 ORGANISM: ARTIFICIAL SEQUENCE
11 FEATURE:
12 OTHER INFORMATION: SYNTHETIC SEQUENCE
13 US-10-109-171 14

Query Match          64.68; Score 42; DB 15; Length 19;
Best Local Similarity 78.98; Pred. No. 2.5;
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

CY 1 FAKAKALKALKAL 15
1 | | | | | | | | |
DB 1 FAKAKALKALKAL 15

RESULT 17
US-09-820-053A-68
1 Sequence 68; Application US/09820053A
2 Publication No. US20030084243A1
3 GENERAL INFORMATION:
4 APPLICANT: OWEN, DONALD R.
5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
6 FILE REFERENCE: HELIX027
7 CURRENT FILING DATE: 2001-04-28
8 NUMBER OF SEQ ID NOS: 165
9 SOFTWARE: PATENTIN VET. 2.1
10 SEQ ID NO: 68
11 LENGTH: 20
12 TYPE: PRT
13 ORGANISM: ARTIFICIAL SEQUENCE
14 FEATURE:
15 OTHER INFORMATION: SYNTHETIC SEQUENCE
16 NAME/KEY: MOD_PES
17 LOCATION: (20)
18 OTHER INFORMATION: AMIDATION
19 US-09-820-053A-68

Query Match          63.68; Score 42; DB 11; Length 20;
Best Local Similarity 70.98; Pred. No. 2.5;
Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

CY 1 FAKAKALKALKAL 13
1 | | | | | | | | |
DB 5 FFAKALFELALF 17

RESULT 18
US-10-109-171 68
1 Sequence 68; Application US/10109171
2 Publication No. US20030109452A1
3 GENERAL INFORMATION:
4 APPLICANT: OWEN, DONALD R.
5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
6 FILE REFERENCE: HELIX028
7 CURRENT FILING DATE: 2002-04-28
8 NUMBER OF SEQ ID NOS: 165
9 SOFTWARE: PATENTIN VET. 2.1
10 SEQ ID NO: 68
11 LENGTH: 20
12 TYPE: PRT
13 ORGANISM: ARTIFICIAL SEQUENCE
14 FEATURE:
15 OTHER INFORMATION: SYNTHETIC SEQUENCE
16 NAME/KEY: MOD_PES
17 LOCATION: (20)
18 OTHER INFORMATION: AMIDATION
19 US-09-820-053A-158

```

```

1  OTHER INFORMATION: SYNTHETIC SEQUENCE
2  NAME/KEY: MOD_PES
3  LOCATION: (20)
4  OTHER INFORMATION: AMIDATION
5  US-10-109-171 68

Query Match          64.68; Score 42; DB 15; Length 20;
Best Local Similarity 76.98; Pred. No. 2.5;
Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

CY 1 FAKAKALKALKAL 13
1 | | | | | | | | |
DB 5 FFAKALFELALF 17

RESULT 19
US-09-820-053A-15
1 Sequence 15; Application US/09820053A
2 Publication No. US20030084243A1
3 GENERAL INFORMATION:
4 APPLICANT: OWEN, DONALD R.
5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
6 FILE REFERENCE: HELIX027
7 CURRENT FILING DATE: 2001-04-28
8 NUMBER OF SEQ ID NOS: 165
9 SOFTWARE: PATENTIN VET. 2.1
10 SEQ ID NO: 15
11 LENGTH: 24
12 TYPE: PRT
13 ORGANISM: ARTIFICIAL SEQUENCE
14 FEATURE:
15 OTHER INFORMATION: SYNTHETIC SEQUENCE
16 NAME/KEY: MOD_PES
17 LOCATION: (24)
18 OTHER INFORMATION: AMIDATION
19 US-09-820-053A-15

Query Match          63.68; Score 42; DB 11; Length 24;
Best Local Similarity 78.68; Pred. No. 2.9;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

CY 2 AVALKALKALKAL 15
1 | | | | | | | | |
DB 2 AVALKALKALKAL 15

RESULT 20
US-09-820-053A-158
1 Sequence 158; Application US/09820053A
2 Publication No. US20030084243A1
3 GENERAL INFORMATION:
4 APPLICANT: OWEN, DONALD R.
5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
6 FILE REFERENCE: HELIX027
7 CURRENT FILING DATE: 2001-04-28
8 NUMBER OF SEQ ID NOS: 165
9 SOFTWARE: PATENTIN VET. 2.1
10 SEQ ID NO: 158
11 LENGTH: 24
12 TYPE: PRT
13 ORGANISM: ARTIFICIAL SEQUENCE
14 FEATURE:
15 OTHER INFORMATION: SYNTHETIC SEQUENCE
16 NAME/KEY: MOD_PES
17 LOCATION: (24)
18 OTHER INFORMATION: AMIDATION
19 US-09-820-053A-158

Query Match          63.68; Score 42; DB 11; Length 24;
Best Local Similarity 78.68; Pred. No. 2.9;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```





## NAME/KEY: MOD\_PES

1 SEQUENCE: 16, Application US/09/820053A  
 2 PUBLICATION NO. US20040083241A1  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Owen, Donald R.  
 5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
 6 FILE REFERENCE: HELIX028  
 7 CURRENT FILING DATE: 2002-03-28  
 8 NUMBER OF SEQ ID NOS: 165  
 9 SOFTWARE: Patent In Ver. 2.1  
 10 SEQ ID NO: 22  
 11 LENGTH: 15  
 12 TYPE: PRT  
 13 ORGANISM: ARTIFICIAL SEQUENCE  
 14 FEATURE:  
 15 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 16 NAME/KEY: MOD\_PES  
 17 LOCATION: (15)  
 18 OTHER INFORMATION: AMINATION  
 19 US-09-820-053A 16

Query Match 62.1% Score 41: DB 11: Length 15:  
 Best Local Similarity 73.8% Pred. No. 2.6:  
 Matches 11: Conservative 0: Mismatches 4: Indels 0: Gaps 0:

1 FAKAKALKALKAL 15  
 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  
 3 FAKAKALKALKAL 15

RESULT 26  
 US-10-109-171 22

1 SEQUENCE: 22, Application US/10109171  
 2 PUBLICATION NO. US20040109452A1  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Owen, Donald R.  
 5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
 6 FILE REFERENCE: HELIX028  
 7 CURRENT FILING DATE: 2002-03-28  
 8 NUMBER OF SEQ ID NOS: 165  
 9 SOFTWARE: Patent In Ver. 2.1  
 10 SEQ ID NO: 22  
 11 LENGTH: 15  
 12 TYPE: PRT  
 13 ORGANISM: ARTIFICIAL SEQUENCE  
 14 FEATURE:  
 15 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 16 NAME/KEY: MOD\_PES  
 17 LOCATION: (15)  
 18 OTHER INFORMATION: AMINATION  
 19 US-10-109-171 22

Query Match 62.1% Score 41: DB 15: Length 15:  
 Best Local Similarity 73.8% Pred. No. 2.6:  
 Matches 11: Conservative 0: Mismatches 4: Indels 0: Gaps 0:

1 FAKAKALKALKAL 15  
 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  
 3 FAKAKALKALKAL 15

RESULT 27  
 US-09-820-053A 16

1 SEQUENCE: 16, Application US/09/820053A  
 2 PUBLICATION NO. US20040083241A1  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Owen, Donald R.  
 5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES  
 6 FILE REFERENCE: HELIX027  
 7 CURRENT FILING DATE: 2001-03-28  
 8 NUMBER OF SEQ ID NOS: 165  
 9 SOFTWARE: Patent In Ver. 2.1  
 10 SEQ ID NO: 16  
 11 LENGTH: 15  
 12 TYPE: PRT  
 13 ORGANISM: ARTIFICIAL SEQUENCE  
 14 FEATURE:  
 15 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 16 NAME/KEY: MOD\_PES  
 17 LOCATION: (15)  
 18 OTHER INFORMATION: AMINATION  
 19 US-09-820-053A 16

Query Match 62.1% Score 41: DB 11: Length 16:  
 Best Local Similarity 76.9% Pred. No. 2.8:  
 Matches 10: Conservative 0: Mismatches 2: Indels 0: Gaps 0:

1 FAKAKALKALKAL 13  
 2 1 1 1 1 1 1 1 1 1 1 1 1  
 3 FAKAKALKALKAL 13

RESULT 28  
 US-10-109-171-16

1 SEQUENCE: 16, Application US/10109171  
 2 PUBLICATION NO. US20040109452A1  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Owen, Donald R.  
 5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
 6 FILE REFERENCE: HELIX028  
 7 CURRENT FILING DATE: 2002-03-28  
 8 NUMBER OF SEQ ID NOS: 165  
 9 SOFTWARE: Patent In Ver. 2.1  
 10 SEQ ID NO: 16  
 11 LENGTH: 16  
 12 TYPE: PRT  
 13 ORGANISM: ARTIFICIAL SEQUENCE  
 14 FEATURE:  
 15 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 16 NAME/KEY: MOD\_PES  
 17 LOCATION: (16)  
 18 OTHER INFORMATION: AMINATION  
 19 US-10-109-171 16

Query Match 62.1% Score 41: DB 15: Length 16:  
 Best Local Similarity 76.9% Pred. No. 2.8:  
 Matches 10: Conservative 0: Mismatches 4: Indels 0: Gaps 0:

1 FAKAKALKALKAL 13  
 2 1 1 1 1 1 1 1 1 1 1 1 1  
 3 FAKAKALKALKAL 13

RESULT 29  
 US-09-820-053A-161

1 SEQUENCE: 161, Application US/09/820053A  
 2 PUBLICATION NO. US20040083241A1  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Owen, Donald R.  
 5 TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES  
 6 FILE REFERENCE: HELIX027  
 7 CURRENT FILING DATE: 2001-03-28  
 8 NUMBER OF SEQ ID NOS: 165  
 9 SOFTWARE: Patent In Ver. 2.1  
 10 SEQ ID NO: 161  
 11 LENGTH: 23  
 12 TYPE: PRT  
 13 ORGANISM: ARTIFICIAL SEQUENCE  
 14 FEATURE:  
 15 OTHER INFORMATION: SYNTHETIC SEQUENCE  
 16 NAME/KEY: MOD\_PES  
 17 LOCATION: (23)  
 18 OTHER INFORMATION: AMINATION  
 19 US-09-820-053A 161

Query Match 62.1% Score 41: DB 11: Length 23:  
 Best Local Similarity 76.9% Pred. No. 4.1:  
 Matches 10: Conservative 0: Mismatches 3: Indels 0: Gaps 0:

1 FAKAKALKALKAL 15  
 2 1 1 1 1 1 1 1 1 1 1 1 1  
 3 FAKAKALKALKAL 15

RESULT 30  
 US-10-109-171-161  
 1 SEQUENCE: 161, Application US/10109171  
 2 PUBLICATION NO. US20040109452A1







```

US 10-109-171-112
Sequence 115: Application US/0109171
Publication No.: US20030109452A1
GENERAL INFORMATION:
APPLICANT: OZON, Donald R.
TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
FILE REFERENCE: HELIX28
CURRENT APPLICATION NUMBER: 2002-07-09, 171
CURRENT FILING DATE: 2002-07-28
NUMBER OF SEQ ID NOS: 165
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO: 112
LENGTH: 17
TYPE: PRT
ORGANISM: ARTIFICIAL SEQUENCE
FEATURES:
OTHER INFORMATION: SYNTHETIC SEQUENCE
NAME/KEY: MOD_RES
LOCATION: (17)
OTHER INFORMATION: AMIDATION
US 10-109-171-112

```

```

Query Match 56.1% Score 37; DB 15; Length 17;
Best Local Similarity 81.8% Pred. No. 12;
Matches 9; Conservation 0; Mismatches 2; Indels 0; Gaps 0;
UY 4 ALKALAKA 14
111 11111
10 ALKALAKA 14

```

```

RESULT 43
US 10-109-171-112
Sequence 115: Application US/0109171
Publication No.: US20030109452A1
GENERAL INFORMATION:
APPLICANT: OZON, Donald R.
TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
FILE REFERENCE: HELIX28
CURRENT APPLICATION NUMBER: 2002-07-09, 171
CURRENT FILING DATE: 2002-07-28
NUMBER OF SEQ ID NOS: 165
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO: 115
LENGTH: 17
TYPE: PRT
ORGANISM: ARTIFICIAL SEQUENCE
FEATURES:
OTHER INFORMATION: SYNTHETIC SEQUENCE
NAME/KEY: MOD_RES
LOCATION: (17)
OTHER INFORMATION: AMIDATION
US 10-109-171-115

```

```

Query Match 56.1% Score 37; DB 15; Length 17;
Best Local Similarity 81.8% Pred. No. 12;
Matches 9; Conservation 0; Mismatches 2; Indels 0; Gaps 0;
UY 4 ALKALAKA 14
111 11111
10 ALKALAKA 14

```

```

RESULT 44
US 10-109-614B-12
Sequence 12: Application US/07065614B
Publication No.: US20030109452A1
GENERAL INFORMATION:
APPLICANT: OZON, Donald R.
TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
FILE REFERENCE: HELIX28
CURRENT APPLICATION NUMBER: 2002-07-09, 171
CURRENT FILING DATE: 2002-07-28
NUMBER OF SEQ ID NOS: 165
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO: 112
LENGTH: 17
TYPE: PRT
ORGANISM: ARTIFICIAL SEQUENCE
FEATURES:
OTHER INFORMATION: SYNTHETIC SEQUENCE
NAME/KEY: MOD_RES
LOCATION: (17)
OTHER INFORMATION: AMIDATION
US 10-109-614B-12

```

```

CURRENT APPLICATION NUMBER: US/09-820-053a-43
CURRENT FILING DATE: 2001-07-10
NUMBER OF SEQ ID NOS: 31
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO: 12
LENGTH: 18
TYPE: PRT
ORGANISM: ARTIFICIAL SEQUENCE
FEATURES:
OTHER INFORMATION: Description of Artificial
OTHER INFORMATION: Sequence: Endothelial
OTHER INFORMATION: Cell binding lipopeptide
NAME/KEY: MOD_RES
LOCATION: (1)
OTHER INFORMATION: 2-n-hexadecylstearyl lys
NAME/KEY: MOD_RES
LOCATION: (18)
OTHER INFORMATION: AMIDATION
US 09-820-053a-43

```

```

Query Match 56.1% Score 37; DB 10; Length 18;
Best Local Similarity 81.8% Pred. No. 14;
Matches 9; Conservation 0; Mismatches 2; Indels 0; Gaps 0;
UY 4 ALKALAKA 14
111 11111
10 ALKALAKA 14

```

```

RESULT 45
US 09-925-715-12
Sequence 12: Application US/090925715
Patent No.: US20020102217A1
GENERAL INFORMATION:
APPLICANT: Nycomed Imaging AS
TITLE OF INVENTION: Improvements in or relating to a device for the treatment of
FILE REFERENCE: HELIX28
CURRENT APPLICATION NUMBER: 2001-08-10
CURRENT FILING DATE: 2001-08-10
NUMBER OF SEQ ID NOS: 27
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO: 12
LENGTH: 18
TYPE: PRT
ORGANISM: ARTIFICIAL SEQUENCE
FEATURES:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Endothelial cell binding lipopeptide
NAME/KEY: MOD_RES
LOCATION: (1)
OTHER INFORMATION: 2-n-hexadecylstearyl lysine
NAME/KEY: MOD_RES
LOCATION: (18)
OTHER INFORMATION: AMIDATION
US 09-925-715-12

```

```

Query Match 56.1% Score 37; DB 10; Length 18;
Best Local Similarity 81.8% Pred. No. 14;
Matches 9; Conservation 0; Mismatches 2; Indels 0; Gaps 0;
UY 4 ALKALAKA 14
111 11111
10 ALKALAKA 14

```

Search completed: August 21, 2003, 08:24:45  
Job time : 55 secs

